US20170298033A1 - Bisphenol derivatives and their use as androgen receptor activity modulators - Google Patents

Bisphenol derivatives and their use as androgen receptor activity modulators Download PDF

Info

Publication number
US20170298033A1
US20170298033A1 US15/489,162 US201715489162A US2017298033A1 US 20170298033 A1 US20170298033 A1 US 20170298033A1 US 201715489162 A US201715489162 A US 201715489162A US 2017298033 A1 US2017298033 A1 US 2017298033A1
Authority
US
United States
Prior art keywords
propan
compound
chloro
phenoxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/489,162
Inventor
Raymond Andersen
Marianne Dorothy Sadar
Kunzhong JIAN
Nasrin R. Mawji
Jun Wang
Carmen Adriana Banuelos
Yu-Chi Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
British Columbia Cancer Agency BCCA
Provincial Health Services Authority
Original Assignee
University of British Columbia
British Columbia Cancer Agency BCCA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, British Columbia Cancer Agency BCCA filed Critical University of British Columbia
Priority to US15/489,162 priority Critical patent/US20170298033A1/en
Publication of US20170298033A1 publication Critical patent/US20170298033A1/en
Assigned to THE UNIVERSITY OF BRITISH COLUMBIA reassignment THE UNIVERSITY OF BRITISH COLUMBIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANDERSEN, RAYMOND JOHN, JIAN, Kunzhong
Assigned to PROVINCIAL HEALTH SERVICES AUTHORITY reassignment PROVINCIAL HEALTH SERVICES AUTHORITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: YANG, YU-CHI, BANUELOS, CARMEN ADRIANA, MAWJI, NASRIN R., SADAR, MARIANNE DOROTHY, WANG, JUN
Priority to US16/848,061 priority patent/US11142508B2/en
Priority to US17/404,589 priority patent/US11919874B2/en
Assigned to NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR reassignment NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: BRITISH COLUMBIA CANCER AGENCY
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms

Definitions

  • This invention generally relates to bisphenol-related compounds and their use for treatment of various indications.
  • the invention relates to bisphenol ether compounds having halogenated phenyl groups and/or sulfone linking groups and their use for treatment of various cancers, for example prostate cancer, including but not limited to, primary/localized prostate cancer (newly diagnosed), locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, metastatic castration-resistant prostate cancer (CRPC), and hormone-sensitive prostate cancer.
  • This invention also relates to bisphenol-related compounds and their use for modulating androgen receptor (AR) activity including truncated AR.
  • AR androgen receptor
  • Androgens mediate their effects through the androgen receptor (AR). Androgens play a role in a wide range of developmental and physiological responses and are involved in male sexual differentiation, maintenance of spermatogenesis, and male gonadotropin regulation (R. K. Ross, G. A. Coetzee, C. L. Pearce, J. K. Reichardt, P. Bretsky, L. N. Kolonel, B. E. Henderson, E. Lander, D. Altshuler & G. Daley, Eur Urol 35, 355 361 (1999); A. A. Thomson, Reproduction 121, 187 195 (2001); N. Tanji, K. Aoki & M. Yokoyama, Arch Androl 47, 1 7 (2001)).
  • prostate cancer does not develop if humans or dogs are castrated before puberty (J Clin Endocrinol Metab 84, 4324-4331 (1999); G. Wilding, Cancer Surv 14, 113-130 (1992)). Castration of adult males causes involution of the prostate and apoptosis of prostatic epithelium while eliciting no effect on other male external genitalia (E. M. Bruckheimer & N. Kyprianou, Cell Tissue Res 301, 153-162 (2000); J. T. Isaacs, Prostate 5, 545-557 (1984)). This dependency on androgens provides the underlying rationale for treating prostate cancer with chemical or surgical castration (androgen ablation).
  • Androgens also play a role in female diseases such as polycystic ovary syndrome as well as cancers.
  • ovarian cancer where elevated levels of androgens are associated with an increased risk of developing ovarian cancer (K. J. Helzlsouer, A. J. Alberg, G. B. Gordon, C. Longcope, T. L. Bush, S. C. Hoffman & G. W. Comstock, JAMA 274, 1926-1930 (1995); R. J. Edmondson, J. M. Monaghan & B. R. Davies, Br J Cancer 86, 879-885 (2002)).
  • the AR has been detected in a majority of ovarian cancers (H. A.
  • prostate cancer can eventually grow again in the absence of testicular androgens (castration-resistant disease) (Huber et al 1987 Scand J. Urol Nephrol. 104, 33-39). Castration-resistant prostate cancer that is still driven by AR is biochemically characterized before the onset of symptoms by a rising titre of serum PSA (Miller et al 1992 J. Urol. 147, 956-961). Once the disease becomes castration-resistant most patients succumb to their disease within two years.
  • the AR has distinct functional domains that include the carboxy-terminal ligand-binding domain (LBD), a DNA-binding domain (DBD) comprising two zinc finger motifs, and an N-terminus domain (NTD) that contains two transcriptional activation units (tau1 and tau5) within activation function-1 (AF-1). Binding of androgen (ligand) to the LBD of the AR results in its activation such that the receptor can effectively bind to its specific DNA consensus site, termed the androgen response element (ARE), on the promoter and enhancer regions of androgen regulated genes, such as PSA, to initiate transcription.
  • LBD carboxy-terminal ligand-binding domain
  • DBD DNA-binding domain
  • NTD N-terminus domain
  • AF-1 activation function-1
  • the AR can be activated in the absence of androgen by stimulation of the cAMP-dependent protein kinase (PKA) pathway, with interleukin-6 (IL-6) and by various growth factors (Culig et al 1994 Cancer Res. 54, 5474-5478; Nazareth et al 1996 J. Biol. Chem. 271, 19900-19907; Sadar 1999 J. Biol. Chem. 274, 7777-7783; Ueda et al 2002 A J. Biol. Chem. 277, 7076-7085; and Ueda et al 2002 B J Biol. Chem. 277, 38087-38094).
  • PKA cAMP-dependent protein kinase pathway
  • IL-6 interleukin-6
  • Clinically available inhibitors of the AR include nonsteroidal antiandrogens such as bicalutamide (CasodexTM), nilutamide, flutamide, and enzalutamide.
  • nonsteroidal antiandrogens such as bicalutamide (CasodexTM), nilutamide, flutamide, and enzalutamide.
  • steroidal antiandrogens such as cyproterone acetate and spironolactone. Both steroidal and non-steroidal antiandrogens target the LBD of the AR and predominantly fail presumably due to poor affinity, mutations that lead to activation of the AR by these same antiandrogens (Taplin, M. E., Bubley, G. J., Kom Y. J., Small E. J., Uptonm M., Rajeshkumarm B., Balkm S.
  • AR antagonists other than the bisphenol ether derivatives previously reported see, WO 2010/000066, WO 2011/082487; WO 2011/082488; WO 2012/145330; WO 2015/031984; WO 2016/058080; WO 2016/058082, WO 2016/112455, and WO 2016/141458 which are hereby incorporated by reference in their entireties, to the British Columbia Cancer Agency Branch and The University of British Columbia
  • AR degraders such as niclosamide (Liu C et al 2014), galeterone (Njar et al 2015; Yu Z at al 2014), and ARV-330 Androgen receptor PROTAC (Neklesa et al 2016 J Clin Oncol 34 suppl 2S; abstr 267); AR DBD inhibitor VPC-14449 (Dalal K et al 2014 J Biol Chem.
  • the AR-NTD is also a target for drug development (e.g. WO 2000/001813), since the NTD contains Activation-Function-1 (AF-1) which is the essential region required for AR transcriptional activity (Jenster et al 1991. Mol Endocrinol. 5, 1396-404).
  • AF-1 Activation-Function-1
  • the AR-NTD importantly plays a role in activation of the AR in the absence of androgens (Sadar, M. D. 1999 J. Biol. Chem. 274, 7777-7783; Sadar M D et al 1999 Endocr Relat Cancer. 6, 487-502; Ueda et al 2002 J. Biol. Chem. 277, 7076-7085; Ueda 2002 J. Biol. Chem.
  • the AR-NTD is important in hormonal progression of prostate cancer as shown by application of decoy molecules (Quayle et al 2007 , Proc Natl Acad Sci USA. 104, 1331-1336).
  • the present disclosure is based in part on the surprising discovery that the compounds described herein, can be used to modulate AR activity either in vivo or in vitro for both research and therapeutic uses.
  • certain compounds disclosed herein are useful for imaging the prostate.
  • the imaging can be for any number of diagnostic purposes.
  • the compounds are useful for imaging benign prostate cancer diseases.
  • the compounds find utility for imaging of certain cancers, including prostate cancer since certain embodiments of the compounds localize in prostate tumor sites.
  • Other imaging agents are androgen mimics; however, in one embodiment, the compounds are useful for imaging AR splice variants or any AR species (i.e., those mutated in other domains or regions).
  • the AR can be mammalian.
  • the AR can be human.
  • the prostate cancer can be castration-resistant prostate cancer.
  • the prostate cancer can be androgen-dependent prostate cancer.
  • the present disclosure relates to compounds of Formula (I):
  • X is —S(O) n — or —C(R 8 R 9 )—;
  • R 1 is H, hydroxyl or OC( ⁇ O)R 13 ;
  • R 2 is hydroxyl or OC( ⁇ O)R 13 ;
  • R 3 is halo, —OH, —OR 4 ; OC( ⁇ O)R 13 , —NH 2 , —NHS(O) n R 5 , —N(C 1 -C 6 alkyl)S(O) n R 5 , —S(O) n R 5 , —N 3 , aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R 6 ;
  • R 4 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R 6 ;
  • R 5 is each independently C 1 -C 6 alkyl or aryl which are optionally substituted with one or more R 6 ;
  • R 6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123 I, hydroxyl, oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 6 -C 12 aryl, wherein each R 6 is optionally substituted with one or more of halogen, 123 I, 18 F, hydroxyl, —OS(O) 2 -aryl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;
  • R 8 and R 9 are each independently H or C 1 -C 6 alkyl
  • R 11a , R 11b , R 11c and R 11d are each independently H, methyl, F, Cl, Br, I, or 123 I;
  • R 13 is C 1 -C 6 alkyl
  • n 0, 1, or 2;
  • R 11a , R 11b , R 11c and R 11d is methyl F, Cl, Br, I, or 123 I.
  • R 11a , R 11b , R 11c and R 11d in Formula I are independently methyl, F, Cl, Br, I, or 123 I.
  • any two of R 11a , R 11b , R 11c and R 11d are independently methyl, F, Cl, Br, I, or 123 I and the remaining two of R 11a , R 11b , R 11c and R 11d are each H.
  • R 11a and R 11b are each H, and R 11c and R 11d are each independently methyl, F, Cl, Br, I, or 123 I.
  • R 11a and R 11b are each H, and R 11c and R 11d are each independently methyl, Cl, or Br.
  • R 11a and R 11b are each H, and R 11c and R 11d are each Cl.
  • R 11a and R 11c in Formula I are each H, and R 11b and R 11d in Formula I are each independently methyl, F, Cl, Br, I, or 123 I. In some embodiments, R 11a and R 11c are each H, and R 11b and R 11d are each independently methyl, Cl, or Br. In another embodiment, R 11a and R 11c are each H, and R 11b and R 11d are each Cl.
  • X in Formula I is —S(O) 2 —. In another embodiment, X in Formula I is —C(R 8 R 9 )— and R 8 and R 9 are each independently C 1 -C 3 alkyl. In one embodiment, X is —C(R 8 R 9 )— and R 8 and R 9 are each methyl.
  • R 1 in Formula I is hydroxyl or OC( ⁇ O)R 13 . In another embodiment R 1 is H.
  • R 3 in Formula I is —OH. In another embodiment, R 3 is —OC( ⁇ O)R 13 , wherein R 13 is methyl. In one embodiment, R 3 is —OR 4 and R 4 is C 1 -C 6 alkyl. In other embodiments, R 3 is —OR 4 and R 4 is methyl.
  • R 3 in Formula I is an optionally substituted 5 or 6 membered heteroaryl or an optionally substituted 3 to 7 membered heterocylyl, wherein said heteroaryl or said heterocyclyl respectively comprise at least one N atom.
  • R 3 is selected from a group consisting of pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, oxazine, triazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, and tetrazine.
  • each R 13 in Formula I when present is C 1 -C 3 alkyl. In a further embodiment, each R 13 when present is methyl.
  • R 1 and R 2 in Formula I are each independently —OH or —OC( ⁇ O)R 13 , wherein R 13 is methyl. In some embodiments, at least one of R 1 , R 2 and R 3 is —OC( ⁇ O)R 13 , wherein R 13 is methyl. In another embodiment, any two of R 1 , R 2 and R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is methyl. In one embodiment, R 1 , R 2 and R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is methyl.
  • the present disclosure relates to compounds of Formula (I):
  • R 1 is H, hydroxyl or —OC( ⁇ O)R 13 ;
  • R 2 is hydroxyl or —OC( ⁇ O)R 13 ;
  • R 3 is halo, —OH, —OR 4 , —OC( ⁇ O)R 13 , —NH 2 , —NHS(O) n R 5 , —N(C 1 -C 6 alkyl)S(O) n R 5 , —S(O) n R 5′ —N 3 , aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R 6 ;
  • R 4 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R 6 ;
  • R 5 is each independently C 1 -C 6 alkyl or aryl which are optionally substituted with one or more R 6 ;
  • R 6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123 I, hydroxyl, oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 6 -C 12 aryl, wherein each R 6 is optionally substituted with one or more of halogen, 123 I, 18 F, hydroxyl, —OS(O) 2 -aryl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;
  • R 8 and R 9 are each independently H or C 1 -C 6 alkyl
  • n 0, 1, or 2;
  • R 11a , R 11b , R 11c and R 11d are each independently H, methyl, F, Cl, Br, I, or 123 I.
  • R 3 in Formula II is —OH.
  • R 3 is —OC( ⁇ O)R 13 , wherein R 13 is methyl.
  • R 3 is —OR 4 , wherein R 4 is C 1 -C 6 alkyl.
  • R 3 is —OR 4 , wherein R 4 is methyl.
  • R 1 in Formula II is hydroxyl or OC( ⁇ O)R 13 . In another embodiment R 1 in Formula II is H.
  • R 3 in Formula II is an optionally substituted 5 or 6 membered heteroaryl or an optionally substituted 3 to 7 membered heterocylyl, wherein said heteroaryl or said heterocyclyl respectively comprise at least one N atom.
  • R 3 is selected from a group consisting of pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, oxazine, triazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, and tetrazine.
  • R 11a , R 11b , R 11c and R 11d in Formula II are each H.
  • each R 13 in Formula II when present is C 1 -C 3 alkyl. In a further embodiment, each R 13 when present is methyl.
  • R 1 and R 2 in Formula II are each independently —OH or —OC( ⁇ O)R 13 , wherein R 13 is methyl. In some embodiments, at least one of R 1 , R 2 and R 3 is —OC( ⁇ O)R 13 , wherein R 13 is methyl. In another embodiment, any two of R 1 , R 2 and R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is methyl. In one embodiment, R 1 , R 2 and R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is methyl.
  • the present disclosure relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I or Formula II or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and an additional therapeutic agent.
  • a pharmaceutical composition comprising a compound of Formula I or Formula II or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, and an additional therapeutic agent.
  • the additional therapeutic agent is for treating prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration.
  • the additional therapeutic agent is enzalutamide, galeterone, abiraterone, bicalutamide, nilutamide, flutamide, cyproterone acetate, docetaxel, bevacizumab (Avastin), OSU-HDAC42, VITAXIN, sunitumib, ZD-4054, cabazitaxel (XRP-6258), MDX-010 (Ipilimumab), OGX 427, OGX 011, finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 28260, SKF105,111, ODM-201, radium 233, ODM-204, niclosamide, apalutamide, ARV-33Q, VPC-14449, TAS3681, 3E10-AR441bsAb, sintokamide, or related compounds thereof.
  • the present disclosure provides a method for modulating androgen receptor activity, comprising administering a compound of Formula I or Formula II or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, or a pharmaceutical composition comprising a compound of Formula I or Formula II or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a patient in need thereof.
  • the method of modulating androgen receptor activity is inhibiting androgen receptor.
  • the present disclosure provides a method for treating a condition or disease that is responsive to modulation of androgen receptor activity, comprising: administering a compound of Formula I or Formula II or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, or a pharmaceutical composition comprising a compound of Formula I or Formula II or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a patient in need thereof.
  • the condition or disease is selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, and age related macular degeneration.
  • the condition is prostate cancer.
  • the condition or disease is castration-resistant prostate cancer.
  • the condition or disease is androgen-dependent prostate cancer.
  • the compounds described herein can be used for diagnostic purposes to investigate diseases of the prostate, including cancer.
  • the compounds are useful for imaging diagnostics in cancer.
  • imaging allows for the detection and/or location of cancer sites (e.g., tumor sites).
  • cancer sites e.g., tumor sites.
  • these compounds can be used individually or as part of a kit for such purposes.
  • FIG. 1 shows a 13 C NMR spectrum of Compound 3a.
  • FIG. 2 shows a dose-response for selected compounds of the present disclosure in LNCaP cells transfected with the PSA (6.1 kb)-luciferase reporter and treated with androgen.
  • FIG. 3 shows tumor volume of LNCaP xenografts in SCID-NOD mice treated with Compound 1a or CMC-treated mice (control) in the course of 26 day treatment.
  • FIG. 4 shows tumor volume of LNCaP xenografts at the start and the finish (day 26) for Compound 1a treated mice and CMC-treated mice.
  • FIG. 5 shows body weight at the start and the finish (day 26) for Compound 1a treated mice and CMC-treated mice.
  • FIG. 6 shows tissues levels of PSA mRNA in five representative xenografts from each treatment group measured by QPCR.
  • Amino refers to the —NH 2 radical.
  • Halo or “halogen” refers to bromo, chloro, fluoro or iodo radical.
  • Niro refers to the —NO 2 radical.
  • Oxo refers to the ⁇ O substituent.
  • Thioxo refers to the ⁇ S substituent.
  • Alkyl or “alkyl group” refers to a fully saturated, straight or branched hydrocarbon chain radical having from one to twelve carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 12 are included. An alkyl comprising up to 12 carbon atoms is a C 1 -C 12 alkyl, an alkyl comprising up to 10 carbon atoms is a C 1 -C 10 alkyl, an alkyl comprising up to 6 carbon atoms is a C 1 -C 6 alkyl and an alkyl comprising up to 5 carbon atoms is a C 1 -C 5 alkyl.
  • a C 1 -C 5 alkyl includes C 5 alkyls, C 4 alkyls, C 3 alkyls, C 2 alkyls and C 1 alkyl (i.e., methyl).
  • a C 1 -C 6 alkyl includes all moieties described above for C 1 -C 5 alkyls but also includes C 6 alkyls.
  • a C 1 -C 10 alkyl includes all moieties described above for C 1 -C 5 alkyls and C 1 -C 6 alkyls, but also includes C 7 , C 8 , C 9 and C 10 alkyls.
  • a C 1 -C 12 alkyl includes all the foregoing moieties, but also includes C 11 and C 12 alkyls.
  • Non-limiting examples of C 1 -C 12 alkyl include methyl, ethyl, n-propyl, i-propyl, sec-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, t-amyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl.
  • an alkyl group can be optionally substituted.
  • Alkylene or “alkylene chain” refers to a fully saturated, straight or branched divalent hydrocarbon chain radical, and having from one to twelve carbon atoms.
  • C 1 -C 12 alkylene include methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, n-butenylene, propynylene, n-butynylene, and the like.
  • the alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain can be optionally substituted.
  • Alkenyl or “alkenyl group” refers to a straight or branched hydrocarbon chain radical having from two to twelve carbon atoms, and having one or more carbon-carbon double bonds. Each alkenyl group is attached to the rest of the molecule by a single bond. Alkenyl group comprising any number of carbon atoms from 2 to 12 are included.
  • An alkenyl group comprising up to 12 carbon atoms is a C 2 -C 12 alkenyl
  • an alkenyl comprising up to 10 carbon atoms is a C 2 -C 10 alkenyl
  • an alkenyl group comprising up to 6 carbon atoms is a C 2 -C 6 alkenyl
  • an alkenyl comprising up to 5 carbon atoms is a C 2 -C 5 alkenyl.
  • a C 2 -C 5 alkenyl includes C 5 alkenyls, C 4 alkenyls, C 3 alkenyls, and C 2 alkenyls.
  • a C 2 -C 6 alkenyl includes all moieties described above for C 2 -C 5 alkenyls but also includes C 6 alkenyls.
  • a C 2 -C 10 alkenyl includes all moieties described above for C 2 -C 5 alkenyls and C 2 -C 6 alkenyls, but also includes C 7 , C 8 , C 9 and C 10 alkenyls.
  • a C 2 -C 12 alkenyl includes all the foregoing moieties, but also includes C 11 and C 12 alkenyls.
  • Non-limiting examples of C 2 -C 12 alkenyl include ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-noneny
  • Examples of C 1 -C 3 alkyl includes methyl, ethyl, n-propyl, and i-propyl.
  • Examples of C 1 -C 4 alkyl includes methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and sec-butyl. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.
  • alkenylene or “alkenylene chain” refers to a straight or branched divalent hydrocarbon chain radical, having from two to twelve carbon atoms, and having one or more carbon-carbon double bonds.
  • C 2 -C 12 alkenylene include ethene, propene, butene, and the like.
  • the alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
  • the points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkenylene chain can be optionally substituted.
  • Alkynyl or “alkynyl group” refers to a straight or branched hydrocarbon chain radical having from two to twelve carbon atoms, and having one or more carbon-carbon triple bonds. Each alkynyl group is attached to the rest of the molecule by a single bond. Alkynyl group comprising any number of carbon atoms from 2 to 12 are included.
  • An alkynyl group comprising up to 12 carbon atoms is a C 2 -C 12 alkynyl
  • an alkynyl comprising up to 10 carbon atoms is a C 2 -C 10 alkynyl
  • an alkynyl group comprising up to 6 carbon atoms is a C 2 -C 6 alkynyl
  • an alkynyl comprising up to 5 carbon atoms is a C 2 -C 5 alkynyl.
  • a C 2 -C 5 alkynyl includes C 5 alkynyls, C 4 alkynyls, C 3 alkynyls, and C 2 alkynyls.
  • a C 2 -C 6 alkynyl includes all moieties described above for C 2 -C 5 alkynyls but also includes C 6 alkynyls.
  • a C 2 -C 10 alkynyl includes all moieties described above for C 2 -C 5 alkynyls and C 2 -C 6 alkynyls, but also includes C 7 , C 8 , C 9 and C 10 alkynyls.
  • a C 2 -C 12 alkynyl includes all the foregoing moieties, but also includes C 11 and C 12 alkynyls.
  • Non-limiting examples of C 2 -C 12 alkenyl include ethynyl, propynyl, butynyl, pentynyl and the like. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.
  • Alkynylene or “alkynylene chain” refers to a straight or branched divalent hydrocarbon chain radical, having from two to twelve carbon atoms, and having one or more carbon-carbon triple bonds.
  • C 2 -C 12 alkynylene include ethynylene, propargylene and the like.
  • the alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkynylene chain can be optionally substituted.
  • Alkoxy refers to a radical of the formula —OR a where R a is an alkyl, alkenyl or alknyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group can be optionally substituted.
  • Alkylamino refers to a radical of the formula —NHR a or —NR a R a where each R a is, independently, an alkyl, alkenyl or alkynyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkylamino group can be optionally substituted.
  • Alkylcarbonyl refers to the —C( ⁇ O)R a moiety, wherein R a is an alkyl, alkenyl or alkynyl radical as defined above.
  • R a is an alkyl, alkenyl or alkynyl radical as defined above.
  • a non-limiting example of an alkyl carbonyl is the methyl carbonyl (“acetal”) moiety.
  • Alkylcarbonyl groups can also be referred to as “Cw-Cz acyl” where w and z depicts the range of the number of carbon in R a , as defined above.
  • C 1 -C 10 acyl refers to alkylcarbonyl group as defined above, where R a is C 1 -C 10 alkyl, C 1 -C 10 alkenyl, or C 1 -C 10 alkynyl radical as defined above. Unless stated otherwise specifically in the specification, an alkyl carbonyl group can be optionally substituted.
  • Aryl refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring.
  • the aryl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems.
  • Aryl radicals include, but are not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.
  • aryl is meant to include aryl radicals that are optionally substituted.
  • Alkyl refers to a radical of the formula —R b —R c where R b is an alkylene, alkenylene or alkynylene group as defined above and R c is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like. Unless stated otherwise specifically in the specification, an aralkyl group can be optionally substituted.
  • Carbocyclyl “carbocyclic ring” or “carbocycle” refers to a rings structure, wherein the atoms which form the ring are each carbon. Carbocyclic rings can comprise from 3 to 20 carbon atoms in the ring. Carbocyclic rings include aryls and cycloalkyl. cycloalkenyl and cycloalkynyl as defined herein. Unless stated otherwise specifically in the specification, a carbocyclyl group can be optionally substituted.
  • Cycloalkyl refers to a stable non-aromatic monocyclic or polycyclic fully saturated hydrocarbon radical consisting solely of carbon and hydrogen atoms, which can include fused or bridged ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond.
  • Monocyclic cycloalkyl radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Polycyclic cycloalkyl radicals include, for example, adamantyl, norbomyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group can be optionally substituted.
  • “Cycloalkenyl” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon double bonds, which can include fused or bridged ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond.
  • Monocyclic cycloalkenyl radicals include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, cycloctenyl, and the like.
  • Polycyclic cycloalkenyl radicals include, for example, bicyclo[2.2.1]hept-2-enyl and the like. Unless otherwise stated specifically in the specification, a cycloalkenyl group can be optionally substituted.
  • Cycloalkynyl refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon triple bonds, which can include fused or bridged ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond.
  • Monocyclic cycloalkynyl radicals include, for example, cycloheptynyl, cyclooctynyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkynyl group can be optionally substituted.
  • Cycloalkylalkyl refers to a radical of the formula —R b -Rd where R b is an alkylene, alkenylene, or alkynylene group as defined above and Rd is a cycloalkyl, cycloalkenyl, cycloalkynyl radical as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group can be optionally substituted.
  • Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group can be optionally substituted.
  • Haloalkenyl refers to an alkenyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., 1-fluoropropenyl, 1,1-difluorobutenyl, and the like. Unless stated otherwise specifically in the specification, a haloalkenyl group can be optionally substituted.
  • Haloalkynyl refers to an alkynyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., 1-fluoropropynyl, 1-fluorobutynyl, and the like. Unless stated otherwise specifically in the specification, a haloalkenyl group can be optionally substituted.
  • Heterocyclyl refers to a stable 3- to 20-membered non-aromatic ring radical which consists of two to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Heterocyclycl or heterocyclic rings include heteroaryls as defined below.
  • the heterocyclyl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical can be optionally oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclyl radical can be partially or fully saturated.
  • heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thio
  • N-heterocyclyl refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical. Unless stated otherwise specifically in the specification, aN-heterocyclyl group can be optionally substituted.
  • Heterocyclylalkyl refers to a radical of the formula —R b —Re where R b is an alkylene, alkenylene, or alkynylene chain as defined above and Re is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl can be attached to the alkyl, alkenyl, alkynyl radical at the nitrogen atom. Unless stated otherwise specifically in the specification, a heterocyclylalkyl group can be optionally substituted.
  • Heteroaryl refers to a 5- to 20-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring.
  • the heteroaryl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical can be optionally oxidized; the nitrogen atom can be optionally quaternized.
  • Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furany
  • N-heteroaryl refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. Unless stated otherwise specifically in the specification, an N-heteroaryl group can be optionally substituted.
  • Heteroarylalkyl refers to a radical of the formula —R b —R f where R b is an alkylene, alkenylene, or alkynylene chain as defined above and R f is a heteroaryl radical as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkyl group can be optionally substituted.
  • 123 I refers to the radioactive isotope of iodine having atomic mass 123.
  • the compounds of Formula I can comprise at least one 123 I moiety. Throughout the present application, where structures depict a 123 I moiety at a certain position it is meant that the I moiety at this position is enriched for 123 I. In other words, the compounds contain more than the natural abundance of 123 I at the indicated position(s). It is not required that the compounds comprise 100% 123 I at the indicated positions, provided 123 I is present in more than the natural abundance.
  • the 123 I isotope is enriched to greater than 50%, greater than 60%, greater than 70%, greater than, 80% or greater than 90%, relative to 127 I.
  • 18 F refers to the radioactive isotope of fluorine having atomic mass 18.
  • F or “ 19 F” refers to the abundant, non-radioactive fluorine isotope having atomic mass 19.
  • the compounds of Formula I can comprise at least one 18 F moiety. Throughout the present application, where structures depict a 18 F moiety at a certain position it is meant that the F moiety at this position is enriched for 18 F. In other words, the compounds contain more than the natural abundance of 18 F at the indicated position(s). It is not required that the compounds comprise 100% 18 F at the indicated positions, provided 18 F is present in more than the natural abundance.
  • the 18 F isotope is enriched to greater than 50%, greater than 60%, greater than 70%, greater than 80% or greater than 90%, relative to 19 F.
  • Thioalkyl refers to a radical of the formula —SR a where R a is an alkyl, alkenyl, or alkynyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, a thioalkyl group can be optionally substituted.
  • substituted means any of the above groups (i.e., alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, alkoxy, alkylamino, alkylcarbonyl, thioalkyl, aryl, aralkyl, carbocyclyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as hydroxyl groups
  • “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • “substituted” includes any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • “substituted” includes any of the above groups in which one or more hydrogen atoms are replaced
  • “Substituted also means any of the above groups in which one or more hydrogen atoms are replaced with —C( ⁇ O)R g , —C( ⁇ O)OR g , —C( ⁇ O)NR g R h , —CH 2 SO 2 R g , —CH 2 SO 2 NR g R h .
  • R g and R h are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl.
  • “Substituted” further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl group.
  • each of the foregoing substituents can also be optionally substituted with one or more of the above substituents.
  • a point of attachment bond denotes a bond that is a point of attachment between two chemical entities, one of which is depicted as being attached to the point of attachment bond and the other of which is not depicted as being attached to the point of attachment bond.
  • fused refers to any ring structure described herein which is fused to an existing ring structure in the compounds of the invention.
  • the fused ring is a heterocyclyl ring or a heteroaryl ring
  • any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring can be replaced with a nitrogen atom.
  • the invention disclosed herein is also meant to encompass the in vivo metabolic products of the disclosed compounds.
  • Such products can result from, for example, the oxidation, reduction, hydrolysis, amidation, esterification, and the like of the administered compound, primarily due to enzymatic processes.
  • the invention includes compounds produced by a process comprising administering a compound of this invention to a mammal for a period of time sufficient to yield a metabolic product thereof.
  • Such products are typically identified by administering a radiolabelled compound of the invention in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to human, allowing sufficient time for metabolism to occur, and isolating its conversion products from the urine, blood or other biological samples.
  • Solid compound and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • a “subject” can be a human, non-human primate, mammal, rat, mouse, cow, horse, pig, sheep, goat, dog, cat and the like.
  • the subject can be suspected of having or at risk for having a cancer, such as prostate cancer, breast cancer, ovarian cancer, salivary gland carcinoma, or endometrial cancer, or suspected of having or at risk for having acne, hirsutism, alopecia, benign prostatic hyperplasia, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration.
  • a cancer such as prostate cancer, breast cancer, ovarian cancer, salivary gland carcinoma, or endometrial cancer, or suspected of having or at risk for having acne, hirsutism, alopecia, benign prostatic hyperplasia, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy
  • Diagnostic methods for various cancers such as prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, salivary gland carcinoma, or endometrial cancer, and diagnostic methods for acne, hirsutism, alopecia, benign prostatic hyperplasia, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration and the clinical delineation of cancer, such as prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, salivary gland carcinoma, or endometrial cancer, diagnoses and the clinical delineation of acne, hirsutism, alopecia, benign prostatic hyperplasia, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration are known to those of ordinary skill in the art.
  • “Mammal” includes humans and both domestic animals such as laboratory animals and household pets (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildlife and the like.
  • Optional or “optionally” means that the subsequently described event of circumstances can or cannot occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.
  • optionally substituted aryl means that the aryl radical can or cannot be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
  • “Pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
  • “Pharmaceutically acceptable salt” includes both acid and base addition salts.
  • “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic
  • “Pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like.
  • Particularly preferred organic bases are isoprop
  • solvate refers to an aggregate that comprises one or more molecules of a compound of the invention with one or more molecules of solvent.
  • the solvent can be water, in which case the solvate can be a hydrate.
  • the solvent can be an organic solvent.
  • the compounds of the present invention can exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms.
  • the compound of the invention can be true solvates, while in other cases, the compound of the invention can merely retain adventitious water or be a mixture of water plus some adventitious solvent.
  • a “pharmaceutical composition” refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, e.g., humans.
  • a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor.
  • an “effective amount” refers to a therapeutically effective amount or a prophylactically effective amount.
  • a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as reduced tumor size, increased life span or increased life expectancy.
  • a therapeutically effective amount of a compound can vary according to factors such as the disease state, age, sex, and weight of the subject, and the ability of the compound to elicit a desired response in the subject. Dosage regimens can be adjusted to provide the optimum therapeutic response.
  • a therapeutically effective amount is also one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects.
  • a “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as smaller tumors, increased life span, increased life expectancy or prevention of the progression of prostate cancer to a castration-resistant form.
  • a prophylactic dose is used in subjects prior to or at an earlier stage of disease, so that a prophylactically effective amount can be less than a therapeutically effective amount.
  • Treating” or “treatment” as used herein covers the treatment of the disease or condition of interest in a mammal, preferably a human, having the disease or condition of interest, and includes:
  • the compounds of the invention, or their pharmaceutically acceptable salts can contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids.
  • the present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms whether or not they are specifically depicted herein.
  • Optically active (+) and ( ⁇ ), (R)- and (S)-, or (D)- and (L)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization.
  • Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC).
  • HPLC high pressure liquid chromatography
  • stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
  • the present invention contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are nonsuperimposable mirror images of one another.
  • a “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule.
  • the present invention includes tautomers of any said compounds.
  • the terms “about” and/or “approximately” can be used in conjunction with numerical values and/or ranges.
  • the term “about” is understood to mean those values near to a recited value.
  • “about 40 [units]” can mean within +25% of 40 (e.g., from 30 to 50), within ⁇ 20%, ⁇ 15%, ⁇ 10%, ⁇ 9%, ⁇ 8%, ⁇ 7%, ⁇ 6%, ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2%, ⁇ 1%, less than ⁇ 1%, or any other value or range of values therein or therebelow.
  • the phrases “less than about [a value]” or “greater than about [a value]” should be understood in view of the definition of the term “about” provided herein.
  • the terms “about” and “approximately” can be used interchangeably.
  • ranges are provided for certain quantities. It is to be understood that these ranges comprise all subranges therein. Thus, the range “from 50 to 80” includes all possible ranges therein (e.g., 51-79, 52-78, 53-77, 54-76, 55-75, 60-70, etc.). Furthermore, all values within a given range can be an endpoint for the range encompassed thereby (e.g., the range 50-80 includes the ranges with endpoints such as 55-80, 50-75, etc.).
  • certain embodiments of the present invention are directed to compounds useful for treatment of various cancers, including various types of prostate cancers. While not wishing to be bound by theory, it is believed that binding of the compounds to the androgen receptor (for example at the N-terminal domain) can contribute to the activity of the disclosed compounds.
  • the compounds of the present invention include halogenated phenyl groups (i.e., R 11a -R 11d in Formula I) and/or sulfone bridging groups (i.e., X in Formula I is —S(O) 2 — or compounds of Formula II) which impart improved properties to the compounds compared to compounds lacking the described R 3 moiety.
  • the improved properties include improved drug-like properties such as improved activity (e.g., androgen receptor (AR) modulation), longer half-life (e.g., in vivo); decreased toxicity; better solubility, improved formulation, better bioavailability, better pharmacokinetic profile; reduction in unwanted metabolites and the like.
  • improved activity e.g., androgen receptor (AR) modulation
  • longer half-life e.g., in vivo
  • decreased toxicity better solubility, improved formulation, better bioavailability, better pharmacokinetic profile
  • reduction in unwanted metabolites and the like are examples of drugs-like properties such as improved activity (e.g., androgen receptor (AR) modulation), longer half-life (e.g., in vivo); decreased toxicity; better solubility, improved formulation, better bioavailability, better pharmacokinetic profile; reduction in unwanted metabolites and the like.
  • improved drug-like properties such as improved activity (e.g., androgen receptor (AR) modulation),
  • the invention includes compounds which form covalent bonds with the androgen receptor (AR) (e.g., at the N-terminal domain), thus resulting in irreversible (or substantially irreversible) inhibition of the same.
  • AR androgen receptor
  • the certain compounds of the present invention are designed to include functional groups capable of forming covalent bonds with a nucleophile under certain in vivo conditions.
  • the reactivity of compounds of the present invention is such that they will not substantially react with various nucleophiles (e.g., glutathione) when the compounds are free in solution.
  • the compounds when the free mobility of the compounds is restricted, and an appropriate nucleophile is brought into close proximity to the compound, for example when the compounds associate with, or bind to, the androgen receptor, the compounds are capable of forming covalent bonds with certain nucleophiles (e.g., thiols).
  • nucleophiles e.g., thiols
  • the present invention includes all compounds which have the above described properties (i.e., binding and/or inhibiting to androgen receptor (AR)).
  • the present invention is directed to a compound having a structure of Formula I:
  • X is —S(O) n — or —C(R 8 R 9 )—;
  • R 1 is H, —OH, or —OC( ⁇ O)R 13 ;
  • R 2 is —OH, or —OC( ⁇ O)R 13 ;
  • R 3 is halo, —OH, —OR 4 , —OC( ⁇ O)R 13 , —NH 2 , —NHC( ⁇ O)R 13 , —N(C( ⁇ O)R 13 ) 2 , —NHS(O) n R 5 , —N(C( ⁇ O)R 13 )(S(O) n R 5 ), —N(C 1 -C 6 alkyl)(S(O) n R 5 ), —S(O) n R 5 , —N 3 , aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R 6 :
  • R 4 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R 6 ;
  • R 5 is each independently C 1 -C 6 alkyl or aryl which are optionally substituted with one or more R 6 ;
  • R 6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123 I, —OH, oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 6 -C 12 aryl, wherein each R 6 is optionally substituted with one or more of halogen, 123 I, 18 F, —OH, —OS(O) 2 -aryl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;
  • R 8 and R 9 are each independently H or C 1 -C 6 alkyl
  • R 11a , R 11b , R 11c and R 11d are each independently H, methyl, F, Cl, Br, I, or 123 I;
  • R 13 is C 1 -C 6 alkyl
  • n 0, 1, or 2;
  • R 11a , R 11b , R 11c and R 11d is methyl, F, Cl, Br, I, or 123 I.
  • stereoisomers of the compound of structure (I) are provided, for example in some embodiments the compound has one of the following structures (Ia), (Ib), (Ic) or (Id):
  • the compound has one of the following structures (le), (If), (Ig) or (Ih):
  • X is —S(O) n —. In some embodiments, X is —S(O) 2 —. In another embodiment, X is —C(R 8 R 9 )—. In one embodiment X is —C(R 8 R 9 )—, wherein R 8 and R 9 are each independently H or C 1 -C 3 alkyl. In another embodiment, X is —C(R 8 R 9 )—, wherein R 8 and R 9 are each C 1 alkyl. In some embodiments, X is —S(O) 2 — or —C(CH 3 ) 2 —.
  • R 1 is —OH. In another embodiment, R 1 is —OC( ⁇ O)R 13 . In some embodiments, R 1 is —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl. In other embodiments, R 1 is —OC( ⁇ O)R 13 , wherein R 13 is methyl. In one embodiment, R 1 is H.
  • R 2 is —OH. In another embodiment, R 2 is —OC( ⁇ O)R 13 . In some embodiments, R 2 is —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl. In other embodiments, R 2 is —OC( ⁇ O)R 13 , wherein R 13 is methyl.
  • R 3 is —OH. In another embodiment, R 3 is —OC( ⁇ O)R 13 . In some embodiments, R 3 is —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl. In other embodiments, R 3 is —OC( ⁇ O)R 13 , wherein R 13 is methyl.
  • At least one of R 1 , R 2 , or R 3 is —OH. In some embodiments, at least two of R 1 , R 2 , or R 3 are each —OH. In other embodiments, R 1 and R 2 are each —OH. In another embodiment, R 1 , R 2 , and R 3 are each —OH.
  • At least one of R 1 , R 2 , or R 3 is —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl. In another embodiment, at least one of R 1 , R 2 , or R 3 is —OC( ⁇ O)R 13 , wherein R 13 is methyl. In some embodiments, at least two of R 1 , R 2 , or R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl. In another embodiment, at least two of R 1 , R 2 , or R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is methyl. In other embodiments, R 1 and R 2 are each —OC( ⁇ O)R 13 , wherein R 13 is methyl.
  • one of R 1 , R 2 , or R 3 is —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl. In another embodiment, one of R 1 , R 2 , or R 3 is —OC( ⁇ O)R 13 , wherein R 13 is methyl. In some embodiments, two of R 1 , R 2 , or R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl. In another embodiment, two of R 1 , R 2 , or R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is methyl.
  • R 1 and R 2 are each —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl. In another embodiment, R 1 and R 2 are each —OC( ⁇ O)R 13 , wherein R 13 is methyl. In some embodiments, R 1 , R 2 , or R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl. In another embodiment, R 1 , R 2 , or R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is methyl.
  • R 3 is —OR 4 .
  • R 3 is —OR 4 , wherein R 4 is C 1 -C 6 alkyl.
  • R 3 is —OR 4 , wherein R 4 is C 1 -C 3 alkyl.
  • R 3 is —OR 4 , wherein R 4 is methyl, ethyl, n-propyl, or i-propyl.
  • R 3 is —OR 4 , wherein R 4 is methyl.
  • R 3 is —OR 4 , wherein R 4 is i-propyl.
  • R 3 is a halogen. In other embodiments, R 3 is F, Cl, Br, or I. In one embodiment, R 3 is F.
  • R 3 is —NH 2 , —NHC( ⁇ O)R 13 , —N(C( ⁇ O)R 13 ) 2 , —NHS(O) n R 5 , —N(C( ⁇ O)R 13 )(S(O) n R 5 ), or —N(C 1 -C 6 alkyl)(S(O) n R 5 ).
  • R 3 is a —NH 2 .
  • R 3 is a —NHC( ⁇ O)R 13 .
  • R 3 is a —N(C( ⁇ O)R 13 ) 2 .
  • R 3 is a —NHS(O) n R 5 .
  • R 3 is a —NHS(O) 2 R 5 . In other embodiments, R 3 is a —NHS(O) 2 R 5 , wherein R 5 is C 1 -C 3 alkyl. In one embodiment, R 3 is a —NHS(O) 2 R 5 , wherein R 5 is C 1 alkyl. In one embodiment, R 3 is a —N(C( ⁇ O)R 13 )(S(O) n R 5 ). In one embodiment, R 3 is a —N(C 1 -C 6 alkyl)(S(O) n R 5 ).
  • R 3 is —NH 2 , —NHC( ⁇ O)(C 1 -C 4 alkyl), —N[(C( ⁇ O)(C 1 -C 4 alkyl)] 2 , —NHS(O) n (C 1 -C 3 alkyl), —N[C( ⁇ O)(C 1 -C 4 alkyl)][(S(O) n (C 1 -C 3 alkyl)], or —N[C 1 -C 6 alkyl][S(O) n (C 1 -C 3 alkyl)].
  • R 3 is —NH(C( ⁇ O)CH 3 ) or —N(C( ⁇ O)CH 3 ) 2 .
  • R 3 is —NHS(O) 2 CH 3 .
  • R 3 is —N(C( ⁇ O)CH 3 ) (S(O) 2 CH 3 ).
  • R 3 is a —S(O) 1 R 5 . In one embodiment, R 3 is a —S(O) 2 R 5 . In another embodiment, R 3 is a —S(O) 2 (C 1 -C 3 alkyl). In other embodiments, R 3 is a —S(O) 2 CH 3 . In other embodiments, R 3 is a —S(O) 2 CH 2 CH 3 .
  • R 3 is an optionally substituted 5 or 6 membered heteroaryl or an optionally substituted 3 to 7 membered heterocylyl, wherein said heteroaryl or said heterocyclyl respectively comprise at least one N atom in the ring.
  • R 3 is selected from a group consisting of pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, oxazine, triazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, and tetrazine.
  • R 3 is selected from a group consisting of pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole,
  • At least one of R 11a , R 11b , R 11c and R 11d is Cl. In another embodiment, at least one of R 11a , R 11b , R 11c and R 11d is Br. In some embodiments, at least one of R 11a , R 11b , R 11c and R 11d is methyl.
  • R 11a , R 11b , R 11c and R 11d are methyl, F, Cl, Br, I, or 123 I. In another embodiment, exactly two of R 11a , R 11b , R 11c and R 11d are methyl, F, Cl, Br, I, or 123 I.
  • R 11a and R 11b are each H and R 11c and R 11d are each independently methyl, F, Cl, Br, I, or 123 I. In one embodiment, R 11a and R 11b are each H, and R 11c and R 11d are each Cl. In one embodiment, R 11a and R 11b are each H, and R 11c and R 11d are each Br. In one embodiment, R 11a and R 11b are each H, and R 11c and R 11d are each methyl.
  • R 11a and R 11c are each H, and R 11b and R 11d are each independently methyl, F, Cl, Br, I, or 123 I. In one embodiment, R 11a and R 11c are each H, and R 11b and R 11d are each Cl. In one embodiment, R 11a and R 11c are each H, and R 11b and R 11d are each Br. In one embodiment, R 11a and R 11c are each H, and R 11b and R 11d are each methyl.
  • R 13 is C 1 -C 3 alkyl. In other embodiments, R 13 is methyl, ethyl, or propyl. In one embodiment, R 13 is a methyl.
  • n is 0. In another embodiment n is 1. In some embodiments, n is 2.
  • the compounds comprise one F, Cl, Br, I, or 123 I substitution.
  • any three of R 11a , R 11b , R 11c and R 11d are each H, and the remaining one of R 11a , R 11b , R 11c or R 11d is F, Cl, Br, I or 123 I.
  • the compounds comprise two F, Cl, Br, I or 123 I substitutions on the phenyl rings (i.e., two of R 11a , R 11b , R 11c and R 11d are H, and the other two of R 11a , R 11b , R 11c or R 11d are F, Cl, Br, I or 123 I).
  • the compounds comprise three F, Cl, Br, I or 123 I substitutions (i.e., any one of R 11a , R 11b , R 11c and R 11d is H, and the remaining R 11a , R 11b , R 11c or R 11d is F, Cl, Br, I or 123 I) and in other embodiments the compounds comprise four F, Cl, Br, I or 123 I substitutions (i.e., each of R 11a , R 11b , R 11c and R 11d are F, Cl, Br, I or 123 I).
  • the compound comprises one or more of F, Cl, Br, I or 123 I substitutions for R 3 . In one embodiment, the compound comprises one or more of I or 123 I substitutions for R 3 .
  • the compound comprises at least one R 6 substituent on R 3 , wherein at least one R 6 is further substituted with at least one of F, Cl, Br, I or 123 I. In another embodiment, R 6 substituent on R 3 is further substituted with at least one of I or 123 I.
  • R 11a is 123 I.
  • R 11c is 123 I.
  • the compound of Formula I has one of the following structures from Table 1, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof:
  • the compound of Formula I has one of the following structures from Table 2, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
  • the compound of Formula I has one of the following structures from Table 3, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof:
  • the compound of Formula I has one of the following structures from Table 4, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof:
  • the compound of Formula I has one of the following structures from Tables 1, 2, 3, or 4, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
  • the present invention includes all compounds which have the above described properties (i.e., binding to androgen receptor (AR)).
  • the present invention is directed to a compound having a structure of Formula II:
  • R 1 is H, hydroxyl or —OC( ⁇ O)R 13 ;
  • R 2 is hydroxyl or —OC( ⁇ O)R 13 ;
  • R 3 is halo, —OH, —OR 4 , —OC( ⁇ O)R 13 , —NH 2 , —NHC( ⁇ O)R 13 , —N(C( ⁇ O)R 13 ) 2 , —NHS(O) n R 5 , —N(C( ⁇ O)R 13 )(S(O) n R 5 ), —N(C 1 -C 6 alkyl)(S(O) n R 5 ), —S(O) n R 5 , —N 3 , aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R 6 ;
  • R 4 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R 6 ;
  • R 5 is each independently C 1 -C 6 alkyl or aryl which are optionally substituted with one or more R 6 ;
  • R 6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123 I, hydroxyl, oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 6 -C 12 aryl, wherein each R 6 is optionally substituted with one or more of halogen, 123 I, 18 F, hydroxyl, —OS(O) 2 -aryl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;
  • R 13 is C 1 -C 6 alkyl
  • n 0, 1, or 2.
  • stereoisomers of the compound of structure (II) are provided, for example in some embodiments the compound has one of the following structures (IIa), (IIb), (IIc) or (IId):
  • the compound has one of the following structures (IIe), (IIf), (IIg) or (IIh):
  • R 1 is hydroxyl. In another embodiment, R 1 is —OC( ⁇ O)R 13 . In some embodiments, R 1 is —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl. In other embodiments, R 1 is —OC( ⁇ O)R 13 , wherein R 13 is methyl. In one embodiment, R 1 is H.
  • R 2 is hydroxyl. In another embodiment, R 2 is —OC( ⁇ O)R 13 . In some embodiments, R 2 is —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl. In other embodiments, R 2 is —OC( ⁇ O)R 13 , wherein R 13 is methyl.
  • R 3 is —OH. In another embodiment, R 3 is —OC( ⁇ O)R 13 . In some embodiments, R 3 is —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl. In other embodiments, R 3 is —OC( ⁇ O)R 13 , wherein R 13 is methyl.
  • At least one of R 1 , R 2 , or R 3 is —OH. In another embodiment, at least one of R 1 , R 2 , or R 3 is —OH. In some embodiments, at least two of R 1 , R 2 , or R 3 are each —OH. In another embodiment, R 1 and R 2 are each —OH. In one embodiment, R 1 , R 2 , or R 3 are each —OH.
  • At least one of R 1 , R 2 , or R 3 is —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl. In another embodiment, at least one of R 1 , R 2 , or R 3 is —OC( ⁇ O)R 13 , wherein R 13 is methyl. In some embodiments, at least two of R 1 , R 2 , or R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl. In another embodiment, at least two of R 1 , R 2 , or R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is methyl.
  • one of R 1 , R 2 , or R 3 is —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl.
  • one of R 1 , R 2 , or R 3 is —OC( ⁇ O)R 13 , wherein R 13 is methyl.
  • two of R 1 , R 2 , or R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl.
  • two of R 1 , R 2 , or R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is methyl.
  • R 1 , R 2 , or R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is C 1 -C 4 alkyl.
  • R 1 , R 2 , or R 3 are each —OC( ⁇ O)R 13 , wherein R 13 is methyl.
  • R 3 is —OR 4 . In one embodiment, R 3 is —OR 4 , wherein R 4 is C 1 -C 6 alkyl. In another embodiment, R 3 is —OR 4 , wherein R 4 is C 1 -C 3 alkyl. In one embodiment, R 3 is —OR 4 , wherein R 4 is C 1 alkyl. In another embodiment, R 3 is —OR 4 , wherein R 4 is isopropyl.
  • R 3 is a halogen. In one embodiment, R 3 is F.
  • R 3 is —NH 2 , —NHC( ⁇ O)R 13 , —N(C( ⁇ O)R 13 ) 2 , —NHS(O) n R 5 , —N(C( ⁇ O)R 13 )(S(O) n R 5 ), or —N(C 1 -C 6 alkyl)(S(O) n R 5 ).
  • R 3 is a —NH 2 .
  • R 3 is a —NHC( ⁇ O)R 13 .
  • R 3 is a —N(C( ⁇ O)R 13 ) 2 .
  • R 3 is a —NHS(O) n R 5 .
  • R 3 is a —NHS(O) 2 R 5 . In other embodiments, R 3 is a —NHS(O) 2 R 5 , wherein R 5 is C 1 -C 3 alkyl. In one embodiment, R 3 is a —NHS(O) 2 R 5 , wherein R 5 is methyl. In one embodiment, R 3 is a —N(C( ⁇ O)R 13 )(S(O) n R 5 ). In one embodiment, R 3 is a —N(C 1 -C 6 alkyl)S(O) n R 5 .
  • R 3 is —NH 2 , —NHC( ⁇ O)(C 1 -C 4 alkyl), —N[(C( ⁇ O)(C 1 -C 4 alkyl)] 2 , —NHS(O) n (C 1 -C 3 alkyl), —N[C( ⁇ O)(C 1 -C 4 alkyl)][(S(O) n (C 1 -C 3 alkyl)], or —N[C 1 -C 6 alkyl][S(O) n (C 1 -C 3 alkyl)].
  • R 3 is —NH(C( ⁇ O)CH 3 ) or —N(C( ⁇ O)CH 3 ) 2 .
  • R 3 is —NHS(O) 2 CH 3 . In other embodiments, R 3 is —N(C( ⁇ O)CH 3 ) (S(O) 2 CH 3 ).
  • R 3 is a —S(O) n R 5 . In one embodiment, R 3 is a —S(O) 2 R 5 . In another embodiment, R 3 is a —S(O) 2 (C 1 -C 3 alkyl). In other embodiments, R 3 is a —S(O) 2 CH 3 . In other embodiments, R 3 is a —S(O) 2 CH 2 CH 3 .
  • R 3 is a —S(O) n R 5 . In one embodiment, R 3 is a —S(O) 2 R 5 . In some embodiments, R 3 is a —S(O) 2 R 5 , wherein R 5 is C 1 -C 3 alkyl. In other embodiments, R 3 is a —S(O) 2 R 5 , wherein R 5 is C 1 alkyl.
  • R 3 is an optionally substituted 5 or 6 membered heteroaryl or an optionally substituted 3 to 7 membered heterocylyl, wherein said heteroaryl or said heterocyclyl respectively comprises at least one N atom in the ring.
  • R 3 is selected from a group consisting of pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, oxazine, triazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, and tetrazine.
  • R 3 is selected from a group consisting of pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole,
  • R 13 is C 1 -C 4 alkyl. In other embodiments, R 13 is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, or sec-butyl. In one embodiment, R 13 is a methyl.
  • n is 0. In another embodiment n is 1. In some embodiments, n is 2.
  • the compounds for use in the imaging and treatment methods described herein.
  • the compounds comprise one F, Cl, Br, I, or 123 I substitution.
  • the compound comprise one or more of F, Cl, Br, I or 123 I substitutions for R 3 . In one embodiment, the compound comprise one or more of I or 123 I substitutions for R 3 .
  • the compound comprises at least one R 6 substituent on R 3 , wherein at least one R 6 is further substituted with at least one of F, Cl, Br, I or 123 I. In another embodiment, R 6 substituent on R 3 is further substituted with at least one of I or 123 I.
  • the compound of Formula II has one of the following structures from Table 5, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof:
  • the present invention is directed to a pharmaceutical composition, comprising a compound of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, as described herein. In one embodiment, the present invention is directed to a pharmaceutical composition, comprising a compound of Formula I or Formula II, or a pharmaceutically acceptable salt or stereoisomer thereof, as described herein.
  • the pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof further comprises a pharmaceutically acceptable carrier.
  • the pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof further comprises an additional therapeutic agent.
  • the pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof further comprises a pharmaceutically acceptable carrier and an additional therapeutic agent.
  • the pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, further comprises an additional therapeutic agent which is for treating prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration.
  • an additional therapeutic agent which is for treating prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration.
  • one embodiment comprises the use of the disclosed compounds in combination therapy with one or more currently-used or experimental pharmacological therapies which are utilized for treating the above disease states irrespective of the biological mechanism of action of such pharmacological therapies, including without limitation pharmacological therapies which directly or indirectly inhibit the androgen receptor, pharmacological therapies which are cytotoxic in nature, and pharmacological therapies which interfere with the biological production or function of androgen (hereinafter, an “additional therapeutic agent”).
  • combination therapy is meant the administration of any one or more of a compound of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, with one or more of another therapeutic agent to the same patient such that their pharmacological effects are contemporaneous with one another, or if not contemporaneous, that their effects are synergistic with one another even though dosed sequentially rather than contemporaneously.
  • Such administration includes without limitation dosing of one or more of a compound of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, and one or more of the additional therapeutic agent(s) as separate agents without any comingling prior to dosing, as well as formulations which include one or more other androgen-blocking therapeutic agents mixed with one or more compound of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, as a pre-mixed formulation.
  • Administration of the compound(s) of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, in combination with the additional therapeutic agents for treatment of the above disease states also includes dosing by any dosing method including without limitation, intravenous delivery (IV), oral delivery, intra-peritoneal delivery, intra-muscular delivery, or intra-tumoral delivery.
  • IV intravenous delivery
  • oral delivery intra-peritoneal delivery
  • intra-muscular delivery intra-tumoral delivery.
  • the one or more of the additional therapeutic agents can be administered to the patient before administration of the compound(s) of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
  • the compound(s) of Formula I can be co-administered with one or more of the additional therapeutic agents.
  • the one or more additional therapeutic agents can be administered to the patient after administration of the compound(s) of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
  • the ratio of the doses of compound(s) of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to that of the one or more additional therapeutic agents can be about 1:1 or can vary, e.g., about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, and can be varied accordingly to achieve the optimal therapeutic benefit.
  • the compound(s) of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, that are combined with the one or more additional therapeutic agents for improved treatment of the above disease states can comprise, but are not limited to any compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, including those compounds shown in Tables 1, 2, 3, 4, or 5.
  • the additional therapeutic agents include without limitation any pharmacological agent which is currently approved by the FDA in the U.S. (or elsewhere by any other regulatory body) for use as pharmacological treatment of any of the above disease states, or which is currently being used experimentally as part of a clinical trial program that relates to the above disease states.
  • Non-limiting examples of the Other Pharmacological Agents comprise, without limitation: the chemical entity known as ODM-201 (also known as BAY1841788) and related compounds, which appears to bind to the AR and blocks its cellular function, and is currently in clinical development as a treatment for prostate cancer); the chemical entity known as ODM-204 and related compounds, which appears to be a dual inhibitor of AR and CYP17A1 and can be useful for treatment of prostate cancer; the chemical entity known as enzalutamide (4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide) and related compounds, which appears to be a blocker of the androgen receptor (AR) LBD and a FDA-approved treatment for prostate cancer; the chemical entity known as Galeterone and related compounds which appears to be a blocker of the androgen receptor (AR) LBD, and a CYP
  • Galeterone is currently in development as a treatment for prostate cancer; the chemical entity known as ARN-509 or apalutamide (4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide) and related compounds which appears to be a blocker of the androgen receptor (AR) LBD and is currently in development as a treatment for prostate cancer; the chemical entity known as abiraterone (or CB-7630; (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl) 2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol), and related molecules, which appears to block the production of androgen and FDA
  • VPC-14449 (4-(4-(4,5-bromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine) and related compounds, which appears to target the DNA-binding domain of full-length AR and can be useful for treatment of prostate cancer.
  • TAS3681 appears to be an AR antagonist with AR downregulating activity and can be useful for treatment of prostate cancer.
  • sintokamides e.g., sintokamide A also known as N-[(2R,4S)-5,5,5-trichloro-1-[(2S)-2-[(2S)-3,3-dichlororopyl]-3-methoxy-5-oxo-2H-pyrrol-1-yl]-4-methyl-1-oxopentan-2-yl]propanamide
  • sintokamide A also known as N-[(2R,4S)-5,5,5-trichloro-1-[(2S)-2-[(2S)-3,3-dichlororopyl]-3-methoxy-5-oxo-2H-pyrrol-1-yl]-4-methyl-1-oxopentan-2-yl]propanamide
  • the pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, further comprises an additional therapeutic agent selected form the group consisting of enzalutamide, galeterone, abiraterone, bicalutamide, nilutamide, flutamide, cyproterone acetate, docetaxel, bevacizumab (Avastin), OSU-HDAC42, VITAXIN, sunitumib, ZD-4054, Cabazitaxel (XRP-6258), MDX-010 (Ipilimumab), OGX 427, OGX 011, finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 28260, SKF105,111, ODM-201, ODM-204, radium 233, niclosamide, apalutamide, ARV-330,
  • an additional therapeutic agent selected
  • compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, which result in unstable structures and/or unsatisfied valences are not included within the scope of the invention.
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising any of the foregoing compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, and a pharmaceutically acceptable carrier.
  • Compounds as described herein can be in the free form or in the form of a salt thereof.
  • compounds as described herein can be in the form of a pharmaceutically acceptable salt, which are known in the art (Berge et al., J. Pharm. Sci. 1977, 66, 1).
  • Pharmaceutically acceptable salt as used herein includes, for example, salts that have the desired pharmacological activity of the parent compound (salts which retain the biological effectiveness and/or properties of the parent compound and which are not biologically and/or otherwise undesirable).
  • Compounds as described herein having one or more functional groups capable of forming a salt can be, for example, formed as a pharmaceutically acceptable salt.
  • Compounds containing one or more basic functional groups can be capable of forming a pharmaceutically acceptable salt with, for example, a pharmaceutically acceptable organic or inorganic acid.
  • Pharmaceutically acceptable salts can be derived from, for example, and without limitation, acetic acid, adipic acid, alginic acid, aspartic acid, ascorbic acid, benzoic acid, benzenesulfonic acid, butyric acid, cinnamic acid, citric acid, camphoric acid, camphorsulfonic acid, cyclopentanepropionic acid, diethylacetic acid, digluconic acid, dodecylsulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, glucoheptanoic acid, gluconic acid, glycerophosphoric acid, glycolic acid, hemisulfonic acid, heptanoic acid, hexanoic acid, hydrochloric acid, hydrobromic acid, hydriodic
  • Compounds containing one or more acidic functional groups can be capable of forming pharmaceutically acceptable salts with a pharmaceutically acceptable base, for example, and without limitation, inorganic bases based on alkaline metals or alkaline earth metals or organic bases such as primary amine compounds, secondary amine compounds, tertiary amine compounds, quaternary amine compounds, substituted amines, naturally occurring substituted amines, cyclic amines or basic ion-exchange resins.
  • inorganic bases based on alkaline metals or alkaline earth metals or organic bases such as primary amine compounds, secondary amine compounds, tertiary amine compounds, quaternary amine compounds, substituted amines, naturally occurring substituted amines, cyclic amines or basic ion-exchange resins.
  • Pharmaceutically acceptable salts can be derived from, for example, and without limitation, a hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation such as ammonium, sodium, potassium, lithium, calcium, magnesium, iron, zinc, copper, manganese or aluminum, ammonia, benzathine, meglumine, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, isopropylamine, tripropylamine, tributylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, glucamine, methylglucamine, theobromine, purines, piperazine, piperidine, procaine, N-ethylpiperidine, theo
  • compounds as described herein can contain both acidic and basic groups and can be in the form of inner salts or zwitterions, for example, and without limitation, betaines.
  • Salts as described herein can be prepared by conventional processes known to a person skilled in the art, for example, and without limitation, by reacting the free form with an organic acid or inorganic acid or base, or by anion exchange or cation exchange from other salts. Those skilled in the art will appreciate that preparation of salts can occur in situ during isolation and purification of the compounds or preparation of salts can occur by separately reacting an isolated and purified compound.
  • compounds and all different forms thereof can be in the solvent addition form, for example, solvates.
  • Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent in physical association the compound or salt thereof.
  • the solvent can be, for example, and without limitation, a pharmaceutically acceptable solvent.
  • hydrates are formed when the solvent is water or alcoholates are formed when the solvent is an alcohol.
  • compounds and all different forms thereof can include crystalline and amorphous forms, for example, polymorphs, pseudopolymorphs, conformational polymorphs, amorphous forms, or a combination thereof.
  • Polymorphs include different crystal packing arrangements of the same elemental composition of a compound. Polymorphs usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability and/or solubility. Those skilled in the art will appreciate that various factors including recrystallization solvent, rate of crystallization and storage temperature can cause a single crystal form to dominate.
  • compounds and all different forms thereof include isomers such as geometrical isomers, optical isomers based on asymmetric carbon, stereoisomers, tautomers, individual enantiomers, individual diastereomers, racemates, diastereomeric mixtures and combinations thereof, and are not limited by the description of the formula illustrated for the sake of convenience.
  • the present compounds find use in any number of methods.
  • the compounds are useful in methods for modulating androgen receptor (AR).
  • the present disclosure provides the use of any one of the foregoing compounds of Formula I for modulating androgen receptor (AR) activity.
  • modulating androgen receptor (AR) activity is in a mammalian cell.
  • Modulating androgen receptor (AR) can be in a subject in need thereof (e.g., a mammalian subject) and for treatment of any of the described conditions or diseases.
  • modulating androgen receptor (AR) activity is for treatment of at least one indication selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, age related macular degeneration, and combinations thereof.
  • the indication is prostate cancer.
  • the prostate cancer is primary/localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, advanced prostate cancer, or metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer. While in other embodiments, the prostate cancer is androgen dependent prostate cancer. In other embodiments, the spinal and bulbar muscular atrophy is Kennedy's disease.
  • compounds as described herein can be administered to a subject.
  • the present invention is directed to a method of treating primary/localized prostate cancer comprising administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
  • the present invention is directed to a method of treating locally advanced prostate cancer comprising administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
  • the present invention is directed to a method of treating recurrent prostate cancer comprising administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
  • the present invention is directed to a method of treating metastatic prostate cancer comprising administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
  • the present invention is directed to a method of treating advanced prostate cancer comprising administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
  • the present invention is directed to a method of treating metastatic castration-resistant prostate cancer (CRPC) comprising administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
  • CRPC metastatic castration-resistant prostate cancer
  • the present invention is directed to a method of treating hormone-sensitive prostate cancer comprising administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
  • the present disclosure provides a method of modulating androgen receptor (AR) activity, the method comprising administering any one of the foregoing compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, or pharmaceutical composition of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, as described herein (including compositions comprising a compound of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, and an additional therapeutic agent), to a subject (e.g., mammal) in need thereof.
  • modulating androgen receptor (AR) activity is in a mammalian cell.
  • modulating androgen receptor (AR) activity is in a mammal.
  • modulating androgen receptor (AR) activity is in a human.
  • the modulating androgen receptor (AR) activity can be for inhibiting AR N-terminal domain activity.
  • the modulating androgen receptor (AR) activity can be for inhibiting androgen receptor (AR) activity.
  • the modulating can be in vivo.
  • the modulating androgen receptor (AR) activity can be for treatment of at least one indication selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy (e.g., Kennedy's disease), and age related macular degeneration.
  • prostate cancer breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycys
  • the indication can be prostate cancer.
  • the prostate cancer can be castration-resistant prostate cancer.
  • the prostate cancer is primary/localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, advanced prostate cancer, or metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer.
  • the prostate cancer can be CRPC.
  • a method of modulating androgen receptor activity comprising administering Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, or pharmaceutical composition of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, as described herein, is provided.
  • the administration can be to a mammal.
  • the administering can be to a mammal in need thereof and in an effective amount for the treatment of at least one indication selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy (e.g., Kennedy's disease), age related macular degeneration, and combinations thereof.
  • at least one indication selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy (e.g., Kennedy's disease), age related macular degeneration, and combinations thereof
  • the presently disclosed compounds can find utility in a number of medical imaging applications, including imaging of the prostate.
  • Many currently available imaging agents tend to accumulate in the bladder, which decreases their effectiveness as imaging tools specifically for the prostate.
  • the present applicants believe the disclosed compounds are unexpectedly effective for imaging of the prostate due to their ability to accumulate in the prostate, rather than the bladder, allowing the prostate gland to be seen.
  • the compounds can be used in methods for imaging the prostate, for example to image benign prostate diseases.
  • the compounds can be used in methods to image cancerous prostate diseases, such as tumors of the prostate.
  • Androgen ablation therapy causes a temporary reduction in prostate cancer tumor burden, but the malignancy will begin to grow again in the absence of testicular androgens to form castrate resistant prostate cancer (CRPC).
  • CRPC castrate resistant prostate cancer
  • PSA serum prostate-specific antigen
  • AR androgen receptor
  • the method identifies the presence of a tumor that expresses AR (both full-length and truncated AR lacking LBD) and then treats the tumor by radiotherapy.
  • the imaging methods provide information to determine if a tumor expresses AR species.
  • AR is a transcription factor and a validated target for prostate cancer therapy.
  • Current therapies include androgen ablation and administration of antiandrogens.
  • Most CRPC is suspected to be AR-dependent.
  • AR has distinct functional domains that include the C-terminus ligand-binding domain (LBD), a DNA-binding domain (DBD), and an amino-terminal domain (NTD).
  • LBD C-terminus ligand-binding domain
  • DBD DNA-binding domain
  • NTD amino-terminal domain
  • AR NTD contains activation function-1 (AF-1) that contributes most of the transcriptional activity to the AR.
  • AF-1 activation function-1
  • Recently, splice variants of the AR that lack the LBD have been reported in prostate cancer cell lines (VCaP, LNCaP95 and 22Rv1), and in CRPC tissues. To date more than 20 splice variants of AR have been detected.
  • Splice variants V7 and V567es are clinically relevant with levels of expression correlated to poor survival and CRPC.
  • AR V567es is solely expressed in 20% of metastases. Abiraterone resistance is associated with expression of AR splice variants.
  • Enzalutamide also increases levels of expression of these constitutively active AR splice variants.
  • These splice variants lack LBD and thereby would not be inhibited by current therapies that target the AR LBD such as antiandrogens or androgen ablation therapy.
  • a single patient with advanced prostate cancer can have many lesions throughout the body and skeleton and each tumor can have differing levels of expression of AR.
  • Biopsy of metastatic tumors in a patient to determine AR species is neither widely accessible nor feasible to sample tumors in a patient that can have multiple metastases.
  • certain embodiments of the present invention provide an AR NTD-targeted molecular imaging probe (e.g., compound of formula I) which can be used to monitor response to therapy and provide insight into the role of AR in resistance mechanisms.
  • the invention employs sequential imaging with 18 F-FDHT to detect full-length AR and gamma radiation emitting probes to specifically detect the AR NTD which would be the sum of both full-length AR and variant AR.
  • the invention employs sequential imaging with two different PET imaging agents to detects only full-length AR and another to specifically detect the AR NTD which would be the sum of both full-length AR and variant AR.
  • NTD variant plus full-length AR detected with NTD isotope minus full-length AR detected with 18 F-FDHT.
  • a discordant distribution or discordant level of uptake between 18 F-FDHT and a radiolabeled compound of this invention indicates the presence of overexpression of splice variants lacking the LBD.
  • radioactive 18 F labeled compounds have found use as imaging agents not only to image AR in prostate cancer but for imaging various organs and various tumors.
  • radioactive 123 I labeled compounds have been known for the use as imaging agents.
  • the compounds of the present disclosure comprise at least one 123 I.
  • the present invention is directed to a method of imaging cancer by administering a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a subject.
  • the present invention is directed to a method of imaging cancer by administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a subject.
  • the method of imaging cancer by administering a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, or a pharmaceutical composition comprising Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a subject and detecting the presence or absence of cancer by use of SPECT or PET.
  • the method of imaging cancer by administering a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a subject and the method identifies the presence or absence of a tumor.
  • the method of imaging cancer by administering a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a subject and the method identifies the location of a tumor.
  • the method of imaging cancer by administering a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a subject and the method identifies a presence of a prostate cancer.
  • the prostate cancer is androgen-dependent prostate cancer.
  • the subject is a mammal such as a human.
  • the method is useful for detecting the presence of AR splice variants or other AR species that cannot be detected by imaging agents that interact with the AR LBD (i.e., mutations, truncations).
  • the present compounds bind to the AR N-terminal domain (NTD)
  • the present methods can be useful for detecting AR species, including mutants and variants, which lack the LBD or have LBD mutations, but do comprise the AR NTD.
  • the method detects the presence or overexpression of AR splice variants lacking the ligand-binding domain.
  • the method can include sequential imaging with 18 F-FDHT and a compound of the invention and a discordant distribution or discordant level of uptake between 18 F-FDHT and the compound of the invention indicates the presence or overexpression of splice variants lacking the ligand-binding domain.
  • the compounds of the invention are used in single photon emission computed tomography methods to monitor a patient's response to therapy.
  • the methods comprise use of a compound of the invention to detect the AR NTD.
  • the method of imaging a cancer is by administering a compound as described anywhere herein.
  • the method of imaging a cancer is by administering a compound of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein said compound comprises at least one 123 I.
  • the administering and imaging can be to a mammal in need of diagnosis of at least one indication selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, benign prostatic hyperplasia, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy (e.g., Kennedy's disease), and age-related macular degeneration.
  • the imaging can be for imaging AR splice variants, mutants or other AR species which contain AR NTD.
  • the compounds as described herein or pharmaceutically acceptable salts thereof can be used for imaging and diagnosis of at least one indication selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, benign prostatic hyperplasia, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, and age-related macular degeneration.
  • the compounds as described herein or acceptable salts thereof above can be used in the preparation of a medicament or a composition for imaging the prostate, for example for imaging benign prostate conditions or for imaging prostate cancer in a subject in need of such imaging (for example for diagnosis and/or location of prostate tumors).
  • compositions useful in modulating androgen receptor (AR) activity or useful for imaging can comprise a salt of such a compound, preferably a pharmaceutically or physiologically acceptable salt.
  • compositions will typically comprise one or more carriers, excipients or diluents acceptable for the mode of administration of the preparation, be it by injection, inhalation, topical administration, lavage, or other modes suitable for the selected treatment.
  • Suitable carriers, excipients or diluents are those known in the art for use in such modes of administration.
  • the imaging method disclosed herein is directed to imaging prostate cancer.
  • the prostate cancer is primary/localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, advanced prostate cancer, or metastatic castration-resistant prostate cancer (CRPC), and hormone-sensitive prostate cancer.
  • the prostate cancer is CRPC.
  • the imaging is for imaging benign prostate conditions such as benign prostatic hyperplasia. Methods of imaging and/or treating any of the indications described herein are also provided. Such methods may include administering a compound as described herein or a composition of a compound as described herein, or an effective amount of a compound as described herein or composition of a compound as described herein to a subject in need thereof.
  • a pharmaceutical composition suitable for imaging is administered intravenously.
  • Suitable pharmaceutical compositions can be formulated by means known in the art and their mode of administration and dose determined by the skilled practitioner.
  • a compound can be dissolved in sterile water or saline or a pharmaceutically acceptable vehicle used for administration of non-water soluble compounds such as those used for vitamin K.
  • the compound can be administered in a tablet, capsule or dissolved in liquid form.
  • the tablet or capsule can be enteric coated, or in a formulation for sustained release.
  • Many suitable formulations are known, including, polymeric or protein microparticles encapsulating a compound to be released, ointments, pastes, gels, hydrogels, or solutions which can be used topically or locally to administer a compound.
  • a sustained release patch or implant can be employed to provide release over a prolonged period of time.
  • Many techniques known to one of skill in the art are described in Remington: the Science & Practice of Pharmacy by Alfonso Gennaro, 20 th ed., Lippencott Williams & Wilkins, (2000).
  • Formulations for parenteral administration can, for example, contain excipients, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes.
  • Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers can be used to control the release of the compounds.
  • Formulations for inhalation can contain excipients, for example, lactose, or can be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or can be oily solutions for administration in the form of nasal drops, or as a gel.
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound as described herein, and an additional therapeutic agent and/or a pharmaceutically acceptable carrier.
  • the additional therapeutic agent is for treating prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy or age related macular degeneration.
  • the additional therapeutic agent is enzalutamide, galeterone, ODN-201 abiraterone, bicalutamide, nilutamide, flutamide, cyproterone acetate, docetaxel, Bevacizumab (Avastin), OSU-HDAC42, VITAXIN, sunitumib, ZD-4054, Cabazitaxel (XRP-6258), MDX-010 (Ipilimumab), OGX 427, OGX 011, finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 28260, SKF105,111, ODM-201 ODM-204, niclosamide, apalutamide, ARV-330, VPC-14449, TAS3681, 3E10-AR441bsAb, sintokamide, or related compounds thereof.
  • Ligand-independent activation of the androgen receptor (AR) refers to transactivation of the full-length androgen receptor (AR) in the absence of androgen (ligand) by, for examples, stimulation of the cAMP dependent protein kinase (PKA) pathway or the interleukin-6 (IL6)/STAT3 pathway.
  • PKA cAMP dependent protein kinase
  • IL6 interleukin-6
  • Such compounds should block a mechanism that is common to both ligand-dependent and ligand-independent activation of the androgen receptor (AR), as well as constitutively active splice variants of the androgen receptor (AR) that lack ligand-binding domain.
  • This could involve any step in activation of the androgen receptor (AR) including dissociation of heatshock proteins, essential posttranslational modifications (e.g., acetylation, phosphorylation), nuclear translocation, protein-protein interactions, formation of the transcriptional complex, release of co repressors, and/or increased degradation.
  • Numerous disorders in addition to prostate cancer involve the androgen axis (e.g., acne, hirsutism, alopecia, benign prostatic hyperplasia) and compounds interfering with this mechanism can be used to treat such conditions.
  • Compounds or pharmaceutical compositions in accordance with this invention or for use in this invention can be administered by means of a medical device or appliance such as an implant, graft, prosthesis, stent, etc.
  • a medical device or appliance such as an implant, graft, prosthesis, stent, etc.
  • implants can be devised which are intended to contain and release such compounds or compositions.
  • An example would be an implant made of a polymeric material adapted to release the compound over a period of time.
  • dosage values can vary with the exact imaging protocol.
  • specific dosage regimens can be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.
  • Dosage ranges set forth herein are exemplary only and do not limit the dosage ranges that can be selected by medical practitioners.
  • the amount of active compound(s) in the composition can vary according to factors such as the disease state, age, sex, and weight of the subject. Dosage regimens can be adjusted to provide the optimum imaging result. For example, a single bolus can be administered, several divided doses can be administered over time or the dose can be proportionally reduced or increased as indicated by the imaging results. It can be advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
  • Toxicity of the compounds of the invention can be determined using standard techniques, for example, by testing in cell cultures or experimental animals and determining the therapeutic index, i.e., the ratio between the LD50 (the dose lethal to 50% of the population) and the LD100 (the dose lethal to 100% of the population). In some circumstances, such as in severe disease conditions, substantial excesses of the compositions can be administered for therapeutic effects. Some compounds of this invention can be toxic at some concentrations. Titration studies can be used to determine toxic and non-toxic concentrations. Toxicity can be evaluated by examining a particular compound's or composition's specificity across cell lines using PC3 or DU145 cells as possible negative controls since these cells do not express functional AR. Animal studies can be used to provide an indication if the compound has any effects on other tissues. Systemic therapy that targets the AR will not likely cause major problems to other tissues since castration, antiandrogens and androgen insensitivity syndrome are not fatal.
  • compounds and all different forms thereof as described herein can be used, for example, and without limitation, in combination with other treatment methods for at least one indication selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, and age related macular degeneration.
  • compounds and all their different forms as described herein can be used as neoadjuvant (prior), adjunctive (during), and/or adjuvant (after) therapy with surgery, radiation (brachytherapy or external beam), or other therapies (eg. HIFU), and in combination with chemotherapies, androgen ablation, antiandrogens or any other therapeutic approach.
  • a dose of the disclosed compounds in solution (typically 5 to 10 millicuries or 200 to 400 MBq) is typically injected rapidly into a saline drip running into a vein, in a patient. Then, the patient is placed in the SPECT for a series of one or more scans which can take from 20 minutes to as long as an hour (often, only about one quarter of the body length can be imaged at a time). Methods for SPECT scanning are well known in the art.
  • the compounds described herein can be used for in vivo or in vitro research uses (i.e. non-clinical) to investigate the mechanisms of orphan and nuclear receptors (including steroid receptors such as androgen receptor (AR)). Furthermore, these compounds can be used individually or as part of a kit for in vivo or in vitro research to investigate signal transduction pathways and/or the activation of orphan and nuclear receptors using recombinant proteins, cells maintained in culture, and/or animal models.
  • orphan and nuclear receptors including steroid receptors such as androgen receptor (AR)
  • AR steroid receptor
  • these compounds can be used individually or as part of a kit for in vivo or in vitro research to investigate signal transduction pathways and/or the activation of orphan and nuclear receptors using recombinant proteins, cells maintained in culture, and/or animal models.
  • exemplary compounds of the present invention can be prepared with reference to the following General Reaction Scheme I:
  • step a (2,2-dimethyl-1,3-dioxolan-4-yl)methanol is toslyated under basic conditions as shown in step a.
  • step c the bisphenol derivative is halogenated on the phenyl ring (e.g., Y and Z can be Cl or Br).
  • step d the unreacted phenol portion undergoes another elimination reaction to afford a bisphenol derivative with an epoxide on one side and a protected diol on the other.
  • step e epoxide is opened using CeCl 3 .7H 2 O and the diol is deprotected in situ.
  • protecting group strategies can be employed for preparation of the compounds disclosed herein. Such strategies are well known to those of skill in the art. Exemplary protecting groups and related strategies are disclosed in Greene's Protective Groups in Organic Synthesis, Wiley-InterScience; 4 edition (Oct. 30, 2006), which is hereby incorporated by reference in its entirety. In certain embodiments, a protecting group is used to mask an alcohol moiety while performing other chemical transformations. After removal of the protecting group, the free hydroxyl is obtained. Such protecting groups and strategies are well known in the art.
  • Thin-layer chromatography plates were visualized by exposure to ultraviolet light and a “Seebach” staining solution (700 mL water, 10.5 g Cerium (IV) sulphate tetrahydrate, 15.0 g molybdato phosphoric acid, 17.5 g sulphuric acid) followed by heating ( ⁇ 1 min) with a heating gun ( ⁇ 250° C.).
  • Organic solutions were concentrated on Buchi R-114 rotatory evaporators at reduced pressure (15-30 torr, house vacuum) at 25-40° C.
  • Steps a and b Synthesis of (S)-4-(2-(4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)propan-2-yl)phenol
  • Step c (S)-2,6-dichloro-4-(2-(4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)propan-2-yl)phenol
  • Step d (S)-4-((4-(2-(3,5-dichloro-4-(((R)-oxiran-2-yl)methoxy)phenyl)propan-2-yl)phenoxy)methyl)-2,2-dimethyl-1,3-dioxolane
  • Step e Synthesis of (R)-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propane-1,2-diol (Compound 1a)
  • Step a Synthesis of (S)-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)-2-hydroxypropyl 4-methylbenzenesulfonate
  • the titled compound was synthesized by tosylation of Compound 1a under basic conditions according to commonly known protocol, such as the protocol referenced for step a in Example 1.
  • Step b Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-(((R)-oxiran-2-yl)methoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol
  • Step c Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)-2-hydroxy-3-methoxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (Compound 5a)
  • Example 8 Synthesis of (R)-1-amino-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (Compound 12a) and N—((R)-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)-2-hydroxypropyl)methanesulfonamide (Compound 13a)
  • Step a Synthesis of (R)-1-azido-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol
  • Step b Synthesis of (R)-1-amino-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (Compound 12a)
  • Step c Synthesis of N—((R)-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)-2-hydroxypropyl)methanesulfonamide (Compound 13a)
  • Step a Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-(((R)-3-(ethylthio)-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol
  • Step b Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)-3-(ethylsulfonyl)-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (Compound 14a)
  • Compound 22a was synthesized according to Example 1 by using 4,4′-(Propane-2,2-diyl)bis(2-methylphenol) (commercially available) instead of 4,4′-(propane-2,2-diyl)diphenol and omitting step c.
  • Compound 40a was synthesized according to Example 1 by using 4,4′-sulfonyldiphenol instead of 4,4′-(propane-2,2-diyl)diphenol and with only 1 equiv of NaCl in step c.
  • Compound 41a was synthesized according to Example 1 by using 4,4′-sulfonyldiphenol instead of 4,4′-(propane-2,2-diyl)diphenol.
  • Compound 48a was synthesized according to Examples 3 and 6 by starting with Compound 41a.
  • Acetic Anhydride (4.1 mg, 0.04 mmol, 4.0 equiv) was added to a solution of Compound 5a (5.0 mg, 0.01 mmol, 1.0 equiv, see Example 3), DMAP (0.1 mg, 0.001 mmol, 0.1 equiv) and Et3N (4.1 mg, 0.04 mmol, 4.0 equiv) in anhydrous dichloromethane (1 mL). The resulting solution was stirred overnight at room temperature. Dichloromethane was removed under reduced pressure and the residue was purified by column chromatography to afford the title compound as a colorless oil (5.8 mg, 98.6%).
  • Compound A1a was synthesized according to Examples 21 by using Compound 1a prepared according to Example 1.
  • Compound A1a was obtained as a colorless oil (63.0 mg, 97.1%).
  • LNCaP cells (3 ⁇ 10 4 ) were seeded into 24-well plates overnight. Next day, LNCaP cells were transiently transfected with 0.25 ⁇ g/well of PSA (6.1 kb)-luciferase reporter plasmid prior to pre-treatment with compounds of the invention or reference compounds (e.g., compounds A, B, C, 1a, 5a, 9a, 11a, 12a, 13a, and 14a) ranging in concentration from 0 ⁇ M to 35 ⁇ M for 1 hour before the addition of vehicle, or synthetic androgen, R1881 (1 nM) to induce luciferase production. After 48 h of exposure, cells were harvested in Passive lysis buffer (Promega).
  • PSA 6.1 kb
  • Luciferase activities were measured and normalized to protein concentration determined by the Bradford assay. IC 50 calculations were done using OriginPro 8.1 Software (Northampton, Mass., USA). Transfection experiments to determine IC 50 values were performed in at least 4 independent experiments (“trials”) using triplicate wells. Dose responses of representative compounds are shown in FIG. 2 . Luciferase activity is presented as the mean ⁇ standard deviation of the technical replicates.
  • Example 30 Compound 1a Treatment in LNCaP Xenograft Model
  • LNCaP cells were passaged prior to seeding in T175flasks at a concentration of ⁇ 2-3 ⁇ 10 7 /mL. The cells were grown for 7 days until 90% confluent. Cell preparations were then prepared in RPMI with 5% FBS/Matrigel (50/50, v/v) yielding a final concentration of 1 ⁇ 10 8 /mL.
  • NOD-SCID mice Six to eight week old NOD-SCID mice were received from BC Cancer Research Centre's Animal Resource Centre and acclimated for 28 days. Tumors were initiated with sub-cutaneous back of each animal. Tumors were allowed to grow to an average size of approximately 100 mm 3 . Mice were then castrated and the tumors allowed to adapt for a period of one week before first dose was administered. Tumor volume was measured as length ⁇ width ⁇ height in mm multiplied by 0.5236.
  • Compound 1a was dissolved in 100% DMSO (ATCC Lot 61908420) to yield a stock solution of 157 mg/mL.
  • Compound 1a was administered as an oral gavage once per day at dose levels of 10 and 30 mg/kg.
  • Vehicle control animals were administered 1% CMC formulation as an oral gavage once daily.
  • Oral treatment was initiated one week after castration. The start of treatment was designated “Day 1” and animals were treated once daily for a total of 24 doses. Two days after the last dose, the tumours were measured and harvested. Body weight was assessed daily throughout the treatment period. Tumor volume was measured on day ⁇ 7 (castration day), and again on days 1, 4, 8, 12, 16, 20, 24 and 26.
  • LNCaP xenografts were homogenized using TRIzol® reagent (InvitrogenTM), and total RNA was extracted using PureLink RNA Mini Kit (Life Technologies). Amplification Grade DNase I treatment (Sigma-Aldrich) was applied to the RNA before RT-PCR using High Capacity RNA-to-DNA kit (Life Technologies) to generate cDNA. cDNA and gene-specific primers were combined with Platinum® SYBR® Green qPCRSuperMix-UDG with ROX (InvitrogenTM). Transcripts were measured by quantitative real-time PCR (QPCR) using ABI PRISM 7900 Sequence Detection System (ABI PRISM®, Applied Biosystems by Life Technologies) in triplicates for each biological sample.
  • QPCR quantitative real-time PCR
  • Compound 1a demonstrated a dose-dependent inhibition of the mRNA expression of PSA, as 30 mg/kg treatment of Compound 1a caused a significant reduction of PSA expression when compared to the 10 mg/kg dose and control treatment. Together, these data indicated that Compound 1a significantly reduced the castration-resistant growth of LNCaP tumors, while demonstrating on-target activity to block androgen receptor transcriptional activity.
  • One-way ANOVA post-hoc Tukey's multiple comparisons test was performed for statistical analysis. *p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.001.

Abstract

Compounds having a structure of Formula I:
Figure US20170298033A1-20171019-C00001
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application claims the benefit of priority to U.S. Provisional Application No. 62/323,196, filed on Apr. 15, 2016 and entitled “BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS,” the disclosure of which is hereby incorporated by reference in its entirety for all purposes.
    • STATEMENT OF GOVERNMENT INTEREST
  • This invention was made in part with government support under Grant No. 2R01 CA105304 awarded by the National Cancer Institute. The United States Government has certain rights in this invention.
    • TECHNICAL FIELD
  • This invention generally relates to bisphenol-related compounds and their use for treatment of various indications. In particular the invention relates to bisphenol ether compounds having halogenated phenyl groups and/or sulfone linking groups and their use for treatment of various cancers, for example prostate cancer, including but not limited to, primary/localized prostate cancer (newly diagnosed), locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, metastatic castration-resistant prostate cancer (CRPC), and hormone-sensitive prostate cancer. This invention also relates to bisphenol-related compounds and their use for modulating androgen receptor (AR) activity including truncated AR.
    • DESCRIPTION OF THE RELATED ART
  • Androgens mediate their effects through the androgen receptor (AR). Androgens play a role in a wide range of developmental and physiological responses and are involved in male sexual differentiation, maintenance of spermatogenesis, and male gonadotropin regulation (R. K. Ross, G. A. Coetzee, C. L. Pearce, J. K. Reichardt, P. Bretsky, L. N. Kolonel, B. E. Henderson, E. Lander, D. Altshuler & G. Daley, Eur Urol 35, 355 361 (1999); A. A. Thomson, Reproduction 121, 187 195 (2001); N. Tanji, K. Aoki & M. Yokoyama, Arch Androl 47, 1 7 (2001)). Several lines of evidence show that androgens are associated with the development of prostate carcinogenesis. Firstly, androgens induce prostatic carcinogenesis in rodent models (R. L. Noble, Cancer Res 37, 1929 1933 (1977); R. L. Noble, Oncology 34, 138 141 (1977)) and men receiving androgens in the form of anabolic steroids have a higher incidence of prostate cancer (J. T. Roberts & D. M. Essenhigh, Lancet 2, 742(1986); J. A. Jackson, J. Waxman & A. M. Spiekerman, Arch Intern Med 149, 2365 2366 (1989); P. D. Guinan, W. Sadoughi, H. Alsheik, R. J. Ablin, D. Alrenga & I. M. Bush, Am J Surg 131, 599 600 (1976)). Secondly, prostate cancer does not develop if humans or dogs are castrated before puberty (J Clin Endocrinol Metab 84, 4324-4331 (1999); G. Wilding, Cancer Surv 14, 113-130 (1992)). Castration of adult males causes involution of the prostate and apoptosis of prostatic epithelium while eliciting no effect on other male external genitalia (E. M. Bruckheimer & N. Kyprianou, Cell Tissue Res 301, 153-162 (2000); J. T. Isaacs, Prostate 5, 545-557 (1984)). This dependency on androgens provides the underlying rationale for treating prostate cancer with chemical or surgical castration (androgen ablation).
  • Androgens also play a role in female diseases such as polycystic ovary syndrome as well as cancers. One example is ovarian cancer where elevated levels of androgens are associated with an increased risk of developing ovarian cancer (K. J. Helzlsouer, A. J. Alberg, G. B. Gordon, C. Longcope, T. L. Bush, S. C. Hoffman & G. W. Comstock, JAMA 274, 1926-1930 (1995); R. J. Edmondson, J. M. Monaghan & B. R. Davies, Br J Cancer 86, 879-885 (2002)). The AR has been detected in a majority of ovarian cancers (H. A. Risch, J Natl Cancer Inst 90, 1774-1786 (1998); B. R. Rao & B. J. Slotman, Endocr Rev 12, 14-26 (1991); G. M. Clinton & W. Hua, Crit Rev Oncol Hematol 25, 1-9 (1997)), whereas estrogen receptor-alpha (ERa) and the progesterone receptor are detected in less than 50% of ovarian tumors.
  • The only effective treatment available for advanced prostate cancer is the withdrawal of androgens which are essential for the survival of prostate luminal cells. Androgen ablation therapy causes a temporary reduction in tumor burden concomitant with a decrease in serum prostate-specific antigen (PSA). Unfortunately prostate cancer can eventually grow again in the absence of testicular androgens (castration-resistant disease) (Huber et al 1987 Scand J. Urol Nephrol. 104, 33-39). Castration-resistant prostate cancer that is still driven by AR is biochemically characterized before the onset of symptoms by a rising titre of serum PSA (Miller et al 1992 J. Urol. 147, 956-961). Once the disease becomes castration-resistant most patients succumb to their disease within two years.
  • The AR has distinct functional domains that include the carboxy-terminal ligand-binding domain (LBD), a DNA-binding domain (DBD) comprising two zinc finger motifs, and an N-terminus domain (NTD) that contains two transcriptional activation units (tau1 and tau5) within activation function-1 (AF-1). Binding of androgen (ligand) to the LBD of the AR results in its activation such that the receptor can effectively bind to its specific DNA consensus site, termed the androgen response element (ARE), on the promoter and enhancer regions of androgen regulated genes, such as PSA, to initiate transcription. The AR can be activated in the absence of androgen by stimulation of the cAMP-dependent protein kinase (PKA) pathway, with interleukin-6 (IL-6) and by various growth factors (Culig et al 1994 Cancer Res. 54, 5474-5478; Nazareth et al 1996 J. Biol. Chem. 271, 19900-19907; Sadar 1999 J. Biol. Chem. 274, 7777-7783; Ueda et al 2002 A J. Biol. Chem. 277, 7076-7085; and Ueda et al 2002 B J Biol. Chem. 277, 38087-38094).
  • Clinically available inhibitors of the AR include nonsteroidal antiandrogens such as bicalutamide (Casodex™), nilutamide, flutamide, and enzalutamide. There is also a class of steroidal antiandrogens, such as cyproterone acetate and spironolactone. Both steroidal and non-steroidal antiandrogens target the LBD of the AR and predominantly fail presumably due to poor affinity, mutations that lead to activation of the AR by these same antiandrogens (Taplin, M. E., Bubley, G. J., Kom Y. J., Small E. J., Uptonm M., Rajeshkumarm B., Balkm S. P., Cancer Res., 59, 2511-2515 (1999)), and constitutively active AR splice variants. Antiandrogens have no effect on the constitutively active AR splice variants that lack the ligand-binding domain (LBD) and are associated with castration-recurrent prostate cancer (Dehm S M, Schmidt L J, Heemers H V, Vessella R L, Tindall D J., Cancer Res 68, 5469-77, 2008; Guo Z, Yang X, Sun F, Jiang R, Linn D E, Chen H, Chen H, Kong X, Melamed J, Tepper C G, Kung H J, Brodie A M, Edwards J, Qiu Y., Cancer Res. 69, 2305-13, 2009; Hu et al 2009 Cancer Res. 69, 16-22; Sun et al 2010 J Clin Invest. 2010 120, 2715-30) and resistant to abiraterone and enzalutamide (Antonarakis et al., N Engl J Med. 2014, 371, 1028-38; Scher et al JAMA Oncol. 2016 doi: 10.1001).
  • AR antagonists other than the bisphenol ether derivatives previously reported (see, WO 2010/000066, WO 2011/082487; WO 2011/082488; WO 2012/145330; WO 2015/031984; WO 2016/058080; WO 2016/058082, WO 2016/112455, and WO 2016/141458 which are hereby incorporated by reference in their entireties, to the British Columbia Cancer Agency Branch and The University of British Columbia) that bind to full-length AR and/or truncated AR splice variants that are currently being developed include: AR degraders such as niclosamide (Liu C et al 2014), galeterone (Njar et al 2015; Yu Z at al 2014), and ARV-330 Androgen receptor PROTAC (Neklesa et al 2016 J Clin Oncol 34 suppl 2S; abstr 267); AR DBD inhibitor VPC-14449 (Dalal K et al 2014 J Biol Chem. 289(38):26417-29; Li H et al 2014 J Med Chem. 57(15):6458-67); antiandrogens apalutamide (Clegg N J et al 2012), ODM-201 (Moilanen A M et al 2015), ODM-204 (Kallio et al J Clin Oncol 2016 vol. 34 no. 2_suppl 230), TAS3681 (Min amiguchi et at 2015 J Clin Oncol 33, suppl 7; abstr 266); and AR NTD inhibitors 3E10-AR441bsAb (Goicochea N L et al 2015), and sintokamide (Sadar et al 2008; Banuelos et al 2016).
  • The AR-NTD is also a target for drug development (e.g. WO 2000/001813), since the NTD contains Activation-Function-1 (AF-1) which is the essential region required for AR transcriptional activity (Jenster et al 1991. Mol Endocrinol. 5, 1396-404). The AR-NTD importantly plays a role in activation of the AR in the absence of androgens (Sadar, M. D. 1999 J. Biol. Chem. 274, 7777-7783; Sadar M D et al 1999 Endocr Relat Cancer. 6, 487-502; Ueda et al 2002 J. Biol. Chem. 277, 7076-7085; Ueda 2002 J. Biol. Chem. 277, 38087-38094; Blaszczyk et al 2004 Clin Cancer Res. 10, 1860-9; Dehm et al2006 J Biol Chem. 28, 27882-93; Gregory et al 2004 J Biol Chem. 279, 7119-30). The AR-NTD is important in hormonal progression of prostate cancer as shown by application of decoy molecules (Quayle et al 2007, Proc Natl Acad Sci USA. 104, 1331-1336).
  • While the crystal structure has been resolved for the AR C-terminus LBD, this has not been the case for the NTD due to its high flexibility and intrinsic disorder in solution (Reid et al 2002 J. Biol. Chem. 277, 20079-20086) thereby hampering virtual docking drug discovery approaches.
  • While significant advances have been made in this field, there remains a need for improved treatment for prostate cancer, especially metastatic castration-resistant prostate cancer.
    • BRIEF SUMMARY
  • The present disclosure is based in part on the surprising discovery that the compounds described herein, can be used to modulate AR activity either in vivo or in vitro for both research and therapeutic uses. In some embodiments, certain compounds disclosed herein are useful for imaging the prostate. The imaging can be for any number of diagnostic purposes. For example, in certain embodiments the compounds are useful for imaging benign prostate cancer diseases. In other embodiments, the compounds find utility for imaging of certain cancers, including prostate cancer since certain embodiments of the compounds localize in prostate tumor sites. Other imaging agents are androgen mimics; however, in one embodiment, the compounds are useful for imaging AR splice variants or any AR species (i.e., those mutated in other domains or regions). The AR can be mammalian. For example, the AR can be human. The prostate cancer can be castration-resistant prostate cancer. The prostate cancer can be androgen-dependent prostate cancer.
  • In one embodiment, the present disclosure relates to compounds of Formula (I):
  • Figure US20170298033A1-20171019-C00002
  • or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
  • X is —S(O)n— or —C(R8R9)—;
  • R1 is H, hydroxyl or OC(═O)R13;
  • R2 is hydroxyl or OC(═O)R13;
  • R3 is halo, —OH, —OR4; OC(═O)R13, —NH2, —NHS(O)nR5, —N(C1-C6 alkyl)S(O)nR5, —S(O)nR5, —N3, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R6;
  • R4 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R6;
  • R5 is each independently C1-C6 alkyl or aryl which are optionally substituted with one or more R6;
  • R6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123I, hydroxyl, oxo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C6-C12 aryl, wherein each R6 is optionally substituted with one or more of halogen, 123I, 18F, hydroxyl, —OS(O)2-aryl, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
  • R8 and R9 are each independently H or C1-C6 alkyl;
  • R11a, R11b, R11c and R11d are each independently H, methyl, F, Cl, Br, I, or 123I;
  • R13 is C1-C6 alkyl; and
  • n is 0, 1, or 2;
  • wherein at least one of R11a, R11b, R11c and R11d is methyl F, Cl, Br, I, or 123I.
  • In some embodiments, at least two of R11a, R11b, R11c and R11d in Formula I are independently methyl, F, Cl, Br, I, or 123I. In other embodiments, any two of R11a, R11b, R11c and R11d are independently methyl, F, Cl, Br, I, or 123I and the remaining two of R11a, R11b, R11c and R11d are each H. In one embodiment, R11a and R11b are each H, and R11c and R11d are each independently methyl, F, Cl, Br, I, or 123I. In another embodiment, R11a and R11b are each H, and R11c and R11d are each independently methyl, Cl, or Br. In a certain embodiment, R11a and R11b are each H, and R11c and R11d are each Cl.
  • In one embodiment, R11a and R11c in Formula I are each H, and R11b and R11d in Formula I are each independently methyl, F, Cl, Br, I, or 123I. In some embodiments, R11a and R11c are each H, and R11b and R11d are each independently methyl, Cl, or Br. In another embodiment, R11a and R11c are each H, and R11b and R11d are each Cl.
  • In some embodiments, X in Formula I is —S(O)2—. In another embodiment, X in Formula I is —C(R8R9)— and R8 and R9 are each independently C1-C3 alkyl. In one embodiment, X is —C(R8R9)— and R8 and R9 are each methyl.
  • In some embodiments, R1 in Formula I is hydroxyl or OC(═O)R13. In another embodiment R1 is H.
  • In some embodiments, R3 in Formula I is —OH. In another embodiment, R3 is —OC(═O)R13, wherein R13 is methyl. In one embodiment, R3 is —OR4 and R4 is C1-C6 alkyl. In other embodiments, R3 is —OR4 and R4 is methyl.
  • In one embodiment, R3 in Formula I is an optionally substituted 5 or 6 membered heteroaryl or an optionally substituted 3 to 7 membered heterocylyl, wherein said heteroaryl or said heterocyclyl respectively comprise at least one N atom. In another embodiment, R3 is selected from a group consisting of pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, oxazine, triazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, and tetrazine.
  • In one embodiment, each R13 in Formula I when present is C1-C3 alkyl. In a further embodiment, each R13 when present is methyl.
  • In one embodiment, R1 and R2 in Formula I are each independently —OH or —OC(═O)R13, wherein R13 is methyl. In some embodiments, at least one of R1, R2 and R3 is —OC(═O)R13, wherein R13 is methyl. In another embodiment, any two of R1, R2 and R3 are each —OC(═O)R13, wherein R13 is methyl. In one embodiment, R1, R2 and R3 are each —OC(═O)R13, wherein R13 is methyl.
  • In one embodiment of the present disclosure relates to compounds disclosed in Tables 1, 2, 3, and 4 or a pharmaceutically acceptable salt thereof.
  • In one embodiment, the present disclosure relates to compounds of Formula (I):
  • Figure US20170298033A1-20171019-C00003
  • or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
  • R1 is H, hydroxyl or —OC(═O)R13;
  • R2 is hydroxyl or —OC(═O)R13;
  • R3 is halo, —OH, —OR4, —OC(═O)R13, —NH2, —NHS(O)nR5, —N(C1-C6 alkyl)S(O)nR5, —S(O)nR5′—N3, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R6;
  • R4 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R6;
  • R5 is each independently C1-C6 alkyl or aryl which are optionally substituted with one or more R6;
  • R6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123I, hydroxyl, oxo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C6-C12 aryl, wherein each R6 is optionally substituted with one or more of halogen, 123I, 18F, hydroxyl, —OS(O)2-aryl, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
  • R8 and R9 are each independently H or C1-C6 alkyl;
  • n is 0, 1, or 2; and
  • R11a, R11b, R11c and R11d are each independently H, methyl, F, Cl, Br, I, or 123I.
  • In one embodiment, R3 in Formula II is —OH. In another embodiment, R3 is —OC(═O)R13, wherein R13 is methyl. In other embodiments, R3 is —OR4, wherein R4 is C1-C6 alkyl. In some embodiments, R3 is —OR4, wherein R4 is methyl.
  • In some embodiments, R1 in Formula II is hydroxyl or OC(═O)R13. In another embodiment R1 in Formula II is H.
  • In one embodiment, R3 in Formula II is an optionally substituted 5 or 6 membered heteroaryl or an optionally substituted 3 to 7 membered heterocylyl, wherein said heteroaryl or said heterocyclyl respectively comprise at least one N atom. In some embodiments, R3 is selected from a group consisting of pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, oxazine, triazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, and tetrazine.
  • In one embodiment, R11a, R11b, R11c and R11d in Formula II are each H.
  • In one embodiment, each R13 in Formula II when present is C1-C3 alkyl. In a further embodiment, each R13 when present is methyl.
  • In one embodiment, R1 and R2 in Formula II are each independently —OH or —OC(═O)R13, wherein R13 is methyl. In some embodiments, at least one of R1, R2 and R3 is —OC(═O)R13, wherein R13 is methyl. In another embodiment, any two of R1, R2 and R3 are each —OC(═O)R13, wherein R13 is methyl. In one embodiment, R1, R2 and R3 are each —OC(═O)R13, wherein R13 is methyl.
  • In one embodiment of the present disclosure relates to compounds disclosed in Table 5 or a pharmaceutically acceptable salt thereof.
  • In one embodiment, the present disclosure relates to a pharmaceutical composition comprising a compound of Formula I or Formula II or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. In one embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and an additional therapeutic agent.
  • In some embodiments, a pharmaceutical composition comprising a compound of Formula I or Formula II or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, and an additional therapeutic agent is provided. In one embodiment, the additional therapeutic agent is for treating prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration. In another embodiment, the additional therapeutic agent is enzalutamide, galeterone, abiraterone, bicalutamide, nilutamide, flutamide, cyproterone acetate, docetaxel, bevacizumab (Avastin), OSU-HDAC42, VITAXIN, sunitumib, ZD-4054, cabazitaxel (XRP-6258), MDX-010 (Ipilimumab), OGX 427, OGX 011, finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 28260, SKF105,111, ODM-201, radium 233, ODM-204, niclosamide, apalutamide, ARV-33Q, VPC-14449, TAS3681, 3E10-AR441bsAb, sintokamide, or related compounds thereof.
  • In one embodiment, the present disclosure provides a method for modulating androgen receptor activity, comprising administering a compound of Formula I or Formula II or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, or a pharmaceutical composition comprising a compound of Formula I or Formula II or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a patient in need thereof. In some embodiments, the method of modulating androgen receptor activity is inhibiting androgen receptor.
  • In one embodiment, the present disclosure provides a method for treating a condition or disease that is responsive to modulation of androgen receptor activity, comprising: administering a compound of Formula I or Formula II or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, or a pharmaceutical composition comprising a compound of Formula I or Formula II or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a patient in need thereof. In one embodiment, the condition or disease is selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, and age related macular degeneration. In one embodiment, the condition is prostate cancer. In another embodiment, the condition or disease is castration-resistant prostate cancer. In some embodiments, the condition or disease is androgen-dependent prostate cancer.
  • Some embodiments of the compounds described herein can be used for diagnostic purposes to investigate diseases of the prostate, including cancer. In particular embodiments, the compounds are useful for imaging diagnostics in cancer. In some embodiments, such imaging allows for the detection and/or location of cancer sites (e.g., tumor sites). Furthermore, these compounds can be used individually or as part of a kit for such purposes.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 shows a 13C NMR spectrum of Compound 3a.
  • FIG. 2 shows a dose-response for selected compounds of the present disclosure in LNCaP cells transfected with the PSA (6.1 kb)-luciferase reporter and treated with androgen.
  • FIG. 3 shows tumor volume of LNCaP xenografts in SCID-NOD mice treated with Compound 1a or CMC-treated mice (control) in the course of 26 day treatment.
  • FIG. 4 shows tumor volume of LNCaP xenografts at the start and the finish (day 26) for Compound 1a treated mice and CMC-treated mice.
  • FIG. 5 shows body weight at the start and the finish (day 26) for Compound 1a treated mice and CMC-treated mice.
  • FIG. 6 shows tissues levels of PSA mRNA in five representative xenografts from each treatment group measured by QPCR.
    •  DETAILED DESCRIPTION Definitions
  • In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the invention can be practiced without these details. In other instances, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments. Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed invention.
  • Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics can be combined in any suitable manner in one or more embodiments. Also, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. It should also be noted that the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
  • The terms below, as used herein, have the following meanings, unless indicated otherwise:
  • “Amino” refers to the —NH2 radical.
  • “Cyano” refers to the —CN radical.
  • “Halo” or “halogen” refers to bromo, chloro, fluoro or iodo radical.
  • “Hydroxy” or “hydroxyl” refers to the —OH radical.
  • “Imino” refers to the ═NH substituent.
  • “Nitro” refers to the —NO2 radical.
  • “Oxo” refers to the ═O substituent.
  • “Thioxo” refers to the ═S substituent.
  • “Acetyl” or “Ac” refers to —C(═O)CH3 substituent.
  • “Alkyl” or “alkyl group” refers to a fully saturated, straight or branched hydrocarbon chain radical having from one to twelve carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 12 are included. An alkyl comprising up to 12 carbon atoms is a C1-C12 alkyl, an alkyl comprising up to 10 carbon atoms is a C1-C10 alkyl, an alkyl comprising up to 6 carbon atoms is a C1-C6 alkyl and an alkyl comprising up to 5 carbon atoms is a C1-C5 alkyl. A C1-C5 alkyl includes C5 alkyls, C4 alkyls, C3 alkyls, C2 alkyls and C1 alkyl (i.e., methyl). A C1-C6 alkyl includes all moieties described above for C1-C5 alkyls but also includes C6 alkyls. A C1-C10 alkyl includes all moieties described above for C1-C5 alkyls and C1-C6 alkyls, but also includes C7, C8, C9 and C10 alkyls. Similarly, a C1-C12 alkyl includes all the foregoing moieties, but also includes C11 and C12 alkyls. Non-limiting examples of C1-C12 alkyl include methyl, ethyl, n-propyl, i-propyl, sec-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, t-amyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.
  • “Alkylene” or “alkylene chain” refers to a fully saturated, straight or branched divalent hydrocarbon chain radical, and having from one to twelve carbon atoms. Non-limiting examples of C1-C12 alkylene include methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, n-butenylene, propynylene, n-butynylene, and the like. The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain can be optionally substituted.
  • “Alkenyl” or “alkenyl group” refers to a straight or branched hydrocarbon chain radical having from two to twelve carbon atoms, and having one or more carbon-carbon double bonds. Each alkenyl group is attached to the rest of the molecule by a single bond. Alkenyl group comprising any number of carbon atoms from 2 to 12 are included. An alkenyl group comprising up to 12 carbon atoms is a C2-C12 alkenyl, an alkenyl comprising up to 10 carbon atoms is a C2-C10 alkenyl, an alkenyl group comprising up to 6 carbon atoms is a C2-C6 alkenyl and an alkenyl comprising up to 5 carbon atoms is a C2-C5 alkenyl. A C2-C5 alkenyl includes C5 alkenyls, C4 alkenyls, C3 alkenyls, and C2 alkenyls. A C2-C6 alkenyl includes all moieties described above for C2-C5 alkenyls but also includes C6 alkenyls. A C2-C10 alkenyl includes all moieties described above for C2-C5 alkenyls and C2-C6 alkenyls, but also includes C7, C8, C9 and C10 alkenyls. Similarly, a C2-C12 alkenyl includes all the foregoing moieties, but also includes C11 and C12 alkenyls. Non-limiting examples of C2-C12 alkenyl include ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8-nonenyl, 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7-decenyl, 8-decenyl, 9-decenyl, 1-undecenyl, 2-undecenyl, 3-undecenyl, 4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, 1-dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6-dodecenyl, 7-dodecenyl, 8-dodecenyl, 9-dodecenyl, 10-dodecenyl, and 11-dodecenyl. Examples of C1-C3 alkyl includes methyl, ethyl, n-propyl, and i-propyl. Examples of C1-C4 alkyl includes methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and sec-butyl. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.
  • “Alkenylene” or “alkenylene chain” refers to a straight or branched divalent hydrocarbon chain radical, having from two to twelve carbon atoms, and having one or more carbon-carbon double bonds. Non-limiting examples of C2-C12 alkenylene include ethene, propene, butene, and the like. The alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkenylene chain can be optionally substituted.
  • “Alkynyl” or “alkynyl group” refers to a straight or branched hydrocarbon chain radical having from two to twelve carbon atoms, and having one or more carbon-carbon triple bonds. Each alkynyl group is attached to the rest of the molecule by a single bond. Alkynyl group comprising any number of carbon atoms from 2 to 12 are included. An alkynyl group comprising up to 12 carbon atoms is a C2-C12 alkynyl, an alkynyl comprising up to 10 carbon atoms is a C2-C10 alkynyl, an alkynyl group comprising up to 6 carbon atoms is a C2-C6 alkynyl and an alkynyl comprising up to 5 carbon atoms is a C2-C5 alkynyl. A C2-C5 alkynyl includes C5 alkynyls, C4 alkynyls, C3 alkynyls, and C2 alkynyls. A C2-C6 alkynyl includes all moieties described above for C2-C5 alkynyls but also includes C6 alkynyls. A C2-C10 alkynyl includes all moieties described above for C2-C5 alkynyls and C2-C6 alkynyls, but also includes C7, C8, C9 and C10 alkynyls. Similarly, a C2-C12 alkynyl includes all the foregoing moieties, but also includes C11 and C12 alkynyls. Non-limiting examples of C2-C12 alkenyl include ethynyl, propynyl, butynyl, pentynyl and the like. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.
  • “Alkynylene” or “alkynylene chain” refers to a straight or branched divalent hydrocarbon chain radical, having from two to twelve carbon atoms, and having one or more carbon-carbon triple bonds. Non-limiting examples of C2-C12 alkynylene include ethynylene, propargylene and the like. The alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkynylene chain can be optionally substituted.
  • “Alkoxy” refers to a radical of the formula —ORa where Ra is an alkyl, alkenyl or alknyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group can be optionally substituted.
  • “Alkylamino” refers to a radical of the formula —NHRa or —NRaRa where each Ra is, independently, an alkyl, alkenyl or alkynyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkylamino group can be optionally substituted.
  • “Alkylcarbonyl” refers to the —C(═O)Ra moiety, wherein Ra is an alkyl, alkenyl or alkynyl radical as defined above. A non-limiting example of an alkyl carbonyl is the methyl carbonyl (“acetal”) moiety. Alkylcarbonyl groups can also be referred to as “Cw-Cz acyl” where w and z depicts the range of the number of carbon in Ra, as defined above. For example, “C1-C10 acyl” refers to alkylcarbonyl group as defined above, where Ra is C1-C10 alkyl, C1-C10 alkenyl, or C1-C10 alkynyl radical as defined above. Unless stated otherwise specifically in the specification, an alkyl carbonyl group can be optionally substituted.
  • “Aryl” refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring. For purposes of this invention, the aryl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems. Aryl radicals include, but are not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, the term “aryl” is meant to include aryl radicals that are optionally substituted.
  • “Aralkyl” refers to a radical of the formula —Rb—Rc where Rb is an alkylene, alkenylene or alkynylene group as defined above and Rc is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like. Unless stated otherwise specifically in the specification, an aralkyl group can be optionally substituted.
  • “Carbocyclyl,” “carbocyclic ring” or “carbocycle” refers to a rings structure, wherein the atoms which form the ring are each carbon. Carbocyclic rings can comprise from 3 to 20 carbon atoms in the ring. Carbocyclic rings include aryls and cycloalkyl. cycloalkenyl and cycloalkynyl as defined herein. Unless stated otherwise specifically in the specification, a carbocyclyl group can be optionally substituted.
  • “Cycloalkyl” refers to a stable non-aromatic monocyclic or polycyclic fully saturated hydrocarbon radical consisting solely of carbon and hydrogen atoms, which can include fused or bridged ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkyl radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl radicals include, for example, adamantyl, norbomyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group can be optionally substituted.
  • “Cycloalkenyl” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon double bonds, which can include fused or bridged ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkenyl radicals include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, cycloctenyl, and the like. Polycyclic cycloalkenyl radicals include, for example, bicyclo[2.2.1]hept-2-enyl and the like. Unless otherwise stated specifically in the specification, a cycloalkenyl group can be optionally substituted.
  • “Cycloalkynyl” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon triple bonds, which can include fused or bridged ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkynyl radicals include, for example, cycloheptynyl, cyclooctynyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkynyl group can be optionally substituted.
  • “Cycloalkylalkyl” refers to a radical of the formula —Rb-Rd where Rb is an alkylene, alkenylene, or alkynylene group as defined above and Rd is a cycloalkyl, cycloalkenyl, cycloalkynyl radical as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group can be optionally substituted.
  • “Haloalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group can be optionally substituted.
  • “Haloalkenyl” refers to an alkenyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., 1-fluoropropenyl, 1,1-difluorobutenyl, and the like. Unless stated otherwise specifically in the specification, a haloalkenyl group can be optionally substituted.
  • “Haloalkynyl” refers to an alkynyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., 1-fluoropropynyl, 1-fluorobutynyl, and the like. Unless stated otherwise specifically in the specification, a haloalkenyl group can be optionally substituted.
  • “Heterocyclyl,” “heterocyclic ring” or “heterocycle” refers to a stable 3- to 20-membered non-aromatic ring radical which consists of two to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Heterocyclycl or heterocyclic rings include heteroaryls as defined below. Unless stated otherwise specifically in the specification, the heterocyclyl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical can be optionally oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclyl radical can be partially or fully saturated. Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in the specification, a heterocyclyl group can be optionally substituted.
  • “N-heterocyclyl” refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical. Unless stated otherwise specifically in the specification, aN-heterocyclyl group can be optionally substituted.
  • “Heterocyclylalkyl” refers to a radical of the formula —Rb—Re where Rb is an alkylene, alkenylene, or alkynylene chain as defined above and Re is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl can be attached to the alkyl, alkenyl, alkynyl radical at the nitrogen atom. Unless stated otherwise specifically in the specification, a heterocyclylalkyl group can be optionally substituted.
  • “Heteroaryl” refers to a 5- to 20-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring. For purposes of this invention, the heteroaryl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical can be optionally oxidized; the nitrogen atom can be optionally quaternized.
  • Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e. thienyl). Unless stated otherwise specifically in the specification, a heteroaryl group can be optionally substituted.
  • “N-heteroaryl” refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. Unless stated otherwise specifically in the specification, an N-heteroaryl group can be optionally substituted.
  • “Heteroarylalkyl” refers to a radical of the formula —Rb—Rf where Rb is an alkylene, alkenylene, or alkynylene chain as defined above and Rf is a heteroaryl radical as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkyl group can be optionally substituted.
  • “123I” refers to the radioactive isotope of iodine having atomic mass 123. The compounds of Formula I can comprise at least one 123I moiety. Throughout the present application, where structures depict a 123I moiety at a certain position it is meant that the I moiety at this position is enriched for 123I. In other words, the compounds contain more than the natural abundance of 123I at the indicated position(s). It is not required that the compounds comprise 100% 123I at the indicated positions, provided 123I is present in more than the natural abundance. Typically the 123I isotope is enriched to greater than 50%, greater than 60%, greater than 70%, greater than, 80% or greater than 90%, relative to 127I.
  • “18F” refers to the radioactive isotope of fluorine having atomic mass 18. “F” or “19F” refers to the abundant, non-radioactive fluorine isotope having atomic mass 19. The compounds of Formula I can comprise at least one 18F moiety. Throughout the present application, where structures depict a 18F moiety at a certain position it is meant that the F moiety at this position is enriched for 18F. In other words, the compounds contain more than the natural abundance of 18F at the indicated position(s). It is not required that the compounds comprise 100% 18F at the indicated positions, provided 18F is present in more than the natural abundance. Typically the 18F isotope is enriched to greater than 50%, greater than 60%, greater than 70%, greater than 80% or greater than 90%, relative to 19F.
  • “Thioalkyl” refers to a radical of the formula —SRa where Ra is an alkyl, alkenyl, or alkynyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, a thioalkyl group can be optionally substituted.
  • The term “substituted” used herein means any of the above groups (i.e., alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, alkoxy, alkylamino, alkylcarbonyl, thioalkyl, aryl, aralkyl, carbocyclyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups. “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles. For example, “substituted” includes any of the above groups in which one or more hydrogen atoms are replaced
  • with —NRgRh, —NRgC(═O)Rh, —NRgC(═O)NRgRh, —NRgC(═O)ORh, —NRgSO2Rh, —OC(═O)NRgRh, —ORg, —SRg, —SORg, —SO2Rg, —OSO2Rg, —SO2ORg, ═NSO2Rg, and —SO2NRgRh. “Substituted also means any of the above groups in which one or more hydrogen atoms are replaced with —C(═O)Rg, —C(═O)ORg, —C(═O)NRgRh, —CH2SO2Rg, —CH2SO2NRgRh. In the foregoing, Rg and Rh are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl. “Substituted” further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl group. In addition, each of the foregoing substituents can also be optionally substituted with one or more of the above substituents.
  • As used herein, the symbol
  • Figure US20170298033A1-20171019-C00004
  • (hereinafter can be referred to as “a point of attachment bond”) denotes a bond that is a point of attachment between two chemical entities, one of which is depicted as being attached to the point of attachment bond and the other of which is not depicted as being attached to the point of attachment bond. For example,
  • Figure US20170298033A1-20171019-C00005
  • indicates that the chemical entity “XY” is bonded to another chemical entity via the point of attachment bond. Furthermore, the specific point of attachment to the non-depicted chemical entity can be specified by inference. For example, the compound CH3—R3, wherein R3 is H or
  • Figure US20170298033A1-20171019-C00006
  • infers that when R3 is “XY”, the point of attachment bond is the same bond as the bond by which R3 is depicted as being bonded to CH3.
  • “Fused” refers to any ring structure described herein which is fused to an existing ring structure in the compounds of the invention. When the fused ring is a heterocyclyl ring or a heteroaryl ring, any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring can be replaced with a nitrogen atom.
  • The invention disclosed herein is also meant to encompass the in vivo metabolic products of the disclosed compounds. Such products can result from, for example, the oxidation, reduction, hydrolysis, amidation, esterification, and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the invention includes compounds produced by a process comprising administering a compound of this invention to a mammal for a period of time sufficient to yield a metabolic product thereof. Such products are typically identified by administering a radiolabelled compound of the invention in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to human, allowing sufficient time for metabolism to occur, and isolating its conversion products from the urine, blood or other biological samples.
  • “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • As used herein, a “subject” can be a human, non-human primate, mammal, rat, mouse, cow, horse, pig, sheep, goat, dog, cat and the like. The subject can be suspected of having or at risk for having a cancer, such as prostate cancer, breast cancer, ovarian cancer, salivary gland carcinoma, or endometrial cancer, or suspected of having or at risk for having acne, hirsutism, alopecia, benign prostatic hyperplasia, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration. Diagnostic methods for various cancers, such as prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, salivary gland carcinoma, or endometrial cancer, and diagnostic methods for acne, hirsutism, alopecia, benign prostatic hyperplasia, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration and the clinical delineation of cancer, such as prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, salivary gland carcinoma, or endometrial cancer, diagnoses and the clinical delineation of acne, hirsutism, alopecia, benign prostatic hyperplasia, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration are known to those of ordinary skill in the art.
  • “Mammal” includes humans and both domestic animals such as laboratory animals and household pets (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildlife and the like.
  • “Optional” or “optionally” means that the subsequently described event of circumstances can or cannot occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, “optionally substituted aryl” means that the aryl radical can or cannot be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
  • “Pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
  • “Pharmaceutically acceptable salt” includes both acid and base addition salts.
  • “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.
  • “Pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.
  • Often crystallizations produce a solvate of the compound of the invention. As used herein, the term “solvate” refers to an aggregate that comprises one or more molecules of a compound of the invention with one or more molecules of solvent. The solvent can be water, in which case the solvate can be a hydrate. Alternatively, the solvent can be an organic solvent.
  • Thus, the compounds of the present invention can exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms. The compound of the invention can be true solvates, while in other cases, the compound of the invention can merely retain adventitious water or be a mixture of water plus some adventitious solvent.
  • A “pharmaceutical composition” refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, e.g., humans. Such a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor.
  • “An “effective amount” refers to a therapeutically effective amount or a prophylactically effective amount. A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as reduced tumor size, increased life span or increased life expectancy. A therapeutically effective amount of a compound can vary according to factors such as the disease state, age, sex, and weight of the subject, and the ability of the compound to elicit a desired response in the subject. Dosage regimens can be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as smaller tumors, increased life span, increased life expectancy or prevention of the progression of prostate cancer to a castration-resistant form. Typically, a prophylactic dose is used in subjects prior to or at an earlier stage of disease, so that a prophylactically effective amount can be less than a therapeutically effective amount.
  • “Treating” or “treatment” as used herein covers the treatment of the disease or condition of interest in a mammal, preferably a human, having the disease or condition of interest, and includes:
      • (i) preventing the disease or condition from occurring in a mammal, in particular, when such mammal is predisposed to the condition but has not yet been diagnosed as having it; (ii) inhibiting the disease or condition, i.e., arresting its development; (iii) relieving the disease or condition, i.e., causing regression of the disease or condition; or
      • (iv) relieving the symptoms resulting from the disease or condition, i.e., relieving pain without addressing the underlying disease or condition. As used herein, the terms “disease” and “condition” can be used interchangeably or can be different in that the particular malady or condition cannot have a known causative agent (so that etiology has not yet been worked out) and it is therefore not yet recognized as a disease but only as an undesirable condition or syndrome, wherein a more or less specific set of symptoms have been identified by clinicians.
  • The compounds of the invention, or their pharmaceutically acceptable salts can contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms whether or not they are specifically depicted herein. Optically active (+) and (−), (R)- and (S)-, or (D)- and (L)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
  • A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present invention contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are nonsuperimposable mirror images of one another.
  • A “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule. The present invention includes tautomers of any said compounds.
  • The chemical naming protocol and structure diagrams used herein are a modified form of the I.U.P.A.C. nomenclature system, using the ACD/Name Version 9.07 software program, ChemDraw Ultra Version 11.0.1 and/or ChemDraw Ultra Version 14.0 and/or ChemDraw Professional 16.0.0.82 software naming program (CambridgeSoft), or the like. For complex chemical names employed herein, a substituent group is named before the group to which it attaches. For example, cyclopropylethyl comprises an ethyl backbone with cyclopropyl substituent. Except as described below, all bonds are identified in the chemical structure diagrams herein, except for some carbon atoms, which are assumed to be bonded to sufficient hydrogen atoms to complete the valency.
  • Throughout the present specification, the terms “about” and/or “approximately” can be used in conjunction with numerical values and/or ranges. The term “about” is understood to mean those values near to a recited value. For example, “about 40 [units]” can mean within +25% of 40 (e.g., from 30 to 50), within ±20%, ±15%, ±10%, ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, ±1%, less than ±1%, or any other value or range of values therein or therebelow. Furthermore, the phrases “less than about [a value]” or “greater than about [a value]” should be understood in view of the definition of the term “about” provided herein. The terms “about” and “approximately” can be used interchangeably.
  • Throughout the present specification, numerical ranges are provided for certain quantities. It is to be understood that these ranges comprise all subranges therein. Thus, the range “from 50 to 80” includes all possible ranges therein (e.g., 51-79, 52-78, 53-77, 54-76, 55-75, 60-70, etc.). Furthermore, all values within a given range can be an endpoint for the range encompassed thereby (e.g., the range 50-80 includes the ranges with endpoints such as 55-80, 50-75, etc.).
    • II. Compounds and Pharmaceutical Compositions
  • As noted above, certain embodiments of the present invention are directed to compounds useful for treatment of various cancers, including various types of prostate cancers. While not wishing to be bound by theory, it is believed that binding of the compounds to the androgen receptor (for example at the N-terminal domain) can contribute to the activity of the disclosed compounds. The compounds of the present invention include halogenated phenyl groups (i.e., R11a-R11d in Formula I) and/or sulfone bridging groups (i.e., X in Formula I is —S(O)2— or compounds of Formula II) which impart improved properties to the compounds compared to compounds lacking the described R3 moiety. For example, the improved properties include improved drug-like properties such as improved activity (e.g., androgen receptor (AR) modulation), longer half-life (e.g., in vivo); decreased toxicity; better solubility, improved formulation, better bioavailability, better pharmacokinetic profile; reduction in unwanted metabolites and the like.
  • In one embodiment the invention includes compounds which form covalent bonds with the androgen receptor (AR) (e.g., at the N-terminal domain), thus resulting in irreversible (or substantially irreversible) inhibition of the same. In this regard, the certain compounds of the present invention are designed to include functional groups capable of forming covalent bonds with a nucleophile under certain in vivo conditions. For example, in some embodiments the reactivity of compounds of the present invention is such that they will not substantially react with various nucleophiles (e.g., glutathione) when the compounds are free in solution.
  • However, when the free mobility of the compounds is restricted, and an appropriate nucleophile is brought into close proximity to the compound, for example when the compounds associate with, or bind to, the androgen receptor, the compounds are capable of forming covalent bonds with certain nucleophiles (e.g., thiols).
  • The present invention includes all compounds which have the above described properties (i.e., binding and/or inhibiting to androgen receptor (AR)). In one embodiment, the present invention is directed to a compound having a structure of Formula I:
  • Figure US20170298033A1-20171019-C00007
  • or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
  • X is —S(O)n— or —C(R8R9)—;
  • R1 is H, —OH, or —OC(═O)R13;
  • R2 is —OH, or —OC(═O)R13;
  • R3 is halo, —OH, —OR4, —OC(═O)R13, —NH2, —NHC(═O)R13, —N(C(═O)R13)2, —NHS(O)nR5, —N(C(═O)R13)(S(O)nR5), —N(C1-C6 alkyl)(S(O)nR5), —S(O)nR5, —N3, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R6:
  • R4 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R6;
  • R5 is each independently C1-C6 alkyl or aryl which are optionally substituted with one or more R6;
  • R6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123I, —OH, oxo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C6-C12 aryl, wherein each R6 is optionally substituted with one or more of halogen, 123I, 18F, —OH, —OS(O)2-aryl, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
  • R8 and R9 are each independently H or C1-C6 alkyl;
  • R11a, R11b, R11c and R11d are each independently H, methyl, F, Cl, Br, I, or 123I;
  • R13 is C1-C6 alkyl; and
  • n is 0, 1, or 2;
  • wherein at least one of R11a, R11b, R11c and R11d is methyl, F, Cl, Br, I, or 123I.
  • In various embodiments, different stereoisomers of the compound of structure (I) are provided, for example in some embodiments the compound has one of the following structures (Ia), (Ib), (Ic) or (Id):
  • Figure US20170298033A1-20171019-C00008
  • In still other embodiments, the compound has one of the following structures (le), (If), (Ig) or (Ih):
  • Figure US20170298033A1-20171019-C00009
  • In one embodiment, X is —S(O)n—. In some embodiments, X is —S(O)2—. In another embodiment, X is —C(R8R9)—. In one embodiment X is —C(R8R9)—, wherein R8 and R9 are each independently H or C1-C3 alkyl. In another embodiment, X is —C(R8R9)—, wherein R8 and R9 are each C1 alkyl. In some embodiments, X is —S(O)2— or —C(CH3)2—.
  • In one embodiment, R1 is —OH. In another embodiment, R1 is —OC(═O)R13. In some embodiments, R1 is —OC(═O)R13, wherein R13 is C1-C4 alkyl. In other embodiments, R1 is —OC(═O)R13, wherein R13 is methyl. In one embodiment, R1 is H.
  • In one embodiment, R2 is —OH. In another embodiment, R2 is —OC(═O)R13. In some embodiments, R2 is —OC(═O)R13, wherein R13 is C1-C4 alkyl. In other embodiments, R2 is —OC(═O)R13, wherein R13 is methyl.
  • In one embodiment, R3 is —OH. In another embodiment, R3 is —OC(═O)R13. In some embodiments, R3 is —OC(═O)R13, wherein R13 is C1-C4 alkyl. In other embodiments, R3 is —OC(═O)R13, wherein R13 is methyl.
  • In some embodiments, at least one of R1, R2, or R3 is —OH. In some embodiments, at least two of R1, R2, or R3 are each —OH. In other embodiments, R1 and R2 are each —OH. In another embodiment, R1, R2, and R3 are each —OH.
  • In some embodiments, at least one of R1, R2, or R3 is —OC(═O)R13, wherein R13 is C1-C4 alkyl. In another embodiment, at least one of R1, R2, or R3 is —OC(═O)R13, wherein R13 is methyl. In some embodiments, at least two of R1, R2, or R3 are each —OC(═O)R13, wherein R13 is C1-C4 alkyl. In another embodiment, at least two of R1, R2, or R3 are each —OC(═O)R13, wherein R13 is methyl. In other embodiments, R1 and R2 are each —OC(═O)R13, wherein R13 is methyl.
  • In some embodiments, one of R1, R2, or R3 is —OC(═O)R13, wherein R13 is C1-C4 alkyl. In another embodiment, one of R1, R2, or R3 is —OC(═O)R13, wherein R13 is methyl. In some embodiments, two of R1, R2, or R3 are each —OC(═O)R13, wherein R13 is C1-C4 alkyl. In another embodiment, two of R1, R2, or R3 are each —OC(═O)R13, wherein R13 is methyl. In some embodiments, R1 and R2 are each —OC(═O)R13, wherein R13 is C1-C4 alkyl. In another embodiment, R1 and R2 are each —OC(═O)R13, wherein R13 is methyl. In some embodiments, R1, R2, or R3 are each —OC(═O)R13, wherein R13 is C1-C4 alkyl. In another embodiment, R1, R2, or R3 are each —OC(═O)R13, wherein R13 is methyl.
  • In other embodiments, R3 is —OR4. In one embodiment, R3 is —OR4, wherein R4 is C1-C6 alkyl. In another embodiment, R3 is —OR4, wherein R4 is C1-C3 alkyl. In one embodiment, R3 is —OR4, wherein R4 is methyl, ethyl, n-propyl, or i-propyl. In one embodiment, R3 is —OR4, wherein R4 is methyl. In another embodiment, R3 is —OR4, wherein R4 is i-propyl.
  • In other embodiments, R3 is a halogen. In other embodiments, R3 is F, Cl, Br, or I. In one embodiment, R3 is F.
  • In other embodiments, R3 is —NH2, —NHC(═O)R13, —N(C(═O)R13)2, —NHS(O)nR5, —N(C(═O)R13)(S(O)nR5), or —N(C1-C6 alkyl)(S(O)nR5). In one embodiment, R3 is a —NH2. In one embodiment, R3 is a —NHC(═O)R13. In one embodiment, R3 is a —N(C(═O)R13)2. In another embodiment, R3 is a —NHS(O)nR5. In some embodiments, R3 is a —NHS(O)2R5. In other embodiments, R3 is a —NHS(O)2R5, wherein R5 is C1-C3 alkyl. In one embodiment, R3 is a —NHS(O)2R5, wherein R5 is C1 alkyl. In one embodiment, R3 is a —N(C(═O)R13)(S(O)nR5). In one embodiment, R3 is a —N(C1-C6 alkyl)(S(O)nR5).
  • In other embodiments, R3 is —NH2, —NHC(═O)(C1-C4 alkyl), —N[(C(═O)(C1-C4 alkyl)]2, —NHS(O)n(C1-C3 alkyl), —N[C(═O)(C1-C4 alkyl)][(S(O)n(C1-C3 alkyl)], or —N[C1-C6 alkyl][S(O)n(C1-C3 alkyl)]. In some embodiments, R3 is —NH(C(═O)CH3) or —N(C(═O)CH3)2. In other embodiments, R3 is —NHS(O)2CH3. In other embodiments, R3 is —N(C(═O)CH3) (S(O)2CH3).
  • In another embodiment, R3 is a —S(O)1R5. In one embodiment, R3 is a —S(O)2R5. In another embodiment, R3 is a —S(O)2(C1-C3 alkyl). In other embodiments, R3 is a —S(O)2CH3. In other embodiments, R3 is a —S(O)2CH2CH3.
  • In some embodiments, R3 is an optionally substituted 5 or 6 membered heteroaryl or an optionally substituted 3 to 7 membered heterocylyl, wherein said heteroaryl or said heterocyclyl respectively comprise at least one N atom in the ring. In one embodiment, R3 is selected from a group consisting of pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, oxazine, triazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, and tetrazine. In a certain embodiment, R3 is
  • Figure US20170298033A1-20171019-C00010
  • In one embodiment, at least one of R11a, R11b, R11c and R11d is Cl. In another embodiment, at least one of R11a, R11b, R11c and R11d is Br. In some embodiments, at least one of R11a, R11b, R11c and R11d is methyl.
  • In one embodiment, at least two of R11a, R11b, R11c and R11d are methyl, F, Cl, Br, I, or 123I. In another embodiment, exactly two of R11a, R11b, R11c and R11d are methyl, F, Cl, Br, I, or 123I.
  • In some embodiments, R11a and R11b are each H and R11c and R11d are each independently methyl, F, Cl, Br, I, or 123I. In one embodiment, R11a and R11b are each H, and R11c and R11d are each Cl. In one embodiment, R11a and R11b are each H, and R11c and R11d are each Br. In one embodiment, R11a and R11b are each H, and R11c and R11d are each methyl.
  • In some embodiments, R11a and R11c are each H, and R11b and R11d are each independently methyl, F, Cl, Br, I, or 123I. In one embodiment, R11a and R11c are each H, and R11b and R11d are each Cl. In one embodiment, R11a and R11c are each H, and R11b and R11d are each Br. In one embodiment, R11a and R11c are each H, and R11b and R11d are each methyl.
  • In some embodiments, R13 is C1-C3 alkyl. In other embodiments, R13 is methyl, ethyl, or propyl. In one embodiment, R13 is a methyl.
  • In one embodiment, n is 0. In another embodiment n is 1. In some embodiments, n is 2.
  • The compounds for use in the imaging and treatment methods are described herein. In some embodiments, the compounds comprise one F, Cl, Br, I, or 123I substitution. For example in certain other embodiments, any three of R11a, R11b, R11c and R11d are each H, and the remaining one of R11a, R11b, R11c or R11d is F, Cl, Br, I or 123I. In some embodiments, the compounds comprise two F, Cl, Br, I or 123I substitutions on the phenyl rings (i.e., two of R11a, R11b, R11c and R11d are H, and the other two of R11a, R11b, R11c or R11d are F, Cl, Br, I or 123I). In other embodiments, the compounds comprise three F, Cl, Br, I or 123I substitutions (i.e., any one of R11a, R11b, R11c and R11d is H, and the remaining R11a, R11b, R11c or R11d is F, Cl, Br, I or 123I) and in other embodiments the compounds comprise four F, Cl, Br, I or 123I substitutions (i.e., each of R11a, R11b, R11c and R11d are F, Cl, Br, I or 123I).
  • In another embodiment, the compound comprises one or more of F, Cl, Br, I or 123I substitutions for R3. In one embodiment, the compound comprises one or more of I or 123I substitutions for R3.
  • In some embodiments, the compound comprises at least one R6 substituent on R3, wherein at least one R6 is further substituted with at least one of F, Cl, Br, I or 123I. In another embodiment, R6 substituent on R3 is further substituted with at least one of I or 123I.
  • Favorable imaging and/or AR NTD modulating results can be obtained by substitution with F, Cl, Br, I or 123I at any of the “R11” positions. In some of the foregoing embodiments, R11a is 123I. In other embodiments, R11c is 123I.
  • In some more specific embodiments of the compound of Formula I, the compound has one of the following structures from Table 1, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof:
  • TABLE 1
    Compounds
    No. Structure Name
     1
    Figure US20170298033A1-20171019-C00011
         		3-(4-(2-(3,5-dichloro-4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
     1a
    Figure US20170298033A1-20171019-C00012
         		(R)-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro- 2-hydroxyproxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
     1b
    Figure US20170298033A1-20171019-C00013
         		(S)-3-(4-(2-(3,5-dichloro-4-((R)-3-chloro- 2-hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
     1c
    Figure US20170298033A1-20171019-C00014
         		(S)-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro- 2-hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
     1d
    Figure US20170298033A1-20171019-C00015
         		(R)-3-(4-(2-(3,5-dichloro-4-((R)-3-chloro- 2-hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
     2
    Figure US20170298033A1-20171019-C00016
         		3-(2-chloro-4-(2-(3-chloro-4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
     2a
    Figure US20170298033A1-20171019-C00017
         		(R)-3-(2-chloro-4-(2-(3-chloro-4-((S)-3- chloro-2-hydroxypropoxy)phenyl)propan- 2-yl)phenoxy)propane-1,2-diol
     2b
    Figure US20170298033A1-20171019-C00018
         		(S)-3-(2-chloro-4-(2-(3-chloro-4-((R)-3- chloro-2-hydroxypropoxy)phenyl)propan- 2-yl)phenoxy)propane-1,2-diol
     2c
    Figure US20170298033A1-20171019-C00019
         		(S)-3-(2-chloro-4-(2-(3-chloro-4-((S)-3- chloro-2-hydroxypropoxy)phenyl)propan- 2-yl)phenoxy)propane-1,2-diol
     2d
    Figure US20170298033A1-20171019-C00020
         		(R)-3-(2-chloro-4-(2-(3-chloro-4-((R)-3- chloro-2-hydroxypropoxy)phenyl)propan- 2-yl)phenoxy)propane-1,2-diol
     3
    Figure US20170298033A1-20171019-C00021
         		3-(4-(2-(3,5-dibromo-4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
     3a
    Figure US20170298033A1-20171019-C00022
         		(R)-3-(4-(2-(3,5-dibromo-4-((S)-3-chloro- 2-hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
     3b
    Figure US20170298033A1-20171019-C00023
         		(S)-3-(4-(2-(3,5-dibromo-4-((R)-3-chloro- 2-hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
     3c
    Figure US20170298033A1-20171019-C00024
         		(S)-3-(4-(2-(3,5-dibromo-4-((S)-3-chloro- 2-hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
     3d
    Figure US20170298033A1-20171019-C00025
         		(R)-3-(4-(2-(3,5-dibromo-4-((R)-3-chloro- 2-hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
     4
    Figure US20170298033A1-20171019-C00026
         		3-(4-(2-(4-(3-chloro-2-hydroxypropoxy)- 3-methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diol
     4a
    Figure US20170298033A1-20171019-C00027
         		(R)-3-(4-(2-(4-((S)-3-chloro-2- hydroxypropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diol
     4b
    Figure US20170298033A1-20171019-C00028
         		(S)-3-(4-(2-(4-((R)-3-chloro-2- hydroxypropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diol
     4c
    Figure US20170298033A1-20171019-C00029
         		(S)-3-(4-(2-(4-((S)-3-chloro-2- hydroxypropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diol
     4d
    Figure US20170298033A1-20171019-C00030
         		(R)-3-(4-(2-(4-((R)-3-chloro-2- hydroxypropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diol
     5
    Figure US20170298033A1-20171019-C00031
         		1-chloro-3-(2,6-dichloro-4-(2-(4-(2- hydroxy-3- methoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     5a
    Figure US20170298033A1-20171019-C00032
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)- 2-hydroxy-3- methoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     5b
    Figure US20170298033A1-20171019-C00033
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)- 2-hydroxy-3- methoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-1,2-ol
     5c
    Figure US20170298033A1-20171019-C00034
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)- 2-hydroxy-3- methoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     5d
    Figure US20170298033A1-20171019-C00035
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)- 2-hydroxy-3- methoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     6
    Figure US20170298033A1-20171019-C00036
         		1-chloro-3-(2-chloro-4-(2-(3-chloro-4-(2- hydroxy-3- methoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     6a
    Figure US20170298033A1-20171019-C00037
         		(S)-1-chloro-3-(2-chloro-4-(2-(3-chloro- 4-((R)-2-hydroxy-3- methoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     6b
    Figure US20170298033A1-20171019-C00038
         		(R)-1-chloro-3-(2-chloro-4-(2-(3-chloro- 4-((S)-2-hydroxy-3- methoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     6c
    Figure US20170298033A1-20171019-C00039
         		(S)-1-chloro-3-(2-chloro-4-(2-(3-chloro- 4-((S)-2-hydroxy-3- methoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     6d
    Figure US20170298033A1-20171019-C00040
         		(R)-1-chloro-3-(2-chloro-4-(2-(3-chloro- 4-((R)-2-hydroxy-3- methoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     7
    Figure US20170298033A1-20171019-C00041
         		1-chloro-3-(2,6-dichloro-4-(2-(4-(2- hydroxy-3- isopropoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     7a
    Figure US20170298033A1-20171019-C00042
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)- 2-hydroxy-3- isopropoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     7b
    Figure US20170298033A1-20171019-C00043
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)- 2-hydroxy-3- isopropoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     7c
    Figure US20170298033A1-20171019-C00044
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)- 2-hydroxy-3- isopropoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     7d
    Figure US20170298033A1-20171019-C00045
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)- 2-hydroxy-3- isopropoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     8
    Figure US20170298033A1-20171019-C00046
         		1-chloro-3-(2,6-dichloro-4-(2-(4-(3- fluoro-2-hydroxypropoxy)phenyl)propan- 2-yl)phenoxy)propan-2-ol
     8a
    Figure US20170298033A1-20171019-C00047
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)- 3-fluoro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     8b
    Figure US20170298033A1-20171019-C00048
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)- 3-fluoro-2- hydroxypropoxy)phenoxy)propan-2- yl)phenoxy)propan-2-ol
     8c
    Figure US20170298033A1-20171019-C00049
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)- 3-fluoro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     8d
    Figure US20170298033A1-20171019-C00050
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)- 3-fluoro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     9
    Figure US20170298033A1-20171019-C00051
         		1-chloro-3-(2,6-dichloro-4-(2-(4-(2- hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     9a
    Figure US20170298033A1-20171019-C00052
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)- 2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     9b
    Figure US20170298033A1-20171019-C00053
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)- 2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     9c
    Figure US20170298033A1-20171019-C00054
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)- 2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
     9d
    Figure US20170298033A1-20171019-C00055
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)- 2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    10
    Figure US20170298033A1-20171019-C00056
         		1-chloro-3-(2-chloro-4-(2-(3-chloro-4-(2- hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    10a
    Figure US20170298033A1-20171019-C00057
         		(S)-1-chloro-3-(2-chloro-4-(2-(3-chloro- 4-((R)-2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    10b
    Figure US20170298033A1-20171019-C00058
         		(R)-1-chloro-3-(2-chloro-4-(2-(3-chloro- 4-((S)-2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    10c
    Figure US20170298033A1-20171019-C00059
         		(S)-1-chloro-3-(2-chloro-4-(2-(3-chloro- 4-((S)-2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    10d
    Figure US20170298033A1-20171019-C00060
         		(R)-1-chloro-3-(2-chloro-4-(2-(3-chloro- 4-((R)-2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    11
    Figure US20170298033A1-20171019-C00061
         		1-chloro-3-(2,6-dichloro-4-(2-(4-(2- hydroxy-3- morpholinopropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    11a
    Figure US20170298033A1-20171019-C00062
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)- 2-hydroxy-3- morpholinopropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    11b
    Figure US20170298033A1-20171019-C00063
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)- 2-hydroxy-3- morpholinopropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    11c
    Figure US20170298033A1-20171019-C00064
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)- 2-hydroxy-3- morpholinopropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    11d
    Figure US20170298033A1-20171019-C00065
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)- 2-hydroxy-3- morpholinopropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    12
    Figure US20170298033A1-20171019-C00066
         		1-amino-3-(4-(2-(3,5-dichloro-4-(3- chloro-2-hydroxypropoxy)phenyl)propan- 2-yl)phenoxy)propan-2-ol
    12a
    Figure US20170298033A1-20171019-C00067
         		(R)-1-amino-3-(4-(2-(3,5-dichloro-4-((S)- 3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    12b
    Figure US20170298033A1-20171019-C00068
         		(S)-1-amino-3-(4-(2-(3,5-dichloro-4-((R)- 3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    12c
    Figure US20170298033A1-20171019-C00069
         		(S)-1-amino-3-(4-(2-(3,5-dichloro-4-((S)- 3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    12d
    Figure US20170298033A1-20171019-C00070
         		(R)-1-amino-3-(4-(2-(3,5-dichloro-4-((R)- 3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    13
    Figure US20170298033A1-20171019-C00071
         		N-(3-(4-(2-(3,5-dichloro-4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2- hydroxypropyl)methanesulfonamide
    13a
    Figure US20170298033A1-20171019-C00072
         		N-((R)-3-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2-hydroxypropoxy)phenyl)propan- 2-yl)phenoxy)-2- hydroxypropyl)methanesulfonamide
    13b
    Figure US20170298033A1-20171019-C00073
         		N-((S)-3-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2-hydroxypropoxy)phenyl)propan- 2-yl)phenoxy)-2- hydroxypropyl)methanesulfonamide
    13c
    Figure US20170298033A1-20171019-C00074
         		N-((S)-3-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2-hydroxypropoxy)phenyl)propan- 2-yl)phenoxy)-2- hydroxypropyl)methanesulfonamide
    13d
    Figure US20170298033A1-20171019-C00075
         		N-((R)-3-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2-hydroxypropoxy)phenyl)propan- 2-yl)phenoxy)-2- hydroxypropyl)methanesulfonamide
    14
    Figure US20170298033A1-20171019-C00076
         		1-chloro-3-(2,6-dichloro-4-(2-(4-(2- hydroxy-3- (ethylsulfonyl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    14a
    Figure US20170298033A1-20171019-C00077
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)- 2-hydroxy-3- (ethylsulfonyl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    14b
    Figure US20170298033A1-20171019-C00078
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)- 2-hydroxy-3- (ethylsulfonyl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    14c
    Figure US20170298033A1-20171019-C00079
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)- 2-hydroxy-3- (ethylsulfonyl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    14d
    Figure US20170298033A1-20171019-C00080
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)- 2-hydroxy-3- (ethylsulfonyl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    15
    Figure US20170298033A1-20171019-C00081
         		1-chloro-3-(2-chloro-4-(2-(3-chloro-4-(2- hydroxy-3- (ethylsulfonyl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    15a
    Figure US20170298033A1-20171019-C00082
         		(S)-1-chloro-3-(2-chloro-4-(2-(3-chloro- 4-((S)-2-hydroxy-3- (ethylsuflonyl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    15b
    Figure US20170298033A1-20171019-C00083
         		(R)-1-chloro-3-(2-chloro-4-(2-(3-chloro- 4-((R)-2-hydroxy-3- (ethylsulfonyl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    15c
    Figure US20170298033A1-20171019-C00084
         		(S)-1-chloro-3-(2-chloro-4-(2-(3-chloro- 4-((R)-2-hydroxy-3- (ethylsulfonyl)propoxy)phenyl)propan-2- yl)phenoxy)porpan-2-ol
    15d
    Figure US20170298033A1-20171019-C00085
         		(R)-1-chloro-3-(2-chloro-4-(2-(3-chloro- 4-((S)-2-hydroxy-3- (ethylsulfonyl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    16
    Figure US20170298033A1-20171019-C00086
         		3-(2,6-dichloro-4-(2-(4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
    16a
    Figure US20170298033A1-20171019-C00087
         		(R)-3-(2,6-dichloro-4-(2-(4-((S)-3-chloro- 2-hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
    16b
    Figure US20170298033A1-20171019-C00088
         		(S)-3-(2,6-dichloro-4-(2-(4-((R)-3-chloro- 2-hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
    16c
    Figure US20170298033A1-20171019-C00089
         		(S)-3-(2,6-dichloro-4-(2-(4-((S)-3-chloro- 2-hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
    16d
    Figure US20170298033A1-20171019-C00090
         		(R)-3-(2,6-dichloro-4-(2-(4-((R)-3-chloro- 2-hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
    17
    Figure US20170298033A1-20171019-C00091
         		1-chloro-3-(4-(2-(3,5-dichloro-4-(3- (ethylsulfonyl)-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    17a
    Figure US20170298033A1-20171019-C00092
         		(S)-1-chloro-3-(4-(2-(3,5-dichloro-4-((S)- 3-(ethylsulfonyl)-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    17b
    Figure US20170298033A1-20171019-C00093
         		(R)-1-chloro-3-(4-(2-(3,5-dichloro-4-((R)- 3-(ethylsulfonyl)-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    17c
    Figure US20170298033A1-20171019-C00094
         		(S)-1-chloro-3-(4-(2-(3,5-dichloro-4-((R)- 3-(ethylsulfonyl)-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    17d
    Figure US20170298033A1-20171019-C00095
         		(R)-1-chloro-3-(4-(2-(3,5-dichloro-4-((S)- 3-(ethylsulfonyl)-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-ol
    18
    Figure US20170298033A1-20171019-C00096
         		3-(4-(2-(3,5-dichloro-4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
    18a
    Figure US20170298033A1-20171019-C00097
         		(R)-3-(4-(2-(3,5-dichloro-4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
    18b
    Figure US20170298033A1-20171019-C00098
         		(S)-3-(4-(2-(3,5-dichloro-4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
    19
    Figure US20170298033A1-20171019-C00099
         		1-(4-(2-(3,5-dichloro-4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan-2-ol
    19a
    Figure US20170298033A1-20171019-C00100
         		(S)-1-(4-(2-(3,5-dichloro-4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan-2-ol
    19b
    Figure US20170298033A1-20171019-C00101
         		(R)-1-(4-(2-(3,5-dichloro-4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan-2-ol
    20
    Figure US20170298033A1-20171019-C00102
         		3-(2,6-dichloro-4-(2-(4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
    20a
    Figure US20170298033A1-20171019-C00103
         		(R)-3-(2,6-dichloro-4-(2-(4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diol
    20b
    Figure US20170298033A1-20171019-C00104
         		(S)-3-(2,6-dichloro-4-(2-(4-(3- cloropropoxy)phenyl)propan-3- yl)phenoxy)propane-1,2-diol
    21
    Figure US20170298033A1-20171019-C00105
         		1-(2,6-dichloro-4-(2-(4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan-2-ol
    21a
    Figure US20170298033A1-20171019-C00106
         		(S)-1-(2,6-dichloro-4-(2-(4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan-2-ol
    21b
    Figure US20170298033A1-20171019-C00107
         		(R)-1-(2,6-dichloro-4-(2-(4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan-2-ol
    22
    Figure US20170298033A1-20171019-C00108
         		3-(4-(2-(4-(3-chloro-2-hydroxypropoxy)- 3-methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diol
    22a
    Figure US20170298033A1-20171019-C00109
         		(R)-3-(4-(2-(4-((S)-3-chloro-2- hydroxypropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diol
    22b
    Figure US20170298033A1-20171019-C00110
         		(S)-3-(4-(2-((R)-3-chloro-2- hydroxypropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diol
    22c
    Figure US20170298033A1-20171019-C00111
         		(S)-3-(4-(2-(4-((S)-3-chloro-2- hydroxypropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diol
    22d
    Figure US20170298033A1-20171019-C00112
         		(R)-3-(4-(2-(4-((R)-3-chloro-2- hydroxypropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diol
  • In some embodiments of the compound of Formula I, the compound has one of the following structures from Table 2, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
  • TABLE 2
    Compounds
    No. Structure Name
    A1
    Figure US20170298033A1-20171019-C00113
         		3-(4-(2-(4-(2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    A1a
    Figure US20170298033A1-20171019-C00114
         		(S)-3-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    A1b
    Figure US20170298033A1-20171019-C00115
         		(R)-3-(4-(2-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    A1c
    Figure US20170298033A1-20171019-C00116
         		(R)-3-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    A1d
    Figure US20170298033A1-20171019-C00117
         		(S)-3-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    B1
    Figure US20170298033A1-20171019-C00118
         		1-(4-(2-(4-(3-acetoxy-2- hydroxypropoxy)phenyl)propan-2-yl)- 2,6-dichlorophenyl)-3-chloropropan- 2-yl acetate
    B1a
    Figure US20170298033A1-20171019-C00119
         		(S)-1-(4-(2-(4-((S)-3-acetoxy-2- hydroxypropoxy)phenyl)propan-2-yl)- 2,6-dichlorophenoxy)-3-chloropropan- 2-yl acetate
    B1b
    Figure US20170298033A1-20171019-C00120
         		(R)-1-(4-(2-((R)-3-acetoxy-2- hydroxypropoxy)phenyl)propan-2-yl)- 2,6-dichlorophenoxy)-3-chloropropan- 2-yl acetate
    B1c
    Figure US20170298033A1-20171019-C00121
         		(S)-1-(4-(2-(4-((R)-3-acetoxy-2- hydroxypropoxy)phenyl)propan-2-yl)- 2,6-dichlorophenoxy)-3-chloropropan- 2-yl acetate
    B1d
    Figure US20170298033A1-20171019-C00122
         		(R)-1-(4-(2-((S)-3-acetoxy-2- hydroxypropoxy)phenyl)propan-2-yl)- 2,6-dichlorophenoxy)-3-chloropropan- 2-yl acetate
    C1
    Figure US20170298033A1-20171019-C00123
         		1-(4-(2-(4-(2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-hydroxypropan-2-yl acetate
    C1a
    Figure US20170298033A1-20171019-C00124
         		(R)-1-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-hydroxypropan-2-yl acetate
    C1b
    Figure US20170298033A1-20171019-C00125
         		(S)-1-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-hydroxypropan-2-yl acetate
    C1c
    Figure US20170298033A1-20171019-C00126
         		(S)-1-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-hydroxypropan-2-yl acetate
    C1d
    Figure US20170298033A1-20171019-C00127
         		(R)-1-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-hydroxypropan-2-yl acetate
    D1
    Figure US20170298033A1-20171019-C00128
         		3-(4-(2-(3,5-dichloro-4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    D1a
    Figure US20170298033A1-20171019-C00129
         		(S)-3-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    D1b
    Figure US20170298033A1-20171019-C00130
         		(R)-3-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diyl deacetate
    D1c
    Figure US20170298033A1-20171019-C00131
         		(R)-3-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diyl acetate
    D1d
    Figure US20170298033A1-20171019-C00132
         		(S)-3-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    E1
    Figure US20170298033A1-20171019-C00133
         		1-(4-(2-(3,5-dichloro-4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-hydroxypropan-2-yl acetate
    E1a
    Figure US20170298033A1-20171019-C00134
         		(R)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-hydroxypropan-2-yl acetate
    E1b
    Figure US20170298033A1-20171019-C00135
         		(S)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-hydroxypropan-2-yl acetate
    E1c
    Figure US20170298033A1-20171019-C00136
         		(S)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-hydroxypropan-2-yl acetate
    E1d
    Figure US20170298033A1-20171019-C00137
         		(R)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-hydroxypropan-2-yl acetate
    F1
    Figure US20170298033A1-20171019-C00138
         		3-(4-(2-(3,5-dichloro-4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2-hydroxypropyl acetate
    F1a
    Figure US20170298033A1-20171019-C00139
         		(S)-3-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2-hydroxypropyl acetate
    F1b
    Figure US20170298033A1-20171019-C00140
         		(R)-3-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2-hydroxypropyl acetate
    F1c
    Figure US20170298033A1-20171019-C00141
         		(R)-3-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2-hydroxypropyl acetate
    F1d
    Figure US20170298033A1-20171019-C00142
         		(S)-3-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydrpxypropoxy)phenyl)propan-2- yl)phenoxy)-2-hydroxypropyl acetate
    G1
    Figure US20170298033A1-20171019-C00143
         		1-chloro-3-(2,6-dichloro-4-(2-(4-(2,3- dihydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    G1a
    Figure US20170298033A1-20171019-C00144
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-2,3- dihydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    G1b
    Figure US20170298033A1-20171019-C00145
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-2,3- dihydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    G1c
    Figure US20170298033A1-20171019-C00146
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-2,3- dihydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    G1d
    Figure US20170298033A1-20171019-C00147
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-2,3- dihydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    A2
    Figure US20170298033A1-20171019-C00148
         		3-(4-(2-(4-(2-acetoxy-3- chloropropoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)propane-1,2-diyl diacetate
    A2a
    Figure US20170298033A1-20171019-C00149
         		(S)-3-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)propane-1,2-diyl diacetate
    A2b
    Figure US20170298033A1-20171019-C00150
         		(R)-3-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)propane-1,2-diyl diacetate
    A2c
    Figure US20170298033A1-20171019-C00151
         		(R)-3-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)propane-1,2-diyl diacetate
    A2d
    Figure US20170298033A1-20171019-C00152
         		(S)-3-(4-(2-((R)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)propane-1,2-diyl diacetate
    A3
    Figure US20170298033A1-20171019-C00153
         		3-(4-(2-(4-(2-acetoxy-3- chloropropoxy)-3,5- dibromophenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    A3a
    Figure US20170298033A1-20171019-C00154
         		(S)-3-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dibromophenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    A3b
    Figure US20170298033A1-20171019-C00155
         		(R)-3-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dibromophenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    A3c
    Figure US20170298033A1-20171019-C00156
         		(R)-3-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dibromophenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    A3d
    Figure US20170298033A1-20171019-C00157
         		(S)-3-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dibromophenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    A4
    Figure US20170298033A1-20171019-C00158
         		3-(4-(2-(4-(2-acetoxy-3- chloropropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diyl diacetate
    A4a
    Figure US20170298033A1-20171019-C00159
         		(S)-3-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diyl diacetate
    A4b
    Figure US20170298033A1-20171019-C00160
         		(R)-3-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diyl diacetate
    A4c
    Figure US20170298033A1-20171019-C00161
         		(R)-3-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diyl diacetate
    A4d
    Figure US20170298033A1-20171019-C00162
         		(S)-3-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diyl diacetate
    A5
    Figure US20170298033A1-20171019-C00163
         		1-(4-(2-(4-(2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-methoxypropan-2-yl acetate
    A5a
    Figure US20170298033A1-20171019-C00164
         		(R)-1-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-methoxypropan-2-yl acetate
    A5b
    Figure US20170298033A1-20171019-C00165
         		(S)-1-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-methoxypropan-2-yl acetate
    A5c
    Figure US20170298033A1-20171019-C00166
         		(S)-1-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-methoxypropan-2-yl acetate
    A5d
    Figure US20170298033A1-20171019-C00167
         		(R)-1-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-methoxypropan-2-yl acetate
    B5
    Figure US20170298033A1-20171019-C00168
         		1-(4-(2-(3,5-dichloro-4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-methoxypropan-2-yl acetate
    B5a
    Figure US20170298033A1-20171019-C00169
         		(R)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-methoxypropan-2-yl acetate
    B5b
    Figure US20170298033A1-20171019-C00170
         		(S)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-methoxypropan-2-yl acetate
    B5c
    Figure US20170298033A1-20171019-C00171
         		(S)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-methoxypropan-2-yl acetate
    B5d
    Figure US20170298033A1-20171019-C00172
         		(R)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-methoxypropan-2-yl acetate
    C5
    Figure US20170298033A1-20171019-C00173
         		1-chloro-3-(2,6-dichloro-4-(2-(4-(2- hydroxy-3- methoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C5a
    Figure US20170298033A1-20171019-C00174
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-2-hydroxy-3- methoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C5b
    Figure US20170298033A1-20171019-C00175
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-2-hydroxy-3- methoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C5c
    Figure US20170298033A1-20171019-C00176
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-2-hydroxy-3- methoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C5d
    Figure US20170298033A1-20171019-C00177
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-2-hydroxy-3- methoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    A6
    Figure US20170298033A1-20171019-C00178
         		1-(4-(2-(4-(2-acetoxy-3- chloropropoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)-3-methoxypropan-2-yl acetate
    A6a
    Figure US20170298033A1-20171019-C00179
         		(R)-1-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)-3-methoxypropan-2-yl acetate
    A6b
    Figure US20170298033A1-20171019-C00180
         		(S)-1-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)-3-methoxypropan-2-yl acetate
    A6c
    Figure US20170298033A1-20171019-C00181
         		(S)-1-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)-3-methoxypropan-2-yl acetate
    A6d
    Figure US20170298033A1-20171019-C00182
         		(R)-1-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)-3-methoxypropan-2-yl acetate
    A7
    Figure US20170298033A1-20171019-C00183
         		1-(4-(2-(4-(2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-isopropoxypropan-2-yl acetate
    A7a
    Figure US20170298033A1-20171019-C00184
         		(R)-1-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-isopropoxypropan-2-yl acetate
    A7b
    Figure US20170298033A1-20171019-C00185
         		(S)-1-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-isopropoxypropan-2-yl acetate
    A7c
    Figure US20170298033A1-20171019-C00186
         		(S)-1-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-isopropoxypropan-2-yl acetate
    A7d
    Figure US20170298033A1-20171019-C00187
         		(R)-1-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-isopropoxypropan-2-yl acetate
    B7
    Figure US20170298033A1-20171019-C00188
         		1-(4-(2-(3,5-dichloro-4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-isopropoxypropan-2-yl acetate
    B7a
    Figure US20170298033A1-20171019-C00189
         		(R)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-isopropoxypropan-2-yl acetate
    B7b
    Figure US20170298033A1-20171019-C00190
         		(S)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-isopropoxypropan-2-yl acetate
    B7c
    Figure US20170298033A1-20171019-C00191
         		(S)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-isopropoxypropan-2-yl acetate
    B7d
    Figure US20170298033A1-20171019-C00192
         		(R)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-isopropoxypropan-2-yl acetate
    C7
    Figure US20170298033A1-20171019-C00193
         		1-chloro-3-(2,6-dichloro-4-(2-(4-(2- hydroxy-3- isopropoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C7a
    Figure US20170298033A1-20171019-C00194
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-2-hydroxy-3- isopropoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C7b
    Figure US20170298033A1-20171019-C00195
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-2-hydroxy-3- isopropoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C7c
    Figure US20170298033A1-20171019-C00196
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-2-hydroxy-3- isopropoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C7d
    Figure US20170298033A1-20171019-C00197
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-2-hydroxy-3- isopropoxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    A8
    Figure US20170298033A1-20171019-C00198
         		1-(4-(2-(4-(2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-fluoropropan-2-yl acetate
    A8a
    Figure US20170298033A1-20171019-C00199
         		(S)-1-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-fluoropropan-2-yl acetate
    A8b
    Figure US20170298033A1-20171019-C00200
         		(R)-1-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-fluoropropan-2-yl acetate
    A8c
    Figure US20170298033A1-20171019-C00201
         		(R)-1-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-fluoropropan-2-yl acetate
    A8d
    Figure US20170298033A1-20171019-C00202
         		(S)-1-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-fluoropropan-2-yl acetate
    A9
    Figure US20170298033A1-20171019-C00203
         		1-(4-(2-(4-(2-acetoxy-3-(1H-imidazol- 1-yl)propoxy)phenyl)propan-2-yl)-2,6- dichlorophenoxy)-3-chloropropan-2-yl acetate
    A9a
    Figure US20170298033A1-20171019-C00204
         		(S)-1-(4-(2-(4-((R)-2-acetoxy-3-(1H- imidazol-1-yl)propoxy)phenyl)propan- 2-yl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    A9b
    Figure US20170298033A1-20171019-C00205
         		(R)-1-(4-(2-(4-((S)-2-acetoxy-3-(1H- imidazol-1-yl)propoxy)phenyl)propan- 2-yl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    A9c
    Figure US20170298033A1-20171019-C00206
         		(S)-1-(4-(2-(4-((S)-2-acetoxy-3-(1H- imidazol-1-yl)propoxy)phenyl)propan- 2-yl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    A9d
    Figure US20170298033A1-20171019-C00207
         		(R)-1-(4-(2-(4-((R)-2-acetoxy-3-(1H- imidazol-1-yl)propoxy)phenyl)propan- 2-yl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    B9
    Figure US20170298033A1-20171019-C00208
         		1-(4-(2-(3,5-dichloro-4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-(1H-imidazol-1- yl)propan-2-yl acetate
    B9a
    Figure US20170298033A1-20171019-C00209
         		(R)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-(1H-imidazol-1- yl)propan-2-yl acetate
    B9b
    Figure US20170298033A1-20171019-C00210
         		(S)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-(1H-imidazol-1- yl)propan-2-yl acetate
    B9c
    Figure US20170298033A1-20171019-C00211
         		(S)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-(1H-imidazol-1- yl)propan-2-yl acetate
    B9d
    Figure US20170298033A1-20171019-C00212
         		(R)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-(1H-imidazol-1- yl)propan-2-yl acetate
    C9
    Figure US20170298033A1-20171019-C00213
         		1-chloro-3-(2,6-dichloro-4-(2-(4-(2- hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C9a
    Figure US20170298033A1-20171019-C00214
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C9b
    Figure US20170298033A1-20171019-C00215
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C9c
    Figure US20170298033A1-20171019-C00216
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C9d
    Figure US20170298033A1-20171019-C00217
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    A10
    Figure US20170298033A1-20171019-C00218
         		1-(4-(2-(4-acetoxy-3-(1H-imidazol- 1-yl)propoxy)-3-chlorophenyl)propan- 2-yl)-2-chlorophenoxy)-3- chloropropan-2-yl acetate
    A10a
    Figure US20170298033A1-20171019-C00219
         		(S)-1-(4-(2-(4-((R)-2-acetoxy-3-(1H- imidazol-1-yl)propoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)-3-chloropropan-2-yl acetate
    A10b
    Figure US20170298033A1-20171019-C00220
         		(R)-1-(4-(2-(4-((S)-2-acetoxy-3-(1H- imidazol-1-yl)propoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)-3-chloropropan-2-yl acetate
    A10c
    Figure US20170298033A1-20171019-C00221
         		(S)-1-(4-(2-(4-((S)-2-acetoxy-3-(1H- imidazol-1-yl)propoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)-3-chloropropan-2-yl acetate
    A10d
    Figure US20170298033A1-20171019-C00222
         		(R)-1-(4-(2-(4-((R)-2-acetoxy-3-(1H- imidazol-1-yl)propoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)-3-chloropropan-2-yl acetate
    A11
    Figure US20170298033A1-20171019-C00223
         		1-(4-(2-(4-(2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-morpholinopropan-2-yl acetate
    A11a
    Figure US20170298033A1-20171019-C00224
         		(R)-1-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-morpholinopropan-2-yl acetate
    A11b
    Figure US20170298033A1-20171019-C00225
         		(S)-1-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-morpholinopropan-2-yl acetate
    A11c
    Figure US20170298033A1-20171019-C00226
         		(S)-1-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-morpholinopropan-2-yl acetate
    A11d
    Figure US20170298033A1-20171019-C00227
         		(R)-1-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-morpholinopropan-2-yl acetate
    B11
    Figure US20170298033A1-20171019-C00228
         		1-(4-(2-(3,5-dichloro-4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-morphlinopropan-2-yl acetate
    B11a
    Figure US20170298033A1-20171019-C00229
         		(R)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-morpholinopropan-2-yl acetate
    B11b
    Figure US20170298033A1-20171019-C00230
         		(S)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-morpholinopropan-2-yl acetate
    B11c
    Figure US20170298033A1-20171019-C00231
         		(S)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-morpholinopropan-2-yl acetate
    B11d
    Figure US20170298033A1-20171019-C00232
         		(R)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-morpholinopropan-2-yl acetate
    C11
    Figure US20170298033A1-20171019-C00233
         		1-chloro-3-(2,6-dichloro-4-(2-(4-(2- hydroxy-3- morpholinopropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C11a
    Figure US20170298033A1-20171019-C00234
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-2-hydroxy-3- morpholinopropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C11b
    Figure US20170298033A1-20171019-C00235
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-2-hydroxy-3- morpholinopropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C11c
    Figure US20170298033A1-20171019-C00236
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-2-hydroxy-3- morpholinopropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C11d
    Figure US20170298033A1-20171019-C00237
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-2-hydroxy-3- morpholinopropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    A12
    Figure US20170298033A1-20171019-C00238
         		1-(4-(2-(4-(2-acetoxy-3-(N- acetylacetamido)propoxy)phenyl) propan-2-yl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    A12a
    Figure US20170298033A1-20171019-C00239
         		N-acetyl-N-((R)-3-(4-(2-(3,5-dichloro- 4-((S)-3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2- hydroxypropyl)acetamide
    A12b
    Figure US20170298033A1-20171019-C00240
         		N-acetyl-N-((R)-3-(4-(2-(3,5-dichloro- 4-((S)-3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2- hydroxypropyl)acetamide
    A12c
    Figure US20170298033A1-20171019-C00241
         		N-acetyl-N-((S)-3-(4-(2-(3,5-dichloro- 4-((S)-3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2- hydroxypropyl)acetamide
    A12d
    Figure US20170298033A1-20171019-C00242
         		N-acetyl-N-((R)-3-(4-(2-(3,5-dichloro- 4-((R)-3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2- hydroxypropyl)acetamide
    B12
    Figure US20170298033A1-20171019-C00243
         		1-(4-(2-(4-(3-acetamido-2- acetoxypropoxy)phenyl)propan-2-yl)- 2,6-dichlorophenoxy)-3-chloropropan- 2-yl acetate
    B12a
    Figure US20170298033A1-20171019-C00244
         		N-((R)-3-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2- hydroxypropyl)acetamide
    B12b
    Figure US20170298033A1-20171019-C00245
         		N-((S)-3-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2- hydroxypropyl)acetamide
    B12c
    Figure US20170298033A1-20171019-C00246
         		N-((S)-3-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2- hydroxypropyl)acetamide
    B12d
    Figure US20170298033A1-20171019-C00247
         		N-((R)-3-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2- hydroxypropyl)acetamide
    A13
    Figure US20170298033A1-20171019-C00248
         		1-(4-(2-(4-(2-acetoxy-3-(N- (methylsulfonyl)acetamido)propoxy) phenyl)propan-2-yl)-2,6- dichlorophenoxy)-3-chloropropan-2- yl acetate
    A13a
    Figure US20170298033A1-20171019-C00249
         		(S)-1-(4-(2-(4-((R)-2-acetoxy-3-(N- (methylsulfonyl)acetamido)propoxy) phenyl)propan-2-yl)-2,6- dichlorophenoxy)-3-chloropropan-2-yl acetate
    A13b
    Figure US20170298033A1-20171019-C00250
         		(R)-1-(4-(2-(4-((S)-2-acetoxy-3-(N- (methylsulfonyl)acetamido)propoxy) phenyl)propan-2-yl)-2,6- dichlorophenoxy)-3-chloropropan-2-yl acetate
    A13c
    Figure US20170298033A1-20171019-C00251
         		(S)-1-(4-(2-(4-((S)-2-acetoxy-3-(N- (methylsulfonyl)acetamido)propoxy) phenyl)propan-2-yl)-2,6- dichlorophenoxy)-3-chloropropan-2-yl acetate
    A13d
    Figure US20170298033A1-20171019-C00252
         		(R)-1-(4-(2-(4-((R)-2-acetoxy-3-(N- (methylsulfonyl)acetamido)propoxy) phenyl)propan-2-yl)-2,6- dichlorophenoxy)-3-chloropropan-2-yl acetate
    B13
    Figure US20170298033A1-20171019-C00253
         		1-chloro-3-(2,6-dichloro-4-(2-(4-(2- hydroxy-3-(N- (methylsulfonyl)acetamido)propoxy) phenyl)propan-2-yl)phenoxy)propan- 2-yl acetate
    B13a
    Figure US20170298033A1-20171019-C00254
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-2-hydroxy-3-(N- (methylsulfonyl)acetamido)propoxy) phenyl)propan-2-yl)phenoxy)propan- 2-yl acetate
    B13b
    Figure US20170298033A1-20171019-C00255
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-2-hydroxy-3-(N- (methylsulfonyl)acetamido)propoxy) phenyl)propan-2-yl)phenoxy)propan- 2-yl acetate
    B13c
    Figure US20170298033A1-20171019-C00256
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-2-hydroxy-3-(N- (methylsulfonyl)acetamido)propoxy) phenyl)propan-2-yl)phenoxy) propan-2-yl acetate
    B13d
    Figure US20170298033A1-20171019-C00257
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-2-hydroxy-3-(N- (methylsulfonyl)acetamido)propoxy) phenyl)propan-2-yl)phenoxy) propan-2-yl acetate
    C13
    Figure US20170298033A1-20171019-C00258
         		1-(4-(2-(4-(2-acetoxy-3- (methylsulfonamido)propoxy)phenyl) propan-2-yl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    C13a
    Figure US20170298033A1-20171019-C00259
         		(S)-1-(4-(2-(4-((R)-2-acetoxy-3- (methylsulfonamido)propoxy)phenyl) propan-2-yl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    C13b
    Figure US20170298033A1-20171019-C00260
         		(R)-1-(4-(2-(4-((S)-2-acetoxy-3- (methylsulfonamido)propoxy) phenyl)propan-2-yl)-2,6-dichloro- phenoxy)-3-chloropropan-2-yl acetate
    C13c
    Figure US20170298033A1-20171019-C00261
         		(S)-1-(4-(2-(4-((S)-2-acetoxy-3- (methylsulfonamido)propoxy) phenyl)propan-2-yl)-2,6- dichlorophenoxy)-3- chloropropan-2-yl acetate
    C13d
    Figure US20170298033A1-20171019-C00262
         		(R)-1-(4-(2-(4-((R)-2-acetoxy-3- (methylsulfonamido)propoxy)phenyl) propan-2-yl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    D13
    Figure US20170298033A1-20171019-C00263
         		1-(4-(2-(3,5-dichloro-4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-(N- (methylsulfonyl)acetamido)propan-2- yl acetate
    D13a
    Figure US20170298033A1-20171019-C00264
         		(R)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-(N- (methylsulfonyl)acetamido)propan-2- yl acetate
    D13b
    Figure US20170298033A1-20171019-C00265
         		(S)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-(N- (methylsulfonyl)acetamido)propan-2- yl acetate
    D13c
    Figure US20170298033A1-20171019-C00266
         		(S)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-(N- (methylsulfonyl)acetamido)propan-2- yl acetate
    D13d
    Figure US20170298033A1-20171019-C00267
         		(R)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-(N- (methylsulfonyl)acetamido)propan-2- yl acetate
    E13
    Figure US20170298033A1-20171019-C00268
         		1-(4-(2-(3,5-dichloro-4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3- (methylsulfonamido)propan-2-yl acetate
    E13a
    Figure US20170298033A1-20171019-C00269
         		(R)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3- (methylsulfonamido)propan-2-yl acetate
    E13b
    Figure US20170298033A1-20171019-C00270
         		(S)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3- (methylsulfonamido)propan-2-yl acetate
    E13c
    Figure US20170298033A1-20171019-C00271
         		(S)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3- (methylsulfonamido)propan-2-yl acetate
    E13d
    Figure US20170298033A1-20171019-C00272
         		(R)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3- (methylsulfonamido)propan-2-yl acetate
    F13
    Figure US20170298033A1-20171019-C00273
         		N-(3-(4-(2-(3,5-dichloro-4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2-hydroxypropyl)-N- (methylsulfonyl)acetamide
    F13a
    Figure US20170298033A1-20171019-C00274
         		N-((R)-3-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2-hydroxypropyl)-N- (methylsulfonyl)acetamide
    F13b
    Figure US20170298033A1-20171019-C00275
         		N-((S)-3-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2-hydroxypropyl)-N- (methylsulfonyl)acetamide
    F13c
    Figure US20170298033A1-20171019-C00276
         		N-((S)-3-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2-hydroxypropyl)-N- (methylsulfonyl)acetamide
    F13d
    Figure US20170298033A1-20171019-C00277
         		N-((R)-3-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-2-hydroxypropyl)-N- (methylsulfonyl)acetamide
    G13
    Figure US20170298033A1-20171019-C00278
         		1-chloro-3-(2,6-dichloro-4-(2-(4-(2- hydroxy-3- (methylsulfonamido)propoxy)phenyl) propan-2-yl)phenoxy)propan-2-yl acetate
    G13a
    Figure US20170298033A1-20171019-C00279
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-2-hydroxy-3- (methylsulfonamido)propoxy)phenyl) propan-2-yl)phenoxy)propan-2-yl acetate
    G13b
    Figure US20170298033A1-20171019-C00280
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-2-hydroxy-3- (methylsulfonamido)propoxy)phenyl) propan-2-yl)phenoxy)propan-2-yl acetate
    G13c
    Figure US20170298033A1-20171019-C00281
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-2-hydroxy-3- (methylsulfonamido)propoxy)phenyl) propan-2-yl)phenoxy)propan-2-yl acetate
    G13d
    Figure US20170298033A1-20171019-C00282
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-2-hydroxy-3- (methylsulfonamido)propoxy)phenyl) propan-2-yl)phenoxy)propan-2-yl acetate
    A14
    Figure US20170298033A1-20171019-C00283
         		1-(4-(2-(4-(2-acetoxy-3- (ethylsulfonyl)propoxy)phenyl)propan- 2-yl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    A14a
    Figure US20170298033A1-20171019-C00284
         		(S)-1-(4-(2-(4-((S)-2-acetoxy-3- (ethylsulfonyl)propoxy)phenyl)propan- 2-yl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    A14b
    Figure US20170298033A1-20171019-C00285
         		(R)-1-(4-(2-(4-((R)-2-acetoxy-3- (ethylsulfonyl)propoxy)phenyl)propan- 2-yl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    A14c
    Figure US20170298033A1-20171019-C00286
         		(S)-1-(4-(2-(4-((R)-2-acetoxy-3- (ethylsulfonyl)propoxy)phenyl)propan- 2-yl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    A14d
    Figure US20170298033A1-20171019-C00287
         		(R)-1-(4-(2-(4-((S)-2-acetoxy-3- (ethylsulfonyl)propoxy)phenyl)propan- 2-yl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    B14
    Figure US20170298033A1-20171019-C00288
         		1-(4-(2-(3,5-dichloro-4-(3-chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan- 2-yl acetate
    B14a
    Figure US20170298033A1-20171019-C00289
         		(S)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan- 2-yl acetate
    B14b
    Figure US20170298033A1-20171019-C00290
         		(R)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan- 2-yl acetate
    B14c
    Figure US20170298033A1-20171019-C00291
         		(R)-1-(4-(2-(3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan- 2-yl acetate
    B14d
    Figure US20170298033A1-20171019-C00292
         		(S)-1-(4-(2-(3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan- 2-yl acetate
    C14
    Figure US20170298033A1-20171019-C00293
         		1-chloro-3-(2,6-dichloro-4-(2-(4-(3- (ethylsulfonyl)-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C14a
    Figure US20170298033A1-20171019-C00294
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-3-(ethylsulfonyl)-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C14b
    Figure US20170298033A1-20171019-C00295
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-3-(ethylsulfonyl)-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C14c
    Figure US20170298033A1-20171019-C00296
         		(S)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((R)-3-(ethylsulfonyl)-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    C14d
    Figure US20170298033A1-20171019-C00297
         		(R)-1-chloro-3-(2,6-dichloro-4-(2-(4- ((S)-3-(ethylsulfonyl)-2- hydroxypropoxy)phenyl)propan-2- yl)phenoxy)propan-2-yl acetate
    A15
    Figure US20170298033A1-20171019-C00298
         		1-(4-(2-(4-(2-acetoxy-3- (ethylsulfonyl)propoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)-3-chloropropan-2-yl acetate
    A15a
    Figure US20170298033A1-20171019-C00299
         		(S)-1-(4-(2-(4-((S)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)-3-chloropropan-2- yl acetate
    A15b
    Figure US20170298033A1-20171019-C00300
         		(R)-1-(4-(2-(4-((R)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)-3-chloropropan-2-yl acetate
    A15c
    Figure US20170298033A1-20171019-C00301
         		(S)-1-(4-(2-(4-((R)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)-3-chloropropan-2- yl acetate
    A15d
    Figure US20170298033A1-20171019-C00302
         		(R)-1-(4-(2-(4-((S)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3- chlorophenyl)propan-2-yl)-2- chlorophenoxy)-3-chloropropan-2-yl acetate
    A16
    Figure US20170298033A1-20171019-C00303
         		3-(4-(2-(4-(2-acetoxy-3- chloropropoxy)phenyl)propan-2-yl)- 2,6-dichlorophenoxy)propane-1,2-diyl diacetate
    A16a
    Figure US20170298033A1-20171019-C00304
         		(S)-3-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)phenyl)propan-2-yl)- 2,6-dichlorophenoxy)propane-1,2-diyl diacetate
    A16b
    Figure US20170298033A1-20171019-C00305
         		(R)-3-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)phenyl)propan-2-yl)- 2,6-dichlorophenoxy)propane-1,2-diyl diacetate
    A16c
    Figure US20170298033A1-20171019-C00306
         		(R)-3-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)phenyl)propan-2-yl)- 2,6-dichlorophenoxy)propane-1,2-diyl diacetate
    A16d
    Figure US20170298033A1-20171019-C00307
         		(S)-3-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)phenyl)propan-2-yl)- 2,6-dichlorophenoxy)propane-1,2-diyl diacetate
    A17
    Figure US20170298033A1-20171019-C00308
         		1-(4-(2-(4-(2-acetoxy-3- (ethylsulfonyl)propoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-chloropropan-2-yl acetate
    A17a
    Figure US20170298033A1-20171019-C00309
         		(S)-1-(4-(2-(4-((S)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-chloropropan-2-yl acetate
    A17b
    Figure US20170298033A1-20171019-C00310
         		(R)-1-(4-(2-(4-((R)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-chloropropan-2-yl acetate
    A17c
    Figure US20170298033A1-20171019-C00311
         		(S)-1-(4-(2-(4-((R)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-chloropropan-2-yl acetate
    A17d
    Figure US20170298033A1-20171019-C00312
         		(R)-1-(4-(2-(4-((S)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3,5- dichlorophenyl)propan-2-yl)phenoxy)- 3-chloropropan-2-yl acetate
    A18
    Figure US20170298033A1-20171019-C00313
         		3-(4-(2-(3,5-dichloro-4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    A18a
    Figure US20170298033A1-20171019-C00314
         		(S)-3-(4-(2-(3,5-dichloro-4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    A18b
    Figure US20170298033A1-20171019-C00315
         		(R)-3-(4-(2-(3,5-dichloro-4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    A19
    Figure US20170298033A1-20171019-C00316
         		1-(4-(2-(3,5-dichloro-4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan- 2-yl acetate
    A19a
    Figure US20170298033A1-20171019-C00317
         		(S)-1-(4-(2-(3,5-dichloro-4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl) propan-2-yl acetate
    A19b
    Figure US20170298033A1-20171019-C00318
         		(R)-1-(4-(2-(3,5-dichloro-4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan- 2-yl acetate
    A20
    Figure US20170298033A1-20171019-C00319
         		3-(2,6-dichloro-4-(2-(4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    A20a
    Figure US20170298033A1-20171019-C00320
         		(S)-3-(2,6-dichloro-4-(2-(4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    A20b
    Figure US20170298033A1-20171019-C00321
         		(R)-3-(2,6-dichloro-4-(2-(4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)propane-1,2-diyl diacetate
    A21
    Figure US20170298033A1-20171019-C00322
         		1-(2,6-dichloro-4-(2-(4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan- 2-yl acetate
    A21a
    Figure US20170298033A1-20171019-C00323
         		(S)-1-(2,6-dichloro-4-(2-(4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan- 2-yl acetate
    A21b
    Figure US20170298033A1-20171019-C00324
         		(R)-1-(2,6-dichloro-4-(2-(4-(3- chloropropoxy)phenyl)propan-2- yl)phenoxy)-3-(ethylsulfonyl)propan- 2-yl acetate
    A22
    Figure US20170298033A1-20171019-C00325
         		3-(4-(2-(4-(2-acetoxy-3- chloropropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diyl diacetate
    A22a
    Figure US20170298033A1-20171019-C00326
         		(S)-3-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diyl diacetate
    A22b
    Figure US20170298033A1-20171019-C00327
         		(R)-3-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diyl diacetate
    A22c
    Figure US20170298033A1-20171019-C00328
         		(R)-3-(4-(2-(4-((S)-2-acetoxy-3- chloropropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diyl diacetate
    A22d
    Figure US20170298033A1-20171019-C00329
         		(S)-3-(4-(2-(4-((R)-2-acetoxy-3- chloropropoxy)-3- methylphenyl)propan-2-yl)-2- methylphenoxy)propane-1,2-diyl diacetate
  • In some more specific embodiments of the compound of Formula I, the compound has one of the following structures from Table 3, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof:
  • TABLE 3
    Compounds
    No. Structure Name
    40
    Figure US20170298033A1-20171019-C00330
         		3-(4-((3-chloro-4-(3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    40a
    Figure US20170298033A1-20171019-C00331
         		(R)-3-(4-((3-chloro-4-((S)-3-chloro- 2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    40b
    Figure US20170298033A1-20171019-C00332
         		(S)-3-(4-((3-chloro-4-((R)-3-chloro- 2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    40c
    Figure US20170298033A1-20171019-C00333
         		(S)-3-(4-((3-chloro-4-((S)-3-chloro- 2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    40d
    Figure US20170298033A1-20171019-C00334
         		(R)-3-(4-((3-chloro-4-((R)-3-chloro- 2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    41
    Figure US20170298033A1-20171019-C00335
         		3-(4-((3,5-dichloro-4-(3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    41a
    Figure US20170298033A1-20171019-C00336
         		(R)-3-(4-((3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    41b
    Figure US20170298033A1-20171019-C00337
         		(S)-3-(4-((3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    41c
    Figure US20170298033A1-20171019-C00338
         		(S)-3-(4-((3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    41d
    Figure US20170298033A1-20171019-C00339
         		(R)-3-(4-((3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    42
    Figure US20170298033A1-20171019-C00340
         		3-(2-chloro-4-((3-chloro-4-(3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    42a
    Figure US20170298033A1-20171019-C00341
         		(R)-3-(2-chloro-4-((3-chloro-4-((S)- 3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    42b
    Figure US20170298033A1-20171019-C00342
         		(S)-3-(2-chloro-4-((3-chloro-4-((R)- 3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    42c
    Figure US20170298033A1-20171019-C00343
         		(S)-3-(2-chloro-4-((3-chloro-4-((S)- 3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    42d
    Figure US20170298033A1-20171019-C00344
         		(R)-3-(2-chloro-4-((3-chloro-4-((R)- 3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    43
    Figure US20170298033A1-20171019-C00345
         		1-chloro-3-(2,6-dichloro-4-((4-(2- hydroxy-3- methoxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    43a
    Figure US20170298033A1-20171019-C00346
         		(S)-1-chloro-3-(2,6-dichloro-4-((4- ((R)-2-hydroxy-3- methoxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    43b
    Figure US20170298033A1-20171019-C00347
         		(R)-1-chloro-3-(2,6-dichloro-4-((4- ((S)-2-hydroxy-3- methoxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    43c
    Figure US20170298033A1-20171019-C00348
         		(S)-1-chloro-3-(2,6-dichloro-4-((4- ((S)-2-hydroxy-3- methoxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    43d
    Figure US20170298033A1-20171019-C00349
         		(R)-1-chloro-3-(2,6-dichloro-4-((4- ((R)-2-hydroxy-3- methoxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    44
    Figure US20170298033A1-20171019-C00350
         		1-chloro-3-(2-chloro-4-((3-chloro-4- (2-hydroxy-3- methoxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    44a
    Figure US20170298033A1-20171019-C00351
         		(S)-1-chloro-3-(2-chloro-4-((3- chloro-4-((R)-2-hydroxy-3- methoxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    44b
    Figure US20170298033A1-20171019-C00352
         		(R)-1-chloro-3-(2-chloro-4-((3- chloro-4-((S)-2-hydroxy-3- methoxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    44c
    Figure US20170298033A1-20171019-C00353
         		(S)-1-chloro-3-(2-chloro-4-((3- chloro-4-((S)-2-hydroxy-3- methoxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    44d
    Figure US20170298033A1-20171019-C00354
         		(R)-1-chloro-3-(2-chloro-4-((3- chloro-4-((R)-2-hydroxy-3- methoxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    45
    Figure US20170298033A1-20171019-C00355
         		1-amino-3-(4-((3,5-dichloro-4-(3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    45a
    Figure US20170298033A1-20171019-C00356
         		(R)-1-amino-3-(4-((3,5-dichloro-4- ((S)-3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    45b
    Figure US20170298033A1-20171019-C00357
         		(S)-1-amino-3-(4-((3,5-dichloro-4- ((R)-3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    45c
    Figure US20170298033A1-20171019-C00358
         		(S)-1-amino-3-(4-((3,5-dichloro-4- ((S)-3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    45d
    Figure US20170298033A1-20171019-C00359
         		(R)-1-amino-3-(4-((3,5-dichloro-4- ((R)-3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    46
    Figure US20170298033A1-20171019-C00360
         		N-(3-(4-((3,5-dichloro-4-(3-chloro- 2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)-2- hydroxypropyl)methanesulfonamide
    46a
    Figure US20170298033A1-20171019-C00361
         		N-(R)-3-(4-((3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)-2- hydroxypropyl)methanesulfonamide
    46b
    Figure US20170298033A1-20171019-C00362
         		N-((S)-3-(4-((3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)-2- hydroxypropyl)methanesulfonamide
    46c
    Figure US20170298033A1-20171019-C00363
         		N-((S)-3-(4-((3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)-2- hydroxypropyl)methanesulfonamide
    46d
    Figure US20170298033A1-20171019-C00364
         		N-((R)-3-(4-((3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)-2- hydroxypropyl)methanesulfonamide
    47
    Figure US20170298033A1-20171019-C00365
         		1-chloro-3-(2,6-dichloro-4-((4-(2- hydroxy-3- morpholinopropoxy)phenyl) sulfonyl)phenoxy)propan-2-ol
    47a
    Figure US20170298033A1-20171019-C00366
         		(S)-1-chloro-3-(2,6-dichloro-4-((4- ((R)-2-hydroxy-3- morpholinopropoxy)phenyl) sulfonyl)phenoxy)propan-2-ol
    47b
    Figure US20170298033A1-20171019-C00367
         		(R)-1-chloro-3-(2,6-dichloro-4-((4- ((S)-2-hydroxy-3- morpholinopropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    47c
    Figure US20170298033A1-20171019-C00368
         		(S)-1-chloro-3-(2,6-dichloro-4-((4- ((S)-2-hydroxy-3- morpholinopropoxy)phenyl) sulfonyl)phenoxy)propan-2-ol
    47d
    Figure US20170298033A1-20171019-C00369
         		(R)-1-chloro-3-(2,6-dichloro-4-((4- ((R)-2-hydroxy-3- morpholinopropoxy)phenyl) sulfonyl)phenoxy)propan-2-ol
    48
    Figure US20170298033A1-20171019-C00370
         		1-chloro-3-(2,6-dichloro-4-((4-(2- hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    48a
    Figure US20170298033A1-20171019-C00371
         		(S)-1-chloro-3-(2,6-dichloro-4-((4- ((R)-2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    48b
    Figure US20170298033A1-20171019-C00372
         		(R)-1-chloro-3-(2,6-dichloro-4-((4- ((S)-2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    48c
    Figure US20170298033A1-20171019-C00373
         		(S)-1-chloro-3-(2,6-dichloro-4-((4- ((S)-2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    48d
    Figure US20170298033A1-20171019-C00374
         		(R)-1-chloro-3-(2,6-dichloro-4-((4- ((R)-2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    49
    Figure US20170298033A1-20171019-C00375
         		1-chloro-3-(2-chloro-4-((3-chloro-4- (2-hydroxy-3-(1H-imidazol-1- yl)propoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    49a
    Figure US20170298033A1-20171019-C00376
         		(S)-1-chloro-3-(2-chloro-4-((3- chloro-4-((R)-2-hydroxy-3-(1H- imidazol-1- yl)propoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    49b
    Figure US20170298033A1-20171019-C00377
         		(R)-1-chloro-3-(2-chloro-4-((3- chloro-4-((S)-2-hydroxy-3-(1H- imidazol-1- yl)propoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    49c
    Figure US20170298033A1-20171019-C00378
         		(S)-1-chloro-3-(2-chloro-4-((3- chloro-4-((S)-2-hydroxy-3-(1H- imidazol-1- yl)propoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    49d
    Figure US20170298033A1-20171019-C00379
         		(R)-1-chloro-3-(2-chloro-4-((3- chloro-4-((R)-2-hydroxy-3-(1H- imidazol-1- yl)propoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    50
    Figure US20170298033A1-20171019-C00380
         		1-chloro-3-(2,6-dichloro-4-((4-(2- hydroxy-3- (ethylsulfonyl)propoxy)phenyl) sulfonyl)phenoxy)propan-2-ol
    50a
    Figure US20170298033A1-20171019-C00381
         		(S)-1-chloro-3-(2,6-dichloro-4-((4- ((S)-2-hydroxy-3- (ethylsulfonyl)propoxy)phenyl) sulfonyl)phenoxy)propan-2-ol
    50b
    Figure US20170298033A1-20171019-C00382
         		(R)-1-chloro-3-(2,6-dichloro-4-((4- ((R)-2-hydroxy-3- (ethylsulfonyl)propoxy)phenyl) sulfonyl)phenoxy)propan-2-ol
    50c
    Figure US20170298033A1-20171019-C00383
         		(S)-1-chloro-3-(2,6-dichloro-4-((4- ((R)-2-hydroxy-3- (ethylsulfonyl)propoxy)phenyl) sulfonyl)phenoxy)propan-2-ol
    50d
    Figure US20170298033A1-20171019-C00384
         		(R)-1-chloro-3-(2,6-dichloro-4-((4- ((S)-2-hydroxy-3- (ethylsulfonyl)propoxy)phenyl) sulfonyl)phenoxy)propan-2-ol
    51
    Figure US20170298033A1-20171019-C00385
         		1-chloro-3-(2-chloro-4-((3-chloro-4- (2-hydroxy-3- (ethylsulfonyl)propoxy)phenyl) sulfonyl)phenoxy)propan-2-ol
    51a
    Figure US20170298033A1-20171019-C00386
         		(S)-1-chloro-3-(2-chloro-4-((3- chloro-4-((S)-2-hydroxy-3- (ethylsulfonyl)propoxy)phenyl) sulfonyl)phenoxy)propan-2-ol
    51b
    Figure US20170298033A1-20171019-C00387
         		(R)-1-chloro-3-(2-chloro-4-((3- chloro-4-((R)-2-hydroxy-3- (ethyIsulfonyl)propoxy)phenyl) sulfonyl)phenoxy)propan-2-ol
    51c
    Figure US20170298033A1-20171019-C00388
         		(S)-1-chloro-3-(2-chloro-4-((3- chloro-4-((R)-2-hydroxy-3- (ethylsulfonyl)propoxy)phenyl) sulfonyl)phenoxy)propan-2-ol
    51d
    Figure US20170298033A1-20171019-C00389
         		(R)-1-chloro-3-(2-chloro-4-((3- chloro-4-((S)-2-hydroxy-3- (ethylsulfonyl)propoxy)phenyl) sulfonyl)phenoxy)propan-2-ol
    52
    Figure US20170298033A1-20171019-C00390
         		3-(2,6-dichloro-4-((4-(3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    52a
    Figure US20170298033A1-20171019-C00391
         		(R)-3-(2,6-dichloro-4-((4-((S)-3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    52b
    Figure US20170298033A1-20171019-C00392
         		(S)-3-(2,6-dichloro-4-((4-((R)-3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    52c
    Figure US20170298033A1-20171019-C00393
         		(S)-3-(2,6-dichloro-4-((4-((S)-3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    52d
    Figure US20170298033A1-20171019-C00394
         		(R)-3-(2,6-dichloro-4-((4-((R)-3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    53
    Figure US20170298033A1-20171019-C00395
         		1-chloro-3-(4-((3,5-dichloro-4-(3- (ethylsulfonyl)-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    53a
    Figure US20170298033A1-20171019-C00396
         		(S)-1-chloro-3-(4-((3,5-dichloro-4- ((S)-3-(ethylsulfonyl)-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    53b
    Figure US20170298033A1-20171019-C00397
         		(R)-1-chloro-3-(4-((3,5-dichloro-4- ((R)-3-(ethylsulfonyl)-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    53c
    Figure US20170298033A1-20171019-C00398
         		(S)-1-chloro-3-(4-((3,5-dichloro-4- ((R)-3-(ethylsulfonyl)-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    53d
    Figure US20170298033A1-20171019-C00399
         		(R)-1-chloro-3-(4-((3,5-dichloro-4- ((S)-3-(ethylsulfonyl)-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propan-2-ol
    54
    Figure US20170298033A1-20171019-C00400
         		3-(4-((3,5-dichloro-4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    54a
    Figure US20170298033A1-20171019-C00401
         		(R)-3-(4-((3,5-dichloro-4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    54b
    Figure US20170298033A1-20171019-C00402
         		(S)-3-(4-((3,5-dichloro-4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    55
    Figure US20170298033A1-20171019-C00403
         		1-(4-((3,5-dichloro-4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)-3-(ethylsulfonyl) propan-2-ol
    55a
    Figure US20170298033A1-20171019-C00404
         		(S)-1-(4-((3,5-dichloro-4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)-3-(ethylsulfonyl)propan- 2-ol
    55b
    Figure US20170298033A1-20171019-C00405
         		(R)-1-(4-((3,5-dichloro-4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)-3-(ethylsulfonyl)propan- 2-ol
    56
    Figure US20170298033A1-20171019-C00406
         		3-(2,6-dichloro-4-((4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    56a
    Figure US20170298033A1-20171019-C00407
         		(R)-3-(2,6-dichloro-4-((4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    56b
    Figure US20170298033A1-20171019-C00408
         		(S)-3-(2,6-dichloro-4-((4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    57
    Figure US20170298033A1-20171019-C00409
         		1-(2,6-dichloro-4-((4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)-3-(ethylsulfonyl)propan-2-ol
    57a
    Figure US20170298033A1-20171019-C00410
         		(S)-1-(2,6-dichloro-4-((4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)-3-(ethylsulfonyl)propan-2-ol
    57b
    Figure US20170298033A1-20171019-C00411
         		(R)-1-(2,6-dichloro-4-((4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)-3-(ethylsulfonyl)propan-2-ol
  • In some more specific embodiments of the compound of Formula I, the compound has one of the following structures from Table 4, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof:
  • TABLE 4
    Compounds
    No. Structure Name
    A40
    Figure US20170298033A1-20171019-C00412
         		3-(4-((4-(2-acetoxy-3- chloropropoxy)-3- chlorophenyl)sulfonyl)phenoxy) propane-1,2-diyl diacetate
    A40a
    Figure US20170298033A1-20171019-C00413
         		(S)-3-(4-((4-((S)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)sulfonyl)phenoxy) propane-1,2-diyl diacetate
    A40b
    Figure US20170298033A1-20171019-C00414
         		(R)-3-(4-((4-((R)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)sulfonyl)phenoxy) propane-1,2-diyl diacetate
    A40c
    Figure US20170298033A1-20171019-C00415
         		(R)-3-(4-((4-((S)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)sulfonyl)phenoxy) propane-1,2-diyl diacetate
    A40d
    Figure US20170298033A1-20171019-C00416
         		(S)-3-(4-((4-((R)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)sulfonyl)phenoxy) propane-1,2-diyl diacetate
    A41
    Figure US20170298033A1-20171019-C00417
         		3-(4-((4-(2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy) propane-1,2-diyl diacetate
    A41a
    Figure US20170298033A1-20171019-C00418
         		(S)-3-(4-((4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy) propane-1,2-diyl diacetate
    A41b
    Figure US20170298033A1-20171019-C00419
         		(R)-3-(4-((4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy) propane-1,2-diyl diacetate
    A41c
    Figure US20170298033A1-20171019-C00420
         		(R)-3-(4-((4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy) propane-1,2-diyl diacetate
    A41d
    Figure US20170298033A1-20171019-C00421
         		(S)-3-(4-((4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy) propane-1,2-diyl diacetate
    A42
    Figure US20170298033A1-20171019-C00422
         		3-(4-((4-(2-acetoxy-3- chloropropoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)propane-1,2-diyl diacetate
    A42a
    Figure US20170298033A1-20171019-C00423
         		(S)-3-(4-((4-((S)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)propane-1,2-diyl diacetate
    A42b
    Figure US20170298033A1-20171019-C00424
         		(R)-3-(4-((4-((R)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)propane-1,2-diyl diacetate
    A42c
    Figure US20170298033A1-20171019-C00425
         		(R)-3-(4-((4-((S)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)propane-1,2-diyl diacetate
    A42d
    Figure US20170298033A1-20171019-C00426
         		(S)-3-(4-((4-((R)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)propane-1,2-diyl diacetate
    A43
    Figure US20170298033A1-20171019-C00427
         		1-(4-((4-(2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy)- 3-methoxypropan-2-yl acetate
    A43a
    Figure US20170298033A1-20171019-C00428
         		(R)-1-(4-((4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy)- 3-methoxypropan-2-yl acetate
    A43b
    Figure US20170298033A1-20171019-C00429
         		(S)-1-(4-((4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy)- 3-methoxypropan-2-yl acetate
    A43c
    Figure US20170298033A1-20171019-C00430
         		(S)-1-(4-((4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy)- 3-methoxypropan-2-yl acetate
    A43d
    Figure US20170298033A1-20171019-C00431
         		(R)-1-(4-((4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy)- 3-methoxypropan-2-yl acetate
    A44
    Figure US20170298033A1-20171019-C00432
         		1-(4-((4-(2-acetoxy-3- chloropropoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)-3-methoxypropan- 2-yl acetate
    A44a
    Figure US20170298033A1-20171019-C00433
         		(R)-1-(4-((4-((S)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)-3-methoxypropan- 2-yl acetate
    A44b
    Figure US20170298033A1-20171019-C00434
         		(S)-1-(4-((4-((R)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)-3-methoxypropan- 2-yl acetate
    A44c
    Figure US20170298033A1-20171019-C00435
         		(S)-1-(4-((4-((S)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)-3-methoxypropan- 2-yl acetate
    A44d
    Figure US20170298033A1-20171019-C00436
         		(R)-1-(4-((4-((R)-2-acetoxy-3- chloropropoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)-3-methoxypropan- 2-yl acetate
    A45
    Figure US20170298033A1-20171019-C00437
         		1-(4-((4-(2-acetoxy-3-(N- acetylacetamido)propoxy)phenyl) sulfonyl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    A45a
    Figure US20170298033A1-20171019-C00438
         		N-acetyl-N-((R)-3-(4-((3,5- dichloro-4-((S)-3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)-2- hydroxypropyl)acetamide
    A45b
    Figure US20170298033A1-20171019-C00439
         		N-acetyl-N-((S)-3-(4-((3,5- dichloro-4-((R)-3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)-2- hydroxypropyl)acetamide
    A45c
    Figure US20170298033A1-20171019-C00440
         		N-acetyl-N-((S)-3-(4-((3,5- dichloro-4-((S)-3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)-2- hydroxypropyl)acetamide
    A45d
    Figure US20170298033A1-20171019-C00441
         		N-acetyl-N-((R)-3-(4-((3,5- dichloro-4-((R)-3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)-2- hydroxypropyl)acetamide
    B45
    Figure US20170298033A1-20171019-C00442
         		1-(4-((4-(3-acetamido-2- acetoxypropoxy)phenyl)sulfonyl)- 2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    B45a
    Figure US20170298033A1-20171019-C00443
         		N-((R)-3-(4-((3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)-2- hydroxypropyl)acetamide
    B45b
    Figure US20170298033A1-20171019-C00444
         		N-((S)-3-(4-((3,5-dichloro-4-((R)-3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)-2- hydroxypropyl)acetamide
    B45c
    Figure US20170298033A1-20171019-C00445
         		N-((S)-3-(4-((3,5-dichloro-4-((S)-3- chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)-2- hydroxypropyl)acetamide
    B45d
    Figure US20170298033A1-20171019-C00446
         		N-((R)-3-(4-((3,5-dichloro-4-((R)- 3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)-2- hydroxypropyl)acetamide
    A46
    Figure US20170298033A1-20171019-C00447
         		1-(4-((4-(2-acetoxy-3-(N- (methylsulfonyl)acetamido)propoxy) phenyl)sulfonyl)-2,6- dichlorophenoxy)-3-chloropropan- 2-yl acetate
    A46a
    Figure US20170298033A1-20171019-C00448
         		(S)-1-(4-((4-((R)-2-acetoxy-3-(N- (methylsulfonyl)acetamido) propoxy)phenyl)sulfonyl)-2,6- dichlorophenoxy)-3-chloropropan- 2-yl acetate
    A46b
    Figure US20170298033A1-20171019-C00449
         		(R)-1-(4-((4-((S)-2-acetoxy-3-(N- (methylsulfonyl)acetamido) propoxy)phenyl)sulfonyl)-2,6- dichlorophenoxy)-3-chloropropan- 2-yl acetate
    A46c
    Figure US20170298033A1-20171019-C00450
         		(S)-1-(4-((4-((S)-2-acetoxy-3-(N- (methylsulfonyl)acetamido)propoxy) phenyl)sulfonyl)-2,6- dichlorophenoxy)-3-chloropropan- 2-yl acetate
    A46d
    Figure US20170298033A1-20171019-C00451
         		(R)-1-(4-((4-((R)-2-acetoxy-3-(N- (methylsulfonyl)acetamido) propoxy)phenyl)sulfonyl)-2,6- dichlorophenoxy)-3-chloropropan- 2-yl acetate
    A47
    Figure US20170298033A1-20171019-C00452
         		1-(4-((4-(2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy)- 3-morpholinopropan-2-yl acetate
    A47a
    Figure US20170298033A1-20171019-C00453
         		(R)-1-(4-((4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy)- 3-morpholinopropan-2-yl acetate
    A47b
    Figure US20170298033A1-20171019-C00454
         		(S)-1-(4-((4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy)- 3-morpholinopropan-2-yl acetate
    A47c
    Figure US20170298033A1-20171019-C00455
         		(S)-1-(4-((4-((S)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy)- 3-morpholinopropan-2-yl acetate
    A47d
    Figure US20170298033A1-20171019-C00456
         		(R)-1-(4-((4-((R)-2-acetoxy-3- chloropropoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy)- 3-morpholinopropan-2-yl acetate
    A48
    Figure US20170298033A1-20171019-C00457
         		1-(4-((4-(2-acetoxy-3-(1H- imidazol-1- yl)propoxy)phenyl)sulfonyl)-2,6- dichlorophenoxy)-3-chloropropan- 2-yl acetate
    A48a
    Figure US20170298033A1-20171019-C00458
         		(S)-1-(4-((4-((R)-2-acetoxy-3-(1H- imidazol-1- yl)propoxy)phenyl)sulfonyl)-2,6- dichlorophenoxy)-3-chloropropan- 2-yl acetate
    A48b
    Figure US20170298033A1-20171019-C00459
         		(R)-1-(4-((4-((S)-2-acetoxy-3-(1H- imdiazol-1- yl)propoxy)phenyl)sulfonyl)-2,6- dichlorophenoxy)-3-chloropropan- 2-yl acetate
    A48c
    Figure US20170298033A1-20171019-C00460
         		(S)-1-(4-((4-((S)-2-acetoxy-3-(1H- imidazol-1- yl)propoxy)phenyl)sulfonyl)-2,6- dichlorophenoxy)-3-chloropropan- 2-yl acetate
    A48d
    Figure US20170298033A1-20171019-C00461
         		(R)-1-(4-((4-((R)-2-acetoxy-3-(1H- imidazol-1- yl)propoxy)phenyl)sulfonyl)-2,6- dichlorophenoxy)-3-chloropropan- 2-yl acetate
    A49
    Figure US20170298033A1-20171019-C00462
         		1-(4-((4-(2-acetoxy-3-(1H- imidazol-1-yl)propoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)-3-chloropropan-2- yl acetate
    A49a
    Figure US20170298033A1-20171019-C00463
         		(S)-1-(4-((4-((R)-2-acetoxy-3-(1H- imidazol-1-yl)propoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)-3-chloropropan-2- yl acetate
    A49b
    Figure US20170298033A1-20171019-C00464
         		(R)-1-(4-((4-((S)-2-acetoxy-3-(1H- imidazol-1-yl)propoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)-3-chloropropan-2- yl acetate
    A49c
    Figure US20170298033A1-20171019-C00465
         		(S)-1-(4-((4-((S)-2-acetoxy-3-(1H- imidazol-1-yl)propoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)-3-chloropropan-2- yl acetate
    A49d
    Figure US20170298033A1-20171019-C00466
         		(R)-1-(4-((4-((R)-2-acetoxy-3-(1H- imidazol-1-yl)propoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)-3-chloropropan-2- yl acetate
    A50
    Figure US20170298033A1-20171019-C00467
         		1-(4-((4-(2-acetoxy-3- (ethylsulfonyl)propoxy)phenyl) sulfonyl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    A50a
    Figure US20170298033A1-20171019-C00468
         		(S)-1-(4-((4-((S)-2-acetoxy-3- (ethylsulfonyl)propoxy)phenyl) sulfonyl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    A50b
    Figure US20170298033A1-20171019-C00469
         		(R)-1-(4-((4-((R)-2-acetoxy-3- (ethylsulfonyl)propoxy)phenyl) sulfonyl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    A50c
    Figure US20170298033A1-20171019-C00470
         		(S)-1-(4-((4-((R)-2-acetoxy-3- (ethylsulfonyl)propoxy)phenyl) sulfonyl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    A50d
    Figure US20170298033A1-20171019-C00471
         		(R)-1-(4-((4-((S)-2-acetoxy-3- (ethylsulfonyl)propoxy)phenyl) sulfonyl)-2,6-dichlorophenoxy)-3- chloropropan-2-yl acetate
    A51
    Figure US20170298033A1-20171019-C00472
         		1-(4-((4-(2-acetoxy-3- (ethylsulfonyl)propoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)-3-chloropropan-2- yl acetate
    A51a
    Figure US20170298033A1-20171019-C00473
         		(S)-1-(4-((4-((S)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)-3-chloropropan-2- yl acetate
    A51b
    Figure US20170298033A1-20171019-C00474
         		(R)-1-(4-((4-((R)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)-3-chloropropan-2- yl acetate
    A51c
    Figure US20170298033A1-20171019-C00475
         		(S)-1-(4-((4-((R)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)-3-chloropropan-2- yl acetate
    A51d
    Figure US20170298033A1-20171019-C00476
         		(R)-1-(4-((4-((S)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3- chlorophenyl)sulfonyl)-2- chlorophenoxy)-3-chloropropan-2- yl acetate
    A52
    Figure US20170298033A1-20171019-C00477
         		3-(4-((4-(2-acetoxy-3- chloropropoxy)phenyl)sulfonyl)- 2,6-dichlorophenoxy)propane-1,2- diyl diacetate
    A52a
    Figure US20170298033A1-20171019-C00478
         		(S)-3-(4-((4-((S)-2-acetoxy-3- chloropropoxy)phenyl)sulfonyl)- 2,6-dichlorophenoxy)propane-1,2- diyl diacetate
    A52b
    Figure US20170298033A1-20171019-C00479
         		(R)-3-(4-((4-((R)-2-acetoxy-3- chloropropoxy)phenyl)sulfonyl)- 2,6-dichlorophenoxy)propane-1,2- diyl diacetate
    A52c
    Figure US20170298033A1-20171019-C00480
         		(R)-3-(4-((4-((S)-2-acetoxy-3- chloropropoxy)phenyl)sulfonyl)- 2,6-dichlorophenoxy)propane-1,2- diyl diacetate
    A52d
    Figure US20170298033A1-20171019-C00481
         		(S)-3-(4-((4-((R)-2-acetoxy-3- chloropropoxy)phenyl)sulfonyl)- 2,6-dichlorophenoxy)propane-1,2- diyl diacetate
    A53
    Figure US20170298033A1-20171019-C00482
         		1-(4-((4-(2-acetoxy-3- (ethylsulfonyl)propoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy)- 3-chloropropan-2-yl acetate
    A53a
    Figure US20170298033A1-20171019-C00483
         		(S)-1-(4-((4-((S)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy)- 3-chloropropan-2-yl acetate
    A53b
    Figure US20170298033A1-20171019-C00484
         		(R)-1-(4-((4-((R)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy)- 3-chloropropan-2-yl acetate
    A53c
    Figure US20170298033A1-20171019-C00485
         		(S)-1-(4-((4-((R)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy)- 3-chloropropan-2-yl acetate
    A53d
    Figure US20170298033A1-20171019-C00486
         		(R)-1-(4-((4-((S)-2-acetoxy-3- (ethylsulfonyl)propoxy)-3,5- dichlorophenyl)sulfonyl)phenoxy)- 3-chloropropan-2-yl acetate
    A54
    Figure US20170298033A1-20171019-C00487
         		3-(4-((3,5-dichloro-4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diyl diacetate
    A54a
    Figure US20170298033A1-20171019-C00488
         		(S)-3-(4-((3,5-dichloro-4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diyl diacetate
    A54b
    Figure US20170298033A1-20171019-C00489
         		(R)-3-(4-((3,5-dichloro-4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diyl diacetate
    A55
    Figure US20170298033A1-20171019-C00490
         		1-(4-((3,5-dichloro-4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)-3-(ethylsulfonyl)propan-2-yl acetate
    A55a
    Figure US20170298033A1-20171019-C00491
         		(S)-1-(4-((3,5-dichloro-4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)-3-(ethylsulfonyl)propan-2-yl acetate
    A55b
    Figure US20170298033A1-20171019-C00492
         		(R)-1-(4-((3,5-dichloro-4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)-3-(ethylsulfonyl)propan-2-yl acetate
    A56
    Figure US20170298033A1-20171019-C00493
         		3-(2,6-dichloro-4-((4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diyl diacetate
    A56a
    Figure US20170298033A1-20171019-C00494
         		(S)-3-(2,6-dichloro-4-((4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diyl diacetate
    A56b
    Figure US20170298033A1-20171019-C00495
         		(R)-3-(2,6-dichloro-4-((4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diyl diacetate
    A57
    Figure US20170298033A1-20171019-C00496
         		1-(2,6-dichloro-4-((4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)-3-(ethylsulfonyl)propan-1-yl acetate
    A57a
    Figure US20170298033A1-20171019-C00497
         		(S)-1-(2,6-dichloro-4-((4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)-3-(ethylsulfonyl)propan-2-yl acetate
    A57b
    Figure US20170298033A1-20171019-C00498
         		(R)-1-(2,6-dichloro-4-((4-(3- chloropropoxy)phenyl)sulfonyl) phenoxy)-3-(ethylsulfonyl)propan-2-yl acetate
  • In some embodiments of the compound of Formula I, the compound has one of the following structures from Tables 1, 2, 3, or 4, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
  • The present invention includes all compounds which have the above described properties (i.e., binding to androgen receptor (AR)). In one embodiment, the present invention is directed to a compound having a structure of Formula II:
  • Figure US20170298033A1-20171019-C00499
  • or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
  • R1 is H, hydroxyl or —OC(═O)R13;
  • R2 is hydroxyl or —OC(═O)R13;
  • R3 is halo, —OH, —OR4, —OC(═O)R13, —NH2, —NHC(═O)R13, —N(C(═O)R13)2, —NHS(O)nR5, —N(C(═O)R13)(S(O)nR5), —N(C1-C6 alkyl)(S(O)nR5), —S(O)nR5, —N3, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R6;
  • R4 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R6;
  • R5 is each independently C1-C6 alkyl or aryl which are optionally substituted with one or more R6;
  • R6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123I, hydroxyl, oxo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C6-C12 aryl, wherein each R6 is optionally substituted with one or more of halogen, 123I, 18F, hydroxyl, —OS(O)2-aryl, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
  • R13 is C1-C6 alkyl; and
  • n is 0, 1, or 2.
  • In various embodiments, different stereoisomers of the compound of structure (II) are provided, for example in some embodiments the compound has one of the following structures (IIa), (IIb), (IIc) or (IId):
  • Figure US20170298033A1-20171019-C00500
  • In still other embodiments, the compound has one of the following structures (IIe), (IIf), (IIg) or (IIh):
  • Figure US20170298033A1-20171019-C00501
  • In one embodiment, R1 is hydroxyl. In another embodiment, R1 is —OC(═O)R13. In some embodiments, R1 is —OC(═O)R13, wherein R13 is C1-C4 alkyl. In other embodiments, R1 is —OC(═O)R13, wherein R13 is methyl. In one embodiment, R1 is H.
  • In one embodiment, R2 is hydroxyl. In another embodiment, R2 is —OC(═O)R13. In some embodiments, R2 is —OC(═O)R13, wherein R13 is C1-C4 alkyl. In other embodiments, R2 is —OC(═O)R13, wherein R13 is methyl.
  • In one embodiment, R3 is —OH. In another embodiment, R3 is —OC(═O)R13. In some embodiments, R3 is —OC(═O)R13, wherein R13 is C1-C4 alkyl. In other embodiments, R3 is —OC(═O)R13, wherein R13 is methyl.
  • In some embodiments, at least one of R1, R2, or R3 is —OH. In another embodiment, at least one of R1, R2, or R3 is —OH. In some embodiments, at least two of R1, R2, or R3 are each —OH. In another embodiment, R1 and R2 are each —OH. In one embodiment, R1, R2, or R3 are each —OH.
  • In some embodiments, at least one of R1, R2, or R3 is —OC(═O)R13, wherein R13 is C1-C4 alkyl. In another embodiment, at least one of R1, R2, or R3 is —OC(═O)R13, wherein R13 is methyl. In some embodiments, at least two of R1, R2, or R3 are each —OC(═O)R13, wherein R13 is C1-C4 alkyl. In another embodiment, at least two of R1, R2, or R3 are each —OC(═O)R13, wherein R13 is methyl.
  • In some embodiments, one of R1, R2, or R3 is —OC(═O)R13, wherein R13 is C1-C4 alkyl.
  • In another embodiment, one of R1, R2, or R3 is —OC(═O)R13, wherein R13 is methyl. In some embodiments, two of R1, R2, or R3 are each —OC(═O)R13, wherein R13 is C1-C4 alkyl. In another embodiment, two of R1, R2, or R3 are each —OC(═O)R13, wherein R13 is methyl. In some embodiments, R1, R2, or R3 are each —OC(═O)R13, wherein R13 is C1-C4 alkyl. In another embodiment, R1, R2, or R3 are each —OC(═O)R13, wherein R13 is methyl.
  • In other embodiments, R3 is —OR4. In one embodiment, R3 is —OR4, wherein R4 is C1-C6 alkyl. In another embodiment, R3 is —OR4, wherein R4 is C1-C3 alkyl. In one embodiment, R3 is —OR4, wherein R4 is C1 alkyl. In another embodiment, R3 is —OR4, wherein R4 is isopropyl.
  • In other embodiments, R3 is a halogen. In one embodiment, R3 is F.
  • In other embodiments, R3 is —NH2, —NHC(═O)R13, —N(C(═O)R13)2, —NHS(O)nR5, —N(C(═O)R13)(S(O)nR5), or —N(C1-C6 alkyl)(S(O)nR5). In one embodiment, R3 is a —NH2. In one embodiment, R3 is a —NHC(═O)R13. In one embodiment, R3 is a —N(C(═O)R13)2. In another embodiment, R3 is a —NHS(O)nR5. In some embodiments, R3 is a —NHS(O)2R5. In other embodiments, R3 is a —NHS(O)2R5, wherein R5 is C1-C3 alkyl. In one embodiment, R3 is a —NHS(O)2R5, wherein R5 is methyl. In one embodiment, R3 is a —N(C(═O)R13)(S(O)nR5). In one embodiment, R3 is a —N(C1-C6 alkyl)S(O)nR5.
  • In other embodiments, R3 is —NH2, —NHC(═O)(C1-C4 alkyl), —N[(C(═O)(C1-C4 alkyl)]2, —NHS(O)n(C1-C3 alkyl), —N[C(═O)(C1-C4 alkyl)][(S(O)n(C1-C3 alkyl)], or —N[C1-C6 alkyl][S(O)n(C1-C3 alkyl)]. In some embodiments, R3 is —NH(C(═O)CH3) or —N(C(═O)CH3)2.
  • In other embodiments, R3 is —NHS(O)2CH3. In other embodiments, R3 is —N(C(═O)CH3) (S(O)2CH3).
  • In another embodiment, R3 is a —S(O)nR5. In one embodiment, R3 is a —S(O)2R5. In another embodiment, R3 is a —S(O)2(C1-C3 alkyl). In other embodiments, R3 is a —S(O)2CH3. In other embodiments, R3 is a —S(O)2CH2CH3.
  • In another embodiment, R3 is a —S(O)nR5. In one embodiment, R3 is a —S(O)2R5. In some embodiments, R3 is a —S(O)2R5, wherein R5 is C1-C3 alkyl. In other embodiments, R3 is a —S(O)2R5, wherein R5 is C1 alkyl.
  • In some embodiments, R3 is an optionally substituted 5 or 6 membered heteroaryl or an optionally substituted 3 to 7 membered heterocylyl, wherein said heteroaryl or said heterocyclyl respectively comprises at least one N atom in the ring. In one embodiment, R3 is selected from a group consisting of pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, oxazine, triazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, and tetrazine. In a certain embodiment, R3 is
  • Figure US20170298033A1-20171019-C00502
  • In some embodiments, R13 is C1-C4 alkyl. In other embodiments, R13 is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, or sec-butyl. In one embodiment, R13 is a methyl.
  • In one embodiment, n is 0. In another embodiment n is 1. In some embodiments, n is 2.
  • The compounds for use in the imaging and treatment methods described herein. In some embodiments, the compounds comprise one F, Cl, Br, I, or 123I substitution.
  • In another embodiment, the compound comprise one or more of F, Cl, Br, I or 123I substitutions for R3. In one embodiment, the compound comprise one or more of I or 123I substitutions for R3.
  • In some embodiments, the compound comprises at least one R6 substituent on R3, wherein at least one R6 is further substituted with at least one of F, Cl, Br, I or 123I. In another embodiment, R6 substituent on R3 is further substituted with at least one of I or 123I.
  • In some more specific embodiments of the compound of Formula II, the compound has one of the following structures from Table 5, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof:
  • TABLE 5
    Compounds
    No. Structure Name
    80
    Figure US20170298033A1-20171019-C00503
         		3-(4-((4-(3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    80a
    Figure US20170298033A1-20171019-C00504
         		(R)-3-(4-((4-((S)-3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    80b
    Figure US20170298033A1-20171019-C00505
         		(S)-3-(4-((4-((R)-3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    80c
    Figure US20170298033A1-20171019-C00506
         		(S)-3-(4-((4-((S)-3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    80d
    Figure US20170298033A1-20171019-C00507
         		(R)-3-(4-((4-((R)-3-chloro-2- hydroxypropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diol
    A80
    Figure US20170298033A1-20171019-C00508
         		3-(4-((4-(2-acetoxy-3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diyl diacetate
    A80a
    Figure US20170298033A1-20171019-C00509
         		(S)-3-(4-((4-((S)-2-acetoxy-3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diyl diacetate
    A80b
    Figure US20170298033A1-20171019-C00510
         		(R)-3-(4-((4-((R)-2-acetoxy-3- chloropropoxy)phenyl)sulfonyl)phenoxy) propane-1,2-diyl diacetate
    A80c
    Figure US20170298033A1-20171019-C00511
         		(R)-3-(4-((4-((S)-2-acetoxy-3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diyl diacetate
    A80d
    Figure US20170298033A1-20171019-C00512
         		(S)-3-(4-((4-((R)-2-acetoxy-3- chloropropoxy)phenyl)sulfonyl) phenoxy)propane-1,2-diyl diacetate
  • In one embodiment, the present invention is directed to a pharmaceutical composition, comprising a compound of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, as described herein. In one embodiment, the present invention is directed to a pharmaceutical composition, comprising a compound of Formula I or Formula II, or a pharmaceutically acceptable salt or stereoisomer thereof, as described herein.
  • In some embodiment, the pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, further comprises a pharmaceutically acceptable carrier. In another embodiment, the pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, further comprises an additional therapeutic agent. In one embodiment, the pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, further comprises a pharmaceutically acceptable carrier and an additional therapeutic agent.
  • In another embodiment, the pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, further comprises an additional therapeutic agent which is for treating prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration.
  • Accordingly, one embodiment comprises the use of the disclosed compounds in combination therapy with one or more currently-used or experimental pharmacological therapies which are utilized for treating the above disease states irrespective of the biological mechanism of action of such pharmacological therapies, including without limitation pharmacological therapies which directly or indirectly inhibit the androgen receptor, pharmacological therapies which are cytotoxic in nature, and pharmacological therapies which interfere with the biological production or function of androgen (hereinafter, an “additional therapeutic agent”). By “combination therapy” is meant the administration of any one or more of a compound of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, with one or more of another therapeutic agent to the same patient such that their pharmacological effects are contemporaneous with one another, or if not contemporaneous, that their effects are synergistic with one another even though dosed sequentially rather than contemporaneously.
  • Such administration includes without limitation dosing of one or more of a compound of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, and one or more of the additional therapeutic agent(s) as separate agents without any comingling prior to dosing, as well as formulations which include one or more other androgen-blocking therapeutic agents mixed with one or more compound of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, as a pre-mixed formulation. Administration of the compound(s) of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, in combination with the additional therapeutic agents for treatment of the above disease states also includes dosing by any dosing method including without limitation, intravenous delivery (IV), oral delivery, intra-peritoneal delivery, intra-muscular delivery, or intra-tumoral delivery.
  • In another aspect of the present disclosure, the one or more of the additional therapeutic agents can be administered to the patient before administration of the compound(s) of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. In another embodiment, the compound(s) of Formula I can be co-administered with one or more of the additional therapeutic agents. In yet another aspect, the one or more additional therapeutic agents can be administered to the patient after administration of the compound(s) of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
  • The ratio of the doses of compound(s) of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to that of the one or more additional therapeutic agents can be about 1:1 or can vary, e.g., about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, and can be varied accordingly to achieve the optimal therapeutic benefit.
  • The compound(s) of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, that are combined with the one or more additional therapeutic agents for improved treatment of the above disease states can comprise, but are not limited to any compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, including those compounds shown in Tables 1, 2, 3, 4, or 5.
  • The additional therapeutic agents include without limitation any pharmacological agent which is currently approved by the FDA in the U.S. (or elsewhere by any other regulatory body) for use as pharmacological treatment of any of the above disease states, or which is currently being used experimentally as part of a clinical trial program that relates to the above disease states. Non-limiting examples of the Other Pharmacological Agents comprise, without limitation: the chemical entity known as ODM-201 (also known as BAY1841788) and related compounds, which appears to bind to the AR and blocks its cellular function, and is currently in clinical development as a treatment for prostate cancer); the chemical entity known as ODM-204 and related compounds, which appears to be a dual inhibitor of AR and CYP17A1 and can be useful for treatment of prostate cancer; the chemical entity known as enzalutamide (4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide) and related compounds, which appears to be a blocker of the androgen receptor (AR) LBD and a FDA-approved treatment for prostate cancer; the chemical entity known as Galeterone and related compounds which appears to be a blocker of the androgen receptor (AR) LBD, and a CYP17 lyase inhibitor, and also appears to decrease overall androgen receptor levels in prostate cancer cells. Galeterone is currently in development as a treatment for prostate cancer; the chemical entity known as ARN-509 or apalutamide (4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide) and related compounds which appears to be a blocker of the androgen receptor (AR) LBD and is currently in development as a treatment for prostate cancer; the chemical entity known as abiraterone (or CB-7630; (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl) 2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol), and related molecules, which appears to block the production of androgen and FDA-approved treatment for prostate cancer; the chemical entity known as bicalutamide (N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide) and related compounds, which appears to be a blocker of the androgen receptor (AR) LBD and which is currently used to treat prostate cancer, the chemical entity known as nilutamide (5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione) and related compounds, which appears to be a blocker of the AR LBD and which is currently used to treat prostate cancer, the chemical entity known as flutamide (2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-propanamide) and related compounds, which appears to be a blocker of the androgen receptor (AR) LBD and which is currently used to treat prostate cancer, the chemical entities known as cyproterone acetate (6-chloro-1β,2β-dihydro-17-hydroxy-3′H-cyclopropa[1,2]pregna-4,6-diene-3,20-dione) and related compounds, which appears to be a blocker of the androgen receptor (AR) LBD and which is currently used to treat prostate cancer, the chemical entity known as docetaxel (Taxotere; 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}) and related compounds, which appears to be a cytotoxic antimicrotubule agent and is currently used in combination with prednisone to treat prostate cancer, the chemical entity known as Bevacizumab (Avastin), a monoclonal antibody that recognizes and blocks vascular endothelial growth factor A (VEGF-A) and can be used to treat prostate cancer, the chemical entity known as OSU-HDAC42 ((S)-(+)-N-hydroxy-4-(3-methyl-2-phenylbutyrylamino)-benzamide), and related compounds, which appears to act as a histone deacetylase inhibitor, and is currently being developed as a treatment for prostate cancer, the chemical entity known as VITAXIN which appears to be a monoclonal antibody against the vascular integrin αvβ3 to prevent angiogenesis, and which can be used to treat prostate cancer, the chemical entity known as sunitumib (N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide) and related compounds, which appears to inhibit multiple receptor tyrosine kinases (RTKs) and can be used for treatment of prostate cancer, the chemical entity known as ZD-4054 (N-(3-Methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridin-3-sulfonamid) and related compounds, which appears to block the edta receptor and which can be used for treatment of prostate cancer; the chemical entity known as Cabazitaxel (XRP-6258), and related compounds, which appears to be a cytotoxic microtubule inhibitor, and which is currently used to treat prostate cancer; the chemical entity known as MDX-010 (Ipilimumab), a fully human monoclonal antibody that binds to and blocks the activity of CTLA-4 which is currently in development as an immunotherapeutic agent for treatment of prostate cancer; the chemical entity known as OGX 427 which appears to target HSP27 as an antisense agent, and which is currently in development for treatment of prostate cancer; the chemical entity known as OGX 011 which appears to target clusterin as an antisense agent, and which is currently in development as a treatment for prostate cancer; the chemical entity known as finasteride (Proscar, Propecia; N-(1,1-dimethylethyl)-3-oxo-(5α,17β)-4-azaandrost-1-ene-17-carboxamide), and related compounds, which appears to be a 5-alpha reductase inhibitor that reduces levels of dihydrotestosterone, and can be used to treat prostate cancer; the chemical entity known as dutasteride (Avodart; 5α, 17β)-N-{2,5 bis(trifluoromethyl) phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide) and related molecules, which appears to be a 5-alpha reductase inhibitor that reduces levels of dihydrotestosterone, and can be used in the treatment of prostate cancer; the chemical entity known as turosteride ((4aR,4bS,6aS,7S,9aS,9bS,11aR)-1,4a,6a-trimethyl-2-oxo-N-(propan-2-yl)-N-(propan-2-ylcarbamoyl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide), and related molecules, which appears to be a 5-alpha reductase inhibitor that reduces levels of dihydrotestosterone and can be used in the treatment of prostate cancer; the chemical entity known as bexlosteride (LY-191,704; (4aS,10bR)-8-chloro-4-methyl-1,2,4α,5,6,10b-hexahydrobenzo[f]quinolin-3-one), and related compounds, which appears to be a 5-alpha reductase inhibitor that reduces levels of dihydrotestosterone and can be used in the treatment of prostate cancer; the chemical entity known as izonsteride (LY-320,236; (4aR,10bR)-8-[(4-ethyl-1,3-benzothiazol-2-yl)sulfanyl]-4,10b-dimethyl-1,4,4α,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one) and related compounds, which appears to be a 5-alpha reductase inhibitor that reduces levels of dihydrotestosterone and can be used for the treatment of prostate cancer; the chemical entity known as FCE 28260 and related compounds, which appears to be a 5-alpha reductase inhibitor that reduces levels of dihydrotestosterone and can be used for the treatment of prostate cancer; the chemical entity known as SKF105,111, and related compounds, which appears to be a 5-alpha reductase inhibitor that reduces levels of dihydrotestosterone and can be used for treatment of prostate cancer. The chemical entity known as niclosamide (4.5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide) and related compounds, which appears to be an antihelminitic that is an AR-V7 inhibitor and can be used for treatment of prostate cancer. The chemical entity known as ARV-330 (Arvinas, Inc.) and related compounds, which appears to degrade androgen receptor in LNCaP and VCaP cells and can be useful for treatment of prostate cancer. The chemical entity known as VPC-14449 (4-(4-(4,5-bromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine) and related compounds, which appears to target the DNA-binding domain of full-length AR and can be useful for treatment of prostate cancer. The chemical entity known as TAS3681 appears to be an AR antagonist with AR downregulating activity and can be useful for treatment of prostate cancer. The chemical entity known as sintokamides (e.g., sintokamide A also known as N-[(2R,4S)-5,5,5-trichloro-1-[(2S)-2-[(2S)-3,3-dichlororopyl]-3-methoxy-5-oxo-2H-pyrrol-1-yl]-4-methyl-1-oxopentan-2-yl]propanamide) and related compounds, which appears to be an AR antagonist and can be useful for treating prostate cancer.
  • Accordingly, in some embodiments, the pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, further comprises an additional therapeutic agent selected form the group consisting of enzalutamide, galeterone, abiraterone, bicalutamide, nilutamide, flutamide, cyproterone acetate, docetaxel, bevacizumab (Avastin), OSU-HDAC42, VITAXIN, sunitumib, ZD-4054, Cabazitaxel (XRP-6258), MDX-010 (Ipilimumab), OGX 427, OGX 011, finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 28260, SKF105,111, ODM-201, ODM-204, radium 233, niclosamide, apalutamide, ARV-330, VPC-14449, TAS3681, 3E10-AR441bsAb, sintokamide or related compounds thereof.
  • In some embodiments, compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, which result in unstable structures and/or unsatisfied valences are not included within the scope of the invention.
  • In another embodiment, the present disclosure provides a pharmaceutical composition comprising any of the foregoing compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, and a pharmaceutically acceptable carrier.
  • Compounds as described herein can be in the free form or in the form of a salt thereof. In some embodiments, compounds as described herein can be in the form of a pharmaceutically acceptable salt, which are known in the art (Berge et al., J. Pharm. Sci. 1977, 66, 1). Pharmaceutically acceptable salt as used herein includes, for example, salts that have the desired pharmacological activity of the parent compound (salts which retain the biological effectiveness and/or properties of the parent compound and which are not biologically and/or otherwise undesirable). Compounds as described herein having one or more functional groups capable of forming a salt can be, for example, formed as a pharmaceutically acceptable salt. Compounds containing one or more basic functional groups can be capable of forming a pharmaceutically acceptable salt with, for example, a pharmaceutically acceptable organic or inorganic acid. Pharmaceutically acceptable salts can be derived from, for example, and without limitation, acetic acid, adipic acid, alginic acid, aspartic acid, ascorbic acid, benzoic acid, benzenesulfonic acid, butyric acid, cinnamic acid, citric acid, camphoric acid, camphorsulfonic acid, cyclopentanepropionic acid, diethylacetic acid, digluconic acid, dodecylsulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, glucoheptanoic acid, gluconic acid, glycerophosphoric acid, glycolic acid, hemisulfonic acid, heptanoic acid, hexanoic acid, hydrochloric acid, hydrobromic acid, hydriodic acid, 2-hydroxyethanesulfonic acid, isonicotinic acid, lactic acid, malic acid, maleic acid, malonic acid, mandelic acid, methanesulfonic acid, 2-napthalenesulfonic acid, naphthalenedisulphonic acid, p-toluenesulfonic acid, nicotinic acid, nitric acid, oxalic acid, pamoic acid, pectinic acid, 3-phenylpropionic acid, phosphoric acid, picric acid, pimelic acid, pivalic acid, propionic acid, pyruvic acid, salicylic acid, succinic acid, sulfuric acid, sulfamic acid, tartaric acid, thiocyanic acid or undecanoic acid. Compounds containing one or more acidic functional groups can be capable of forming pharmaceutically acceptable salts with a pharmaceutically acceptable base, for example, and without limitation, inorganic bases based on alkaline metals or alkaline earth metals or organic bases such as primary amine compounds, secondary amine compounds, tertiary amine compounds, quaternary amine compounds, substituted amines, naturally occurring substituted amines, cyclic amines or basic ion-exchange resins. Pharmaceutically acceptable salts can be derived from, for example, and without limitation, a hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation such as ammonium, sodium, potassium, lithium, calcium, magnesium, iron, zinc, copper, manganese or aluminum, ammonia, benzathine, meglumine, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, isopropylamine, tripropylamine, tributylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, glucamine, methylglucamine, theobromine, purines, piperazine, piperidine, procaine, N-ethylpiperidine, theobromine, tetramethylammonium compounds, tetraethylammonium compounds, pyridine, N,N-dimethylaniline, N-methylpiperidine, morpholine, N-methylmorpholine, N-ethylmorpholine, dicyclohexylamine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, N,N′-dibenzylethylenediamine or polyamine resins. In some embodiments, compounds as described herein can contain both acidic and basic groups and can be in the form of inner salts or zwitterions, for example, and without limitation, betaines. Salts as described herein can be prepared by conventional processes known to a person skilled in the art, for example, and without limitation, by reacting the free form with an organic acid or inorganic acid or base, or by anion exchange or cation exchange from other salts. Those skilled in the art will appreciate that preparation of salts can occur in situ during isolation and purification of the compounds or preparation of salts can occur by separately reacting an isolated and purified compound.
  • In some embodiments, compounds and all different forms thereof (e.g. free forms, salts, polymorphs, isomeric forms) as described herein can be in the solvent addition form, for example, solvates. Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent in physical association the compound or salt thereof. The solvent can be, for example, and without limitation, a pharmaceutically acceptable solvent. For example, hydrates are formed when the solvent is water or alcoholates are formed when the solvent is an alcohol.
  • In some embodiments, compounds and all different forms thereof (e.g. free forms, salts, solvates, isomeric forms) as described herein can include crystalline and amorphous forms, for example, polymorphs, pseudopolymorphs, conformational polymorphs, amorphous forms, or a combination thereof. Polymorphs include different crystal packing arrangements of the same elemental composition of a compound. Polymorphs usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability and/or solubility. Those skilled in the art will appreciate that various factors including recrystallization solvent, rate of crystallization and storage temperature can cause a single crystal form to dominate.
  • In some embodiments, compounds and all different forms thereof (e.g. free forms, salts, solvates, polymorphs) as described herein include isomers such as geometrical isomers, optical isomers based on asymmetric carbon, stereoisomers, tautomers, individual enantiomers, individual diastereomers, racemates, diastereomeric mixtures and combinations thereof, and are not limited by the description of the formula illustrated for the sake of convenience.
    • III. Methods
  • The present compounds find use in any number of methods. For example, in some embodiments the compounds are useful in methods for modulating androgen receptor (AR). Accordingly, in one embodiment, the present disclosure provides the use of any one of the foregoing compounds of Formula I for modulating androgen receptor (AR) activity. For example in some embodiments, modulating androgen receptor (AR) activity is in a mammalian cell. Modulating androgen receptor (AR) can be in a subject in need thereof (e.g., a mammalian subject) and for treatment of any of the described conditions or diseases.
  • In other embodiments, modulating androgen receptor (AR) activity is for treatment of at least one indication selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, age related macular degeneration, and combinations thereof. For example in some embodiments, the indication is prostate cancer. In other embodiments, the prostate cancer is primary/localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, advanced prostate cancer, or metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer. While in other embodiments, the prostate cancer is androgen dependent prostate cancer. In other embodiments, the spinal and bulbar muscular atrophy is Kennedy's disease.
  • In some embodiments, compounds as described herein can be administered to a subject. In one embodiment, the present invention is directed to a method of treating primary/localized prostate cancer comprising administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. In some embodiments, the present invention is directed to a method of treating locally advanced prostate cancer comprising administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. In other embodiments, the present invention is directed to a method of treating recurrent prostate cancer comprising administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. In other embodiments, the present invention is directed to a method of treating metastatic prostate cancer comprising administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. In other embodiments, the present invention is directed to a method of treating advanced prostate cancer comprising administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. In other embodiments, the present invention is directed to a method of treating metastatic castration-resistant prostate cancer (CRPC) comprising administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. In other embodiments, the present invention is directed to a method of treating hormone-sensitive prostate cancer comprising administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
  • In other embodiments, the present disclosure provides a method of modulating androgen receptor (AR) activity, the method comprising administering any one of the foregoing compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, or pharmaceutical composition of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, as described herein (including compositions comprising a compound of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, and an additional therapeutic agent), to a subject (e.g., mammal) in need thereof. In some embodiments, modulating androgen receptor (AR) activity is in a mammalian cell. In other embodiments, modulating androgen receptor (AR) activity is in a mammal. In one embodiment, modulating androgen receptor (AR) activity is in a human.
  • The modulating androgen receptor (AR) activity can be for inhibiting AR N-terminal domain activity. The modulating androgen receptor (AR) activity can be for inhibiting androgen receptor (AR) activity. The modulating can be in vivo. The modulating androgen receptor (AR) activity can be for treatment of at least one indication selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy (e.g., Kennedy's disease), and age related macular degeneration. The indication can be prostate cancer. The prostate cancer can be castration-resistant prostate cancer. In one embodiment, the prostate cancer is primary/localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, advanced prostate cancer, or metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer. The prostate cancer can be CRPC.
  • In accordance with another embodiment, there is provided a use of the compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, or pharmaceutical composition of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, as described herein for preparation of a medicament for modulating androgen receptor (AR).
  • Alternatively, in one embodiment, a method of modulating androgen receptor activity, comprising administering Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, or pharmaceutical composition of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, as described herein, is provided. In some embodiments, the administration can be to a mammal. In other embodiments, the administering can be to a mammal in need thereof and in an effective amount for the treatment of at least one indication selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy (e.g., Kennedy's disease), age related macular degeneration, and combinations thereof.
  • As noted above, the presently disclosed compounds can find utility in a number of medical imaging applications, including imaging of the prostate. Many currently available imaging agents tend to accumulate in the bladder, which decreases their effectiveness as imaging tools specifically for the prostate. While not wishing to be bound by theory, the present applicants believe the disclosed compounds are unexpectedly effective for imaging of the prostate due to their ability to accumulate in the prostate, rather than the bladder, allowing the prostate gland to be seen. Accordingly, the compounds can be used in methods for imaging the prostate, for example to image benign prostate diseases. In other embodiments, the compounds can be used in methods to image cancerous prostate diseases, such as tumors of the prostate.
  • Androgen ablation therapy causes a temporary reduction in prostate cancer tumor burden, but the malignancy will begin to grow again in the absence of testicular androgens to form castrate resistant prostate cancer (CRPC). A rising titer of serum prostate-specific antigen (PSA) after androgen ablation therapy indicates biochemical failure, the emergence of CRPC, and re-initiation of an androgen receptor (AR) transcription program. Most patients succumb to CRPC within two years of biochemical failure.
  • In one embodiment, the method identifies the presence of a tumor that expresses AR (both full-length and truncated AR lacking LBD) and then treats the tumor by radiotherapy. In another embodiment, the imaging methods provide information to determine if a tumor expresses AR species.
  • AR is a transcription factor and a validated target for prostate cancer therapy. Current therapies include androgen ablation and administration of antiandrogens. Most CRPC is suspected to be AR-dependent. AR has distinct functional domains that include the C-terminus ligand-binding domain (LBD), a DNA-binding domain (DBD), and an amino-terminal domain (NTD). AR NTD contains activation function-1 (AF-1) that contributes most of the transcriptional activity to the AR. Recently, splice variants of the AR that lack the LBD have been reported in prostate cancer cell lines (VCaP, LNCaP95 and 22Rv1), and in CRPC tissues. To date more than 20 splice variants of AR have been detected. Splice variants V7 and V567es are clinically relevant with levels of expression correlated to poor survival and CRPC. AR V567es is solely expressed in 20% of metastases. Abiraterone resistance is associated with expression of AR splice variants. Enzalutamide also increases levels of expression of these constitutively active AR splice variants. These splice variants lack LBD and thereby would not be inhibited by current therapies that target the AR LBD such as antiandrogens or androgen ablation therapy. A single patient with advanced prostate cancer can have many lesions throughout the body and skeleton and each tumor can have differing levels of expression of AR.
  • Biopsy of metastatic tumors in a patient to determine AR species is neither widely accessible nor feasible to sample tumors in a patient that can have multiple metastases. Thus it is essential to develop approaches to detect the expression of all AR species for the molecular classification of tumors based on the level and extent of expression of AR splice variants, or other AR species that cannot be detected using an imaging agent that interacts with the LBD, to identify patients with potentially aggressive disease and poor prognosis, or to identify patients that will not respond to hormone therapies that target the AR LBD. Accordingly, certain embodiments of the present invention provide an AR NTD-targeted molecular imaging probe (e.g., compound of formula I) which can be used to monitor response to therapy and provide insight into the role of AR in resistance mechanisms.
  • One current approach to image AR in prostate cancer uses positron emission tomography (PET) with 16β-[18F]-fluoro-5a dihydrotestosterone (18F-FDHT) that binds to AR LBD. Unfortunately this imaging agent cannot detect splice variants lacking LBD. In some embodiments, the invention employs sequential imaging with 18F-FDHT to detect full-length AR and gamma radiation emitting probes to specifically detect the AR NTD which would be the sum of both full-length AR and variant AR. In other embodiments, the invention employs sequential imaging with two different PET imaging agents to detects only full-length AR and another to specifically detect the AR NTD which would be the sum of both full-length AR and variant AR. Together these data reveal patients with tumors that express variant AR (NTD of variant plus full-length AR detected with NTD isotope minus full-length AR detected with 18F-FDHT). By using sequential imaging, a discordant distribution or discordant level of uptake between 18F-FDHT and a radiolabeled compound of this invention (i.e., compound of Formula I) indicates the presence of overexpression of splice variants lacking the LBD.
  • As described above, radioactive 18F labeled compounds have found use as imaging agents not only to image AR in prostate cancer but for imaging various organs and various tumors. Similarly, radioactive 123I labeled compounds have been known for the use as imaging agents. In one embodiment, the compounds of the present disclosure comprise at least one 123I.
  • In one embodiment, the present invention is directed to a method of imaging cancer by administering a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a subject. In another embodiment, the present invention is directed to a method of imaging cancer by administering a pharmaceutical composition comprising a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a subject.
  • In some embodiment, the method of imaging cancer by administering a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, or a pharmaceutical composition comprising Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a subject and detecting the presence or absence of cancer by use of SPECT or PET. In other embodiments, the method of imaging cancer by administering a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a subject and the method identifies the presence or absence of a tumor. In one embodiment, the method of imaging cancer by administering a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a subject and the method identifies the location of a tumor. In one embodiment, the method of imaging cancer by administering a compound having a structure of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, to a subject and the method identifies a presence of a prostate cancer. In other embodiments, the prostate cancer is androgen-dependent prostate cancer. In some embodiments, the subject is a mammal such as a human.
  • In some other embodiments, the method is useful for detecting the presence of AR splice variants or other AR species that cannot be detected by imaging agents that interact with the AR LBD (i.e., mutations, truncations). Without wishing to be bound by any particular theory, since the present compounds bind to the AR N-terminal domain (NTD), even mutants or variants which lack the AR LBD can be imaged employing the present compounds. Thus, the present methods can be useful for detecting AR species, including mutants and variants, which lack the LBD or have LBD mutations, but do comprise the AR NTD. In other embodiments the method detects the presence or overexpression of AR splice variants lacking the ligand-binding domain. For example, the method can include sequential imaging with 18F-FDHT and a compound of the invention and a discordant distribution or discordant level of uptake between 18F-FDHT and the compound of the invention indicates the presence or overexpression of splice variants lacking the ligand-binding domain.
  • In other embodiments, the compounds of the invention are used in single photon emission computed tomography methods to monitor a patient's response to therapy. In other embodiments, the methods comprise use of a compound of the invention to detect the AR NTD.
  • In accordance with a further embodiment, the method of imaging a cancer is by administering a compound as described anywhere herein. In one embodiment, the method of imaging a cancer is by administering a compound of Formula I or Formula II, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein said compound comprises at least one 123I.
  • The administering and imaging can be to a mammal in need of diagnosis of at least one indication selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, benign prostatic hyperplasia, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy (e.g., Kennedy's disease), and age-related macular degeneration. The imaging can be for imaging AR splice variants, mutants or other AR species which contain AR NTD.
  • In some embodiments, the compounds as described herein or pharmaceutically acceptable salts thereof can be used for imaging and diagnosis of at least one indication selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, benign prostatic hyperplasia, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, and age-related macular degeneration.
  • In some embodiments, the compounds as described herein or acceptable salts thereof above can be used in the preparation of a medicament or a composition for imaging the prostate, for example for imaging benign prostate conditions or for imaging prostate cancer in a subject in need of such imaging (for example for diagnosis and/or location of prostate tumors).
  • In some embodiments, pharmaceutical compositions useful in modulating androgen receptor (AR) activity or useful for imaging, in accordance with this invention can comprise a salt of such a compound, preferably a pharmaceutically or physiologically acceptable salt.
  • Pharmaceutical preparations will typically comprise one or more carriers, excipients or diluents acceptable for the mode of administration of the preparation, be it by injection, inhalation, topical administration, lavage, or other modes suitable for the selected treatment. Suitable carriers, excipients or diluents are those known in the art for use in such modes of administration.
  • In one embodiment, the imaging method disclosed herein is directed to imaging prostate cancer. In some embodiments, the prostate cancer is primary/localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, advanced prostate cancer, or metastatic castration-resistant prostate cancer (CRPC), and hormone-sensitive prostate cancer. In some embodiments the prostate cancer is CRPC. In other embodiments, the imaging is for imaging benign prostate conditions such as benign prostatic hyperplasia. Methods of imaging and/or treating any of the indications described herein are also provided. Such methods may include administering a compound as described herein or a composition of a compound as described herein, or an effective amount of a compound as described herein or composition of a compound as described herein to a subject in need thereof. In one embodiment, a pharmaceutical composition suitable for imaging is administered intravenously.
  • Suitable pharmaceutical compositions can be formulated by means known in the art and their mode of administration and dose determined by the skilled practitioner. For parenteral administration, a compound can be dissolved in sterile water or saline or a pharmaceutically acceptable vehicle used for administration of non-water soluble compounds such as those used for vitamin K. For enteral administration, the compound can be administered in a tablet, capsule or dissolved in liquid form. The tablet or capsule can be enteric coated, or in a formulation for sustained release. Many suitable formulations are known, including, polymeric or protein microparticles encapsulating a compound to be released, ointments, pastes, gels, hydrogels, or solutions which can be used topically or locally to administer a compound. A sustained release patch or implant can be employed to provide release over a prolonged period of time. Many techniques known to one of skill in the art are described in Remington: the Science & Practice of Pharmacy by Alfonso Gennaro, 20th ed., Lippencott Williams & Wilkins, (2000). Formulations for parenteral administration can, for example, contain excipients, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers can be used to control the release of the compounds. Other potentially useful parenteral delivery systems for modulatory compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation can contain excipients, for example, lactose, or can be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or can be oily solutions for administration in the form of nasal drops, or as a gel.
  • In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound as described herein, and an additional therapeutic agent and/or a pharmaceutically acceptable carrier. In some embodiments, the additional therapeutic agent is for treating prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy or age related macular degeneration. In other embodiments, the additional therapeutic agent is enzalutamide, galeterone, ODN-201 abiraterone, bicalutamide, nilutamide, flutamide, cyproterone acetate, docetaxel, Bevacizumab (Avastin), OSU-HDAC42, VITAXIN, sunitumib, ZD-4054, Cabazitaxel (XRP-6258), MDX-010 (Ipilimumab), OGX 427, OGX 011, finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 28260, SKF105,111, ODM-201 ODM-204, niclosamide, apalutamide, ARV-330, VPC-14449, TAS3681, 3E10-AR441bsAb, sintokamide, or related compounds thereof.
  • Compounds described herein can also be used in assays and for research purposes. Definitions used include ligand dependent activation of the androgen receptor (AR) by androgens such as dihydrotestosterone (DHT) or the synthetic androgen (R1881) used for research purposes. Ligand-independent activation of the androgen receptor (AR) refers to transactivation of the full-length androgen receptor (AR) in the absence of androgen (ligand) by, for examples, stimulation of the cAMP dependent protein kinase (PKA) pathway or the interleukin-6 (IL6)/STAT3 pathway. Such compounds should block a mechanism that is common to both ligand-dependent and ligand-independent activation of the androgen receptor (AR), as well as constitutively active splice variants of the androgen receptor (AR) that lack ligand-binding domain. This could involve any step in activation of the androgen receptor (AR) including dissociation of heatshock proteins, essential posttranslational modifications (e.g., acetylation, phosphorylation), nuclear translocation, protein-protein interactions, formation of the transcriptional complex, release of co repressors, and/or increased degradation. Numerous disorders in addition to prostate cancer involve the androgen axis (e.g., acne, hirsutism, alopecia, benign prostatic hyperplasia) and compounds interfering with this mechanism can be used to treat such conditions.
  • Compounds or pharmaceutical compositions in accordance with this invention or for use in this invention can be administered by means of a medical device or appliance such as an implant, graft, prosthesis, stent, etc. Also, implants can be devised which are intended to contain and release such compounds or compositions. An example would be an implant made of a polymeric material adapted to release the compound over a period of time.
  • It is to be noted that dosage values can vary with the exact imaging protocol. For any particular subject, specific dosage regimens can be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions. Dosage ranges set forth herein are exemplary only and do not limit the dosage ranges that can be selected by medical practitioners. The amount of active compound(s) in the composition can vary according to factors such as the disease state, age, sex, and weight of the subject. Dosage regimens can be adjusted to provide the optimum imaging result. For example, a single bolus can be administered, several divided doses can be administered over time or the dose can be proportionally reduced or increased as indicated by the imaging results. It can be advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
  • In general, compounds of the invention should be used without causing substantial toxicity. Toxicity of the compounds of the invention can be determined using standard techniques, for example, by testing in cell cultures or experimental animals and determining the therapeutic index, i.e., the ratio between the LD50 (the dose lethal to 50% of the population) and the LD100 (the dose lethal to 100% of the population). In some circumstances, such as in severe disease conditions, substantial excesses of the compositions can be administered for therapeutic effects. Some compounds of this invention can be toxic at some concentrations. Titration studies can be used to determine toxic and non-toxic concentrations. Toxicity can be evaluated by examining a particular compound's or composition's specificity across cell lines using PC3 or DU145 cells as possible negative controls since these cells do not express functional AR. Animal studies can be used to provide an indication if the compound has any effects on other tissues. Systemic therapy that targets the AR will not likely cause major problems to other tissues since castration, antiandrogens and androgen insensitivity syndrome are not fatal.
  • Compounds for use in the present invention can be obtained from medical sources or modified using known methodologies from naturally occurring compounds. In addition, methods of preparing or synthesizing compounds of the present invention will be understood by a person of skill in the art having reference to known chemical synthesis principles. For example, Auzou et al 1974 European Journal of Medicinal Chemistry 9(5), 548-554 describes suitable synthetic procedures that can be considered and suitably adapted for preparing compounds of any one of the compounds of structure (I) as set out above. Other references that can be helpful include: Debasish Das, Jyh-Fu Lee and Soofin Cheng “Sulfonic acid functionalized mesoporous MCM-41 silica as a convenient catalyst for Bisphenol-A synthesis” Chemical Communications, (2001) 2178-2179; U.S. Pat. No. 2,571,217 Davis, Orris L.; Knight, Horace S.; Skinner, John R. (Shell Development Co.) “Halohydrin ethers of phenols.” (1951); and Rokicki, G.; Pawlicki, J.; Kuran, W. “Reactions of 4-chloromethyl-1,3-dioxolan-2-one with phenols as a new route to polyols and cyclic carbonates.” Journal fuer Praktische Chemie (Leipzig) (1985) 327, 718-722.
  • In some embodiments, compounds and all different forms thereof as described herein can be used, for example, and without limitation, in combination with other treatment methods for at least one indication selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, and age related macular degeneration. For example, compounds and all their different forms as described herein can be used as neoadjuvant (prior), adjunctive (during), and/or adjuvant (after) therapy with surgery, radiation (brachytherapy or external beam), or other therapies (eg. HIFU), and in combination with chemotherapies, androgen ablation, antiandrogens or any other therapeutic approach.
  • In an exemplary embodiment for imaging the prostate, a dose of the disclosed compounds in solution (typically 5 to 10 millicuries or 200 to 400 MBq) is typically injected rapidly into a saline drip running into a vein, in a patient. Then, the patient is placed in the SPECT for a series of one or more scans which can take from 20 minutes to as long as an hour (often, only about one quarter of the body length can be imaged at a time). Methods for SPECT scanning are well known in the art.
  • The compounds described herein can be used for in vivo or in vitro research uses (i.e. non-clinical) to investigate the mechanisms of orphan and nuclear receptors (including steroid receptors such as androgen receptor (AR)). Furthermore, these compounds can be used individually or as part of a kit for in vivo or in vitro research to investigate signal transduction pathways and/or the activation of orphan and nuclear receptors using recombinant proteins, cells maintained in culture, and/or animal models.
  • For example, exemplary compounds of the present invention can be prepared with reference to the following General Reaction Scheme I:
  • Figure US20170298033A1-20171019-C00513
  • It should be noted that, although General Reaction Scheme I depicts a racemic synthesis, one skilled in the art would recognize that different stereoisomers and diastereomers can be synthesized by using starting materials of different stereochemistry, e.g., stereospecific (2,2-dimethyl-1,3-dioxolan-4-yl)methanol and/or stereospecific oxiran-2-ylmethyl 4-methylbenzenesulfonate.
  • Referring to General Reaction Scheme I, (2,2-dimethyl-1,3-dioxolan-4-yl)methanol is toslyated under basic conditions as shown in step a. In step b, tosly group (p-toulenesulfonate) is displaced with bisphenol derivatives under basic conditions (X can be —S(O)n— where n=0, 1, or 2, or divalent linear or branched C1-C6 alkyl). Optionally, in step c, the bisphenol derivative is halogenated on the phenyl ring (e.g., Y and Z can be Cl or Br). In step d, the unreacted phenol portion undergoes another elimination reaction to afford a bisphenol derivative with an epoxide on one side and a protected diol on the other. In step e, epoxide is opened using CeCl3.7H2O and the diol is deprotected in situ.
  • One skilled in the art will recognize that variations to the order of the steps and reagents discussed in reference to the above General Synthetic Schemes I are possible.
  • In addition, protecting group strategies can be employed for preparation of the compounds disclosed herein. Such strategies are well known to those of skill in the art. Exemplary protecting groups and related strategies are disclosed in Greene's Protective Groups in Organic Synthesis, Wiley-InterScience; 4 edition (Oct. 30, 2006), which is hereby incorporated by reference in its entirety. In certain embodiments, a protecting group is used to mask an alcohol moiety while performing other chemical transformations. After removal of the protecting group, the free hydroxyl is obtained. Such protecting groups and strategies are well known in the art.
  • Various alternative embodiments and examples of the invention are described herein. These embodiments and examples are illustrative and should not be construed as limiting the scope of the invention. The following examples are provided for purposes of illustration, not limitation.
    • EXAMPLES
  • All non-aqueous reactions were performed in flame-dried round bottomed flasks. The flasks were fitted with rubber septa and reactions were conducted under a positive pressure of argon unless otherwise specified. Stainless steel syringes were used to transfer air- and moisture-sensitive liquids. Flash column chromatography was performed as described by Still et al. (Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923) using 230-400 mesh silica gel. Thin-layer chromatography was performed using aluminum plates pre-coated with 0.25 mm 230-400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Thin-layer chromatography plates were visualized by exposure to ultraviolet light and a “Seebach” staining solution (700 mL water, 10.5 g Cerium (IV) sulphate tetrahydrate, 15.0 g molybdato phosphoric acid, 17.5 g sulphuric acid) followed by heating (˜1 min) with a heating gun (˜250° C.). Organic solutions were concentrated on Buchi R-114 rotatory evaporators at reduced pressure (15-30 torr, house vacuum) at 25-40° C.
  • Commercial regents and solvents were used as received. All solvents used for extraction and chromatography were HPLC grade. Normal-phase Si gel Sep Paks™ were purchased from waters, Inc. Thin-layer chromatography plates were Kieselgel 60F254. All synthetic reagents were purchased from Sigma Aldrich and Fisher Scientific Canada.
    • Example 1: Synthesis of (R)-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propane-1,2-diol (Compound 1a)
  • Figure US20170298033A1-20171019-C00514
    • Steps a and b: Synthesis of (S)-4-(2-(4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)propan-2-yl)phenol
  • The titled compound was synthesized as previously reported. See, WO 2014/179867.
    • Step c: (S)-2,6-dichloro-4-(2-(4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)propan-2-yl)phenol
  • To a solution of (S)-4-(2-(4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)propan-2-yl)phenol (500 mg, 1.46 mmol, 1.0 equiv) in MeOH (12 mL) was added NaCl (256 mg, 4.38 mmol, 3.0 equiv) and NaOH (87.6 mg, 2.19 mmol, 1.5 equiv). Aqueous sodium hypochlorite (6035 mg, 5.4% in H2O, 4.38 mmol, 3.0 equiv) was then added dropwise over 2 min at 0° C. After 2 hours, the mixture was extracted with ethyl acetate (2×30 mL). The organic layer was washed with deionized water (2×30 mL), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by gradient flash Si gel column chromatography (elution: 10% ethyl acetate in hexane to 20% ethyl acetate in hexane) to provide the tile compound (454 mg, 75.6%) as a sticky oil. 1H NMR (600 MHz, DMSO-D6) δ (ppm)=9.92 (s, 1H), 7.11 (d, J=9.0 Hz, 2H), 7.07 (s, 2H), 6.84 (d, J=8.4 Hz, 2H), 4.38-4.34 (m, 1H), 4.08-4.05 (m, 1H), 3.97-3.91 (m, 2H), 3.74-3.70 (m, 1H), 1.55 (s, 6H), 1.33 (s, 3H), 1.28 (s, 3H). 13C NMR (150 MHz, DMSO-D6) δ (ppm)=156.33, 146.75, 143.77, 141.55, 127.47, 126.58, 121.78, 114.03, 108.79, 73.69, 68.60, 65.78, 41.36, 30.23, 26.59, 25.37.
    • Step d: (S)-4-((4-(2-(3,5-dichloro-4-(((R)-oxiran-2-yl)methoxy)phenyl)propan-2-yl)phenoxy)methyl)-2,2-dimethyl-1,3-dioxolane
  • Sodium hydride (60% dispersion in mineral oil, 63.6 mg, 1.59 mmol, 1.5 equiv) was added slowly to a stirred solution of (S)-2,6-dichloro-4-(2-(4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)propan-2-yl)phenol (434 mg, 1.06 mmol, 1.0 equiv) in anhydrous DMF (8 mL) at room temperature and the contents were stirred under an atmosphere of argon for 10 min. A solution of (2R)-(−)-glycidyl tosylate (363 mg, 1.59 mmol, 1.5 equiv) in anhydrous DMF (4 mL) was added via syringe and the mixture was allowed to react at 60° C. for 16 h. The reaction was quenched by the addition of a saturated solution of ammonium chloride (1 mL), and the mixture was extracted with ethyl acetate (60 mL). The organic layer was washed with deionized water (2×30 mL), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by gradient flash Si gel column chromatography (elution: 10% ethyl acetate in hexane to 20% ethyl acetate in hexane) to provide the titled compound (476 mg, 96.1%) as a sticky oil. 1H NMR (600 MHz, DMSO-D6) δ (ppm)=7.20 (s, 2H), 7.13 (d, J=9.0 Hz, 2H), 6.86 (d, J=9.0 Hz, 2H), 4.38-4.34 (m, 1H), 4.25-4.22 (m, 1H), 4.07-4.05 (m, 1H), 3.98-3.91 (m, 2H), 3.82-3.80 (m, 1H), 3.74-3.70 (m, 1H), 3.35-3.32 (m, 1H), 2.79-2.77 (m, 1H), 2.62-2.60 (m, 1H), 1.58 (s, 6H), 1.32 (s, 3H), 1.28 (s, 3H). 13C NMR (150 MHz, DMSO-D6) δ (ppm)=156.46, 149.15, 148.21, 141.01, 127.77, 127.54, 127.24, 114.10, 108.80, 75.01, 73.68, 68.61, 65.77, 49.88, 43.42, 41.80, 30.08, 26.59, 25.37.
    • Step e: Synthesis of (R)-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propane-1,2-diol (Compound 1a)
  • To a solution of (S)-4-((4-(2-(3,5-dichloro-4-(((R)-oxiran-2-yl)methoxy)phenyl)propan-2-yl)phenoxy)methyl)-2,2-dimethyl-1,3-dioxolane (560 mg, 1.2 mmol, 1.0 equiv) in MeCN (12 mL) was added CeCl3.7H2O (1118 mg, 3.0 mmol, 2.5 equiv) and the mixture was heated to reflux for 16 h. The resulting white paste was collected by filtration and washed with ethyl acetate and the clear suspension was concentrated under reduced pressure. The resulting residue was purified by column chromatography to provide the titled compound (512 mg, 92%) as a sticky oil. 1H NMR (600 MHz, CDCl3) δ (ppm)=7.15-7.12 (m, 4H), 6.86 (d, J=9.0 Hz, 2H), 4.26-4.23 (m, 1H), 4.21-4.15 (m, 2H), 4.15-4.11 (m, 1H), 4.08-4.03 (m, 2H), 3.86 (dd, J=4.8 Hz, 10.8 Hz, 2H), 3.78 (dd, J=6.6 Hz, 12.6 Hz, 2H), 1.64 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=156.76, 149.30, 148.26, 141.84, 128.52, 127.87, 127.67, 114.35, 73.69, 70.48, 69.26, 63.78, 45.55, 42.34, 30.79; ESI-LRMS calcd for [M+Na]+ 485.1, found 485.4.
    • Example 2: Synthesis of (R)-3-(4-(2-(3,5-dibromo-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propane-1,2-diol (Compound 3a)
  • Figure US20170298033A1-20171019-C00515
  • Compound 3a was synthesized according to Example 1 by suing NaBr instead of NaCl in step c. 1H NMR (400 MHz, DMSO-D6) δ (ppm)=7.39 (s, 1H), 7.30 (dd, J=2.0 Hz, 34.4 Hz, 1H), 7.15 (d, J=8.8 Hz, 2H), 6.86 (d, J=8.8 Hz, 2H), 5.57-5.54 (m, 1H), 4.91 (d, J=4.8 Hz, 1H), 4.64 (t, J=5.6 Hz, 1H), 4.10-4.08 (m, 1H), 3.98-3.92 (m, 3H), 3.86-3.81 (m, 2H), 3.79-3.76 (m, 1H), 3.71 (dd, J=5.6 Hz, 11.2 Hz, 1H), 3.45-3.42 (m, 2H), 1.60 (s, 6H). 13C NMR spectrum of Compound 3a as synthesized is shown in FIG. 1.
    • Example 3: Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)-2-hydroxy-3-methoxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (Compound 5a)
  • Figure US20170298033A1-20171019-C00516
    • Step a: Synthesis of (S)-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)-2-hydroxypropyl 4-methylbenzenesulfonate
  • The titled compound was synthesized by tosylation of Compound 1a under basic conditions according to commonly known protocol, such as the protocol referenced for step a in Example 1.
    • Step b: Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-(((R)-oxiran-2-yl)methoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol
  • The titled compound was synthesized via epoxidation reaction commonly known in the art under basic conditions. 1H NMR (400 MHz, CDCl3) δ (ppm)=7.13-7.10 (m, 4H), 6.86 (d, J=6.8 Hz, 2H), 4.24-4.12 (m, 4H), 3.99-3.94 (m, 1H), 3.85 (dd, J=5.2 Hz, 11.2 Hz, 1H), 3.77 (dd, J=5.6 Hz, 11.2 Hz, 1H), 3.38-3.33 (m, 1H), 2.93-2.89 (m, 1H), 2.76 (dd, J=2.4 Hz, 4.8 Hz, 1H), 1.62 (s, 6H).
    • Step c: Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)-2-hydroxy-3-methoxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (Compound 5a)
  • To a solution of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-(((R)-oxiran-2-yl)methoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (15 mg, 0.034 mmol, 1.0 equiv) in anhydrous methanol (2 mL) was added Erbium (III) trifluoromethanesulfonate (2.1 mg, 0.0034 mmol, 0.1 equiv) and the mixture was stirred at room temperature for 40 h. The reaction was quenched by the addition of a saturated solution of ammonium chloride (0.5 ml) and the mixture was extracted with ethyl acetate (2×10 ml). The organic layer was washed with deionized water (2×10 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by gradient flash column chromatography on silica gel (elution: 30% ethyl acetate in hexane to 50% ethyl acetate in hexane) to provide Compound 5a (12.5 mg, 77.1%) as a colorless oil. 1H NMR (600 MHz, CDCl3) δ (ppm)=7.14-7.10 (m, 4H), 6.87 (d, J=6.0 Hz, 2H), 4.26-4.22 (m, 1H), 4.21-4.15 (m, 3H), 4.06-4.01 (m, 2H), 3.87 (dd, J=6.0 Hz, 11.4 Hz, 1H), 3.79 (dd, J=5.4 Hz, 11.4 Hz, 1H), 3.61 (dd, J=4.2 Hz, 9.6 Hz, 1H), 3.57 (dd, J=6.0 Hz, 9.6 Hz, 1H), 3.44 (s, 3H), 1.64 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=156.37, 148.81, 147.69, 141.04, 127.95, 127.25, 127.05, 113.81, 73.13, 73.00, 69.93, 68.58, 68.44, 58.88, 45.00, 41.78, 30.25.
    • Example 4: Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)-2-hydroxy-3-isopropoxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (Compound 7a)
  • Figure US20170298033A1-20171019-C00517
  • Compound 7a was synthesized according to Example 2 by using isopropanol in step c instead of methanol. 1H NMR (400 MHz, CDCl3) δ (ppm)=7.13-7.10 (m, 4H), 6.86 (d, J=8.8 Hz, 2H), 4.25-4.12 (m, 4H), 4.03-3.98 (m, 2H), 3.85 (dd, J=5.2 Hz, 10.8 Hz, 1H), 3.77 (dd, J=5.6 Hz, 11.2 Hz, 1H), 3.67-3.53 (m, 3H), 2.83 (s, 1H), 2.57 (s, 1H), 1.62 (s, 6H), 1.18 (d, J=6.0 Hz, 6H).
    • Example 5: Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)-3-fluoro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (Compound 8a)
  • Figure US20170298033A1-20171019-C00518
  • To a solution of Compound 1a (1 equiv; synthesized according to Example 1) in dichloromethane were successively added triethylamine trihydrofluoride (2 equiv) and XtalFluor-M (2 equiv). After 3 h, the reaction mixture was quenched at room temperature with a 5% aqueous sodium bicarbonate solution and stirred for 15 min, and the resulting mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous magnesium sulfate, and filtered. Solvents were evaporated, and the resulting crude material was purified by silica gel chromatography to provide Compound 8a. 1H NMR (600 MHz, CDCl3) δ (ppm)=7.16-7.14 (m, 4H), 6.87 (d, J=8.4 Hz, 2H), 4.69-4.56 (m, 2H), 4.30-4.22 (m, 2H), 4.22-4.16 (m, 2H), 4.10-4.09 (m, 2H), 3.87 (dd, J=6.0 Hz, 11.4 Hz, 1H), 3.79 (dd, J=5.4 Hz, 10.8 Hz, 1H), 1.64 (s, 6H).
    • Example 6: Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)-2-hydroxy-3-(1H-imidazol-1-yl)propoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (Compound 9a)
  • Figure US20170298033A1-20171019-C00519
  • To a solution of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-(((R)-oxiran-2-yl)methoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (12.6 mg, 0.028 mmol, 1.0 equiv) in anhydrous MeCN (2 mL) was added Bismuth (III) trifluoromethanesulfonate (1.8 mg, 0.0028 mmol, 0.1 equiv) and the mixture was stirred at room temperature for 40 h. The reaction was quenched by the addition of a saturated solution of ammonium chloride (0.5 ml) and the mixture was extracted with ethyl acetate (2×10 ml). The organic layer was washed with deionized water (2×10 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash column chromatography to provide Compound 9a (8.7 mg, 60.4%) as a colorless oil. 1H NMR (600 MHz, CDCl3) δ (ppm)=7.56 (s, 1H), 7.16-7.14 (m, 4H), 7.04 (s, 1H), 7.01 (s, 1H), 6.86 (d, J=8.4 Hz, 2H), 4.29-4.23 (m, 3H), 4.22-4.13 (m, 3H), 3.98-3.92 (m, 2H), 3.87 (dd, J=6.0 Hz, 11.4 Hz, 1H), 3.79 (dd, J=4.8 Hz, 10.8 Hz, 1H), 1.65 (s, 6H).
    • Example 7: Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((R)-2-hydroxy-3-morpholinopropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (Compound 1a)
  • Figure US20170298033A1-20171019-C00520
  • Compound 11a was synthesized according to Example 6 by using morpholine instead of 1H-imidazole. 1H NMR (400 MHz, CDCl3) δ (ppm)=7.16-7.11 (m, 4H), 6.88 (d, J=8.8 Hz, 2H), 4.27-4.13 (m, 4H), 4.07-3.98 (m, 2H), 3.90-3.77 (m, 6H), 2.84-2.80 (m, 2H), 2.73-2.72 (m, 2H), 2.71-2.67 (m, 2H), 1.65 (s, 6H); ESI-LRMS calcd for [M+H]+ 532.1, found 534.6.
    • Example 8: Synthesis of (R)-1-amino-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (Compound 12a) and N—((R)-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)-2-hydroxypropyl)methanesulfonamide (Compound 13a)
  • Figure US20170298033A1-20171019-C00521
    • Step a: Synthesis of (R)-1-azido-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol
  • To a solution of (S)-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)-2-hydroxypropyl 4-methylbenzenesulfonate (90 mg, 0.146 mmol, 1.0 equiv) in anhydrous DMF (3 mL) was added sodium azide (9.5 mg, 0.146 mmol, 1.0 equiv) and the mixture was heated to 60-70° C. for 16 h. The reaction was quenched by the addition of a saturated solution of ammonium chloride (10 ml) and the mixture was extracted with ethyl acetate (2×30 ml). The organic layer was washed with deionized water (2×30 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by gradient flash column chromatography on Si gel (elution: 20% ethyl acetate in hexane to 50% ethyl acetate in hexane) to provide the titled compound (57.4 mg, 80.1%) as a colorless oil. 1H NMR (600 MHz, CDCl3) δ (ppm)=7.15-7.13 (m, 4H), 6.86 (d, J=9.0 Hz, 2H), 4.25-4.23 (m, 1H), 4.21-4.12 (m, 3H), 4.03-4.01 (m, 2H), 3.86 (dd, J=5.4 Hz, 10.8 Hz, 1H), 3.78 (dd, J=5.4 Hz, 11.4 Hz, 1H), 3.58-3.50 (m, 2H), 3.01 (s, 1H), 2.78 (s, 1H) 1.64 (s, 6H).
    • Step b: Synthesis of (R)-1-amino-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (Compound 12a)
  • To a solution of (R)-1-azido-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (57 mg, 0.117 mmol, 1.0 equiv) in MeCN (6 mL) was added triphenylphosphine (36.7 mg, 0.14 mmol, 1.2 equiv) and the mixture was heated to reflux for 16 h. The reaction was quenched by deionized water (2 ml) and the mixture was extracted with ethyl acetate (2×30 ml). The organic layer was washed with deionized water (2×30 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by gradient flash column chromatography on Si gel (elution: 2% methanol in dichloromethane to 30% methanol in dichloromethane) to provide Compound 12a (24.3 mg, 44.9%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ (ppm)=7.12-7.09 (m, 4H), 6.84 (d, J=8.4 Hz, 2H), 4.24-4.21 (m, 1H), 4.17-4.13 (m, 2H), 3.97 (m, 3H), 3.84 (dd, J=5.6 Hz, 11.2 Hz, 1H), 3.76 (dd, J=5.6 Hz, 11.2 Hz, 1H), 3.00-2.85 (m, 2H), 1.61 (s, 6H); 13C NMR (100 MHz, CDCl3) δ (ppm)=157.00, 149.35, 148.31, 141.60, 128.52, 127.81, 127.61, 114.37, 73.78, 70.47, 70.42, 70.14, 45.65, 44.11, 42.34, 30.25; ESI-LRMS calcd for [M+H]+ 462.1, found 463.9.
    • Step c: Synthesis of N—((R)-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)-2-hydroxypropyl)methanesulfonamide (Compound 13a)
  • To a solution of (R)-1-azido-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (14.3 mg, 0.031 mmol, 1.0 equiv) in anhydrous dichloromethane (3 mL) was treated triethylamine (12.5 mg, 0.124 mmol, 4.0 equiv) and methane sulfonyl chloride (3.6 mg, 0.031 mmol, 1.0 equiv) sequentially at 0° C. for 10 minutes. Then it was warmed to room temperature for 16 hours. The reaction was quenched by the addition of a saturated solution of ammonium chloride (2 ml) and the mixture was extracted with ethyl acetate (2×20 ml). The organic layer was washed with deionized water (2×20 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by gradient flash column chromatography on silica gel (elution: 50% ethyl acetate in hexane to 75% ethyl acetate in hexane) to provide Compound 13a (9.7 mg, 57.9%) as a colorless oil. 1H NMR (600 MHz, CDCl3) δ (ppm)=7.15-7.13 (m, 4H), 6.87 (d, J=5.4 Hz, 2H), 4.93-4.90 (m, 1H), 4.26-4.23 (m, 1H), 4.21-4.13 (m, 3H), 4.06-4.01 (m, 2H), 3.87 (dd, J=5.4 Hz, 11.4 Hz, 1H), 3.79 (dd, J=5.4 Hz, 10.8 Hz, 1H), 3.50-3.45 (m, 1H), 3.26-3.31 (m, 1H), 3.03 (s, 3H), 1.64 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=155.94, 148.69, 147.73, 141.57, 127.99, 127.39, 127.05, 113.81, 73.14, 69.92, 68.85, 68.54, 45.19, 44.99, 41.81, 39.98, 30.22.
    • Example 9: Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)-3-(ethylsulfonyl)-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (Compound 14a)
  • Figure US20170298033A1-20171019-C00522
    • Step a: Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-(((R)-3-(ethylthio)-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol
  • To a solution of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-(((R)-oxiran-2-yl)methoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (50 mg, 0.081 mmol, 1.0 equiv) in anhydrous DMF (3 mL) was added sodium ethanethiolate (6.8 mg, 0.081 mmol, 1.0 equiv) and the mixture was heated to 60-70° C. for 16 h. The reaction was quenched by the addition of a saturated solution of ammonium chloride (2 ml) and the mixture was extracted with ethyl acetate (2×30 ml). The organic layer was washed with deionized water (2×30 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by gradient flash column chromatography on silica gel (elution: 20% ethyl acetate in hexane to 50% ethyl acetate in hexane) to provide the titled compound (16.4 mg, 39.5%) as a colorless oil.
    • Step b: Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)-3-(ethylsulfonyl)-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (Compound 14a)
  • To a solution of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)-3-(ethylthio)-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (14.6 mg, 0.029 mmol, 1.0 equiv) in anhydrous dichloromethane (3 mL) was treated 3-chloroperbenzoic acid (14.0 mg, 0.081 mmol, 2.8 equiv) at 0° C. for 10 minutes. Then it was warmed to room temperature for 3 hours. The reaction was quenched by the addition of a saturated solution of ammonium chloride (2 ml) and the mixture was extracted with ethyl acetate (2×20 ml). The organic layer was washed with saturated NaHCO3 (20 ml), deionized water (2×20 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by gradient flash column chromatography on Si gel (elution: 30% ethyl acetate in hexane to 75% ethyl acetate in hexane) to provide Compound 14a (4.7 mg, 31.0%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ (ppm)=7.18-7.15 (m, 4H), 6.88 (d, J=8.8 Hz, 2H), 4.69-4.67 (m, 1H), 4.27-4.15 (m, 3H), 4.10-4.07 (m, 2H), 3.88 (dd, J=5.2 Hz, J=11.2 Hz, 1H), 3.80 (dd, J=5.2 Hz, J=10.8 Hz, 1H), 3.39-3.20 (m, 4H), 1.66 (s, 6H), 1.48 (t, J=7.2 Hz, 3H); ESI-LRMS calcd for [M+Na]+ 561.1, found 561.5.
    • Example 10: Synthesis of (R)-3-(4-(2-(4-((S)-3-chloro-2-hydroxypropoxy)-3-methylphenyl)propan-2-yl)-2-methylphenoxy)propane-1,2-diol (Compound 22a)
  • Figure US20170298033A1-20171019-C00523
  • Compound 22a was synthesized according to Example 1 by using 4,4′-(Propane-2,2-diyl)bis(2-methylphenol) (commercially available) instead of 4,4′-(propane-2,2-diyl)diphenol and omitting step c. 1H NMR (400 MHz, DMSO-D6) δ (ppm)=6.97-6.94 (m, 4H), 6.81-6.76 (m, 2H), 5.50 (d, J=4.8 Hz, 1H), 4.86 (s, 1H), 4.61 (s, 1H), 4.06-4.00 (m, 1H), 3.97-3.89 (m, 3H), 3.86-3.76 (m, 3H), 3.69 (dd, J=5.6 Hz, 11.2 Hz, 1H), 3.50-3.44 (m, 2H), 2.10 (s, 6H), 1.55 (s, 6H); 13C NMR (100 MHz, DMSO-D6) δ (ppm)=155.14, 154.74, 143.23, 142.75, 129.32, 129.23, 125.66, 125.62, 125.22, 125.16, 111.28, 111.16, 70.67, 70.02, 69.48, 69.32, 63.43, 55.50, 47.53, 31.42, 16.86, 16.79.
    • Example 11: Synthesis of (R)-3-(4-((3-chloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)sulfonyl)phenoxy)propane-1,2-diol (Compound 40a)
  • Figure US20170298033A1-20171019-C00524
  • Compound 40a was synthesized according to Example 1 by using 4,4′-sulfonyldiphenol instead of 4,4′-(propane-2,2-diyl)diphenol and with only 1 equiv of NaCl in step c. 1H NMR (400 MHz, MeOD) δ (ppm)=7.92-7.82 (m, 4H), 7.26 (d, J=8.8 Hz, 1H), 7.13 (d, J=8.8 Hz, 2H), 4.23-4.12 (m, 4H), 4.08-4.03 (m, 1H), 4.00-3.96 (m, 1H), 3.81 (dd, J=4.8 Hz, 11.6 Hz, 1H), 3.72 (dd, J=5.2 Hz, 11.2 Hz, 1H), 3.68-3.61 (m, 2H); 13C NMR (100 MHz, MeOD) δ (ppm)=163.24, 157.96, 135.21, 133.24, 129.56, 128.90, 127.82, 123.46, 115.12, 113.49, 70.23, 70.16, 69.62, 69.30, 62.64, 45.28; ESI-LRMS calcd for [M+Na]+ 473.0, found 472.8.
    • Example 12: Synthesis of (R)-3-(4-((3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)sulfonyl)phenoxy)propane-1,2-diol (Compound 41a)
  • Figure US20170298033A1-20171019-C00525
  • Compound 41a was synthesized according to Example 1 by using 4,4′-sulfonyldiphenol instead of 4,4′-(propane-2,2-diyl)diphenol. 1H NMR (400 MHz, MeOD) δ (ppm)=7.94-7.89 (m, 4H), 7.14 (d, J=8.8 Hz, 2H), 4.21-4.13 (m, 4H), 4.09-4.04 (m, 1H), 4.01-3.95 (m, 1H), 3.84 (dd, J=4.4 Hz, 11.6 Hz, 1H, 3.72 (dd, J=5.2 Hz, 11.2 Hz, 1H), 3.69-3.62 (m, 2H); 13C NMR (100 MHz, MeOD) δ (ppm)=165.08, 156.38, 141.20, 133.48, 131.65, 131.46, 129.37, 116.74, 75.60, 71.62, 71.46, 71.11, 64.06, 46.76; ESI-LRMS calcd for [M+Na]+ 506.9, found 506.9.
    • Example 13: Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-((4-((R)-2-hydroxy-3-methoxypropoxy)phenyl)sulfonyl)phenoxy)propan-2-ol (Compound 43a)
  • Figure US20170298033A1-20171019-C00526
  • Compound 43a was synthesized according to Examples 3 by starting with Compound 41a. 1H NMR (600 MHz, CD3Cl) δ (ppm)=7.91-7.85 (m, 4H), 7.06 (d, J=9.0 Hz, 2H), 4.27-4.16 (m, 4H), 4.13-4.07 (m, 2H), 3.85 (dd, J=4.8 Hz, 10.8 Hz, 1H), 3.79 (dd, J=5.4 Hz, 11.4 Hz, 1H), 3.62-3.54 (m, 2H), 3.43 (s, 3H); 13C NMR (150 MHz, CD3Cl) δ (ppm)=163.22, 154.58, 139.94, 132.47, 130.56, 130.47, 128.37, 115.67, 74.18, 73.31, 70.42, 69.70, 69.01, 59.62, 45.56; ESI-LRMS calcd for [M+Na]+521.0, found 520.9.
    • Example 14: Synthesis of (R)-1-amino-3-(4-((3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)sulfonyl)phenoxy)propan-2-ol (Compound 45a)
  • Figure US20170298033A1-20171019-C00527
  • Compound 45a was synthesized according to Examples 3 and 8 by starting with Compound 41a. 1H NMR (400 MHz, MeOD) δ (ppm)=7.93-7.90 (m, 4H), 7.14 (d, J=9.2 Hz, 2H), 4.19-4.13 (m, 3H), 4.10-4.01 (m, 2H), 3.95-3.91 (m, 1H), 3.85-3.80 (m, 1H), 3.74-3.69 (m, 1H), 2.85 (dd, J=4.4 Hz, 13.2 Hz, 1H), 2.74 (dd, J=5.2 Hz, 13.2 Hz, 1H); 13C NMR (100 MHz, MeOD) δ (ppm)=165.08, 156.51, 141.32, 133.70, 131.76, 131.57, 129.46, 116.86, 75.71, 72.15, 71.73, 71.57, 46.83, 45.26; ESI-LRMS calcd for [M+Na]+ 506.0, found 507.9.
    • Example 15: Synthesis of N—((R)-3-(4-((3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)sulfonyl)phenoxy)-2-hydroxypropyl)methanesulfonamide (Compound 46a)
  • Figure US20170298033A1-20171019-C00528
  • Compound 46a was synthesized according to Examples 3 and 8 by starting with Compound 41a. 1H NMR (600 MHz, MeOD) δ (ppm)=7.93-7.90 (m, 4H), 7.14 (d, J=9.0 Hz, 2H), 4.18-4.10 (m, 4H), 4.07-4.01 (m, 2H), 3.82 (dd, J=4.2 Hz, 11.4 Hz, 1H), 3.71 (dd, J=4.8 Hz, 10.8 Hz, 1H), 3.30-3.27 (m, 1H), 3.20 (dd, J=6.0 Hz, 13.2 Hz, 1H), 2.95 (s, 3H); 13C NMR (150 MHz, MeOD) δ (ppm)=165.01, 156.49, 141.31, 133.74, 131.75, 131.56, 129.46, 116.86, 75.68, 71.55, 71.47, 70.27, 46.81, 46.70, 40.22; ESI-LRMS calcd for [M+Na]+ 584.0, found 584.0.
    • Example 16: Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-((4-((R)-2-hydroxy-3-morpholinopropoxy)phenyl)sulfonyl)phenoxy)propan-2-ol (Compound 47a)
  • Figure US20170298033A1-20171019-C00529
  • Compound 47a was synthesized according to Examples 3 and 7 by starting with Compound 41a. 1H NMR (600 MHz, CDCl3) δ (ppm)=7.90-7.86 (m, 4H), 7.06 (d, J=9.0 Hz, 2H), 4.28-4.19 (m, 4H), 4.08-4.07 (m, 2H), 3.87-3.77 (m, 6H), 2.77-2.58 (m, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=162.51, 153.88, 139.21, 131.79, 129.85, 129.75, 127.66, 114.97, 73.48, 70.03, 69.71, 66.14, 64.45, 60.50, 53.26, 44.85; ESI-LRMS calcd for [M+H]+ 554.1, found 556.0.
    • Example 17: Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-((4-((R)-2-hydroxy-3-(1H-imidazol-1-yl)propoxy 4phenyl)sulfonyl)phenoxy)propan-2-ol (Compound 48a)
  • Figure US20170298033A1-20171019-C00530
  • Compound 48a was synthesized according to Examples 3 and 6 by starting with Compound 41a. 1H NMR (400 MHz, CDCl3) δ (ppm)=7.88-7.83 (m, 4H), 7.65 (s, 1H), 7.03-6.97 (m, 4H), 4.27-4.10 (m, 6H), 4.02 (dd, J=4.8 Hz, 9.6 Hz, 1H), 3.96-3.90 (m, 1H), 3.82 (dd, J=4.8 Hz, 11.2 Hz, 1H), 3.75 (dd, J=5.2 Hz, 11.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ (ppm)=162.53, 154.66, 139.49, 137.72, 132.85, 130.46, 130.40, 128.24, 128.00, 120.24, 115.50, 74.12, 70.14, 69.22, 68.64, 50.29, 45.48; ESI-LRMS calcd for [M+H]+ 535.0, found 535.0.
    • Example 18: Synthesis of (S)-1-chloro-3-(2,6-dichloro-4-((4-((S)-3-(ethylsulfonyl)-2-hydroxypropoxy)phenyl)sulfonyl)phenoxy)propan-2-ol (Compound 50a)
  • Figure US20170298033A1-20171019-C00531
  • Compound 50a was synthesized according to Examples 3 and 9 by starting with Compound 41a. 1H NMR (400 MHz, CDCl3) δ (ppm)=7.89 (d, J=9.2 Hz, 2H), 7.85 (s, 2H), 7.04 (d, J=9.2 Hz, 2H), 4.72-4.66 (m, 1H), 4.26-4.19 (m, 3H), 4.14-4.09 (m, 2H), 3.83 (dd, J=5.2 Hz, 11.2 Hz, 1H), 3.77 (dd, J=4.8 Hz, 11.2 Hz, 1H), 3.35-3.14 (m, 4H), 1.45 (t, J=7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ (ppm)=162.37, 154.56, 139.59, 133.08, 130.46, 130.43, 128.27, 115.56, 74.08, 70.82, 70.29, 65.20, 54.87, 49.39, 45.41, 6.70; ESI-LRMS calcd for [M+Na]+ 583.0, found 582.9.
    • Example 19: Synthesis of (R)-3-(4-((4-((S)-3-chloro-2-hydroxypropoxy)phenyl)sulfonyl)phenoxy)propane-1,2-diol (Compound 80a)
  • Figure US20170298033A1-20171019-C00532
  • Compound 80a was synthesized according to Examples 1 by using 4,4′-sulfonyldiphenol instead of 4,4′-(propane-2,2-diyl)diphenol and omitting step c. 1H NMR (400 MHz, MeOD) δ (ppm)=7.84 (dd, J=2.8 Hz, 9.2 Hz, 4H), 7.09 (dd, J=2.0 Hz, 9.2 Hz, 4H), 4.15-4.08 (m, 4H), 4.05-4.01 (m, 1H), 3.99-3.93 (m, 1H), 3.76-3.71 (m, 1H), 3.70-3.60 (m, 3H); 13C NMR (100 MHz, MeOD) δ (ppm)=164.50, 164.17, 135.74, 135.40, 130.89, 130.87, 116.52, 71.78, 71.12, 70.97, 70.87, 64.19, 46.74; ESI-LRMS calcd for [M+Na]+ 439.1, found 438.9.
    • Example 20: Synthesis (R)-1-(4-(2-(4-((R)-2-acetoxy-3-chloropropoxy)-3,5-dichlorophenyl)propan-2-yl)phenoxy)-3-methoxypropan-2-yl acetate (Compound A5d)
  • Figure US20170298033A1-20171019-C00533
  • Ac2O (128 mg, 1.26 mmol, 6.0 equiv.), Et3N (127 mg, 1.26 mmol, 6.0 equiv.) and DMAP (26 mg, 0.21 mmol, 1.0 equiv.) were added to a solution of Compound 5a (100 mg, 0.21 mmol, 1.0 equiv., see Example 3) in anhydrous DCM (5 mL) at room temperature and the resultant mixture was stirred at the same temperature overnight. The mixture was diluted with EtOAc (30 mL) and the organic layer was washed with water (15 mL) and brine (15 mL). The organic layer was further dried over anhydrous MgSO4 and evaporated under reduced pressure. The crude was loaded onto a silica gel column and eluted with Hexane/EtOAc (13/1 to 6/1) to give 111 mg of the titled compound as colorless oil (yield: 95.0%).
  • 1H NMR (600 MHz, CHLOROFORM-d) δ 7.11-7.12 (m, 2H), 7.09-7.11 (m, 2H), 6.82-6.87 (m, 2H), 5.32-5.35 (m, 1H), 5.28-5.32 (m, 1H), 4.18-4.26 (m, 2H), 4.09-4.16 (m, 2H), 3.97 (dd, J=5.14, 11.74 Hz, 1H), 3.88 (dd, J=5.14, 11.74 Hz, 1H), 3.66 (dd, J=2.20, 4.40 Hz, 2H), 3.40 (s, 3H), 2.14 (s, 3H), 2.11 (s, 3H), 1.61 (s, 6H).
  • 13C NMR (151 MHz, CHLOROFORM-d) δ 170.8, 170.4, 156.9, 149.4, 148.4, 141.8, 128.7, 127.9, 127.7, 114.5, 71.9, 71.1, 70.9, 66.4, 59.6, 42.7, 42.4, 30.9, 21.4, 21.2.
    • Example 21: Synthesis (R)-1-(4-(2-(4-((S)-2-acetoxy-3-chloropropoxy)-3,5-dichlorophenyl)propan-2-yl)phenoxy)-3-methoxypropan-2-yl acetate (Compound A5a)
  • Figure US20170298033A1-20171019-C00534
  • Acetic Anhydride (4.1 mg, 0.04 mmol, 4.0 equiv) was added to a solution of Compound 5a (5.0 mg, 0.01 mmol, 1.0 equiv, see Example 3), DMAP (0.1 mg, 0.001 mmol, 0.1 equiv) and Et3N (4.1 mg, 0.04 mmol, 4.0 equiv) in anhydrous dichloromethane (1 mL). The resulting solution was stirred overnight at room temperature. Dichloromethane was removed under reduced pressure and the residue was purified by column chromatography to afford the title compound as a colorless oil (5.8 mg, 98.6%). 1H NMR (400 MHz, CDCl3) δ (ppm)=7.11-7.08 (m, 4H), 6.83 (d, J=8.8, 2H), 5.35-5.26 (m, 2H), 4.26-4.17 (m, 2H), 4.16-4.07 (m, 2H), 3.96 (dd, J=5.2 Hz, 11.6 Hz, 1H), 3.86 (dd, J=5.6 Hz, 11.6 Hz, 1H), 3.66-3.61 (m, 2H), 3.38 (s, 3H), 2.13 (s, 3H), 2.10 (s, 3H), 1.60 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=170.80, 170.45, 156.96, 149.41, 148.39, 141.80, 128.69, 127.90, 127.70, 114.54, 71.91, 71.12, 70.54, 66.44, 59.62, 42.73, 42.43, 30.90, 21.38, 21.18; ESI-LRMS calcd for [M+H]+ 561.1, found 561.1.
    • Example 22: Synthesis of (R)-1-(4-(2-(4-((S)-2-acetoxy-3-chloropropoxy)-3,5-dichlorophenyl)propan-2-yl)phenoxy)-3-isopropoxypropan-2-yl acetate (Compound A7a)
  • Figure US20170298033A1-20171019-C00535
  • Compound A7a was synthesized according to Examples 21 by using Compound 7a prepared according to Example 4. Compound A7a was obtained as a colorless oil (6.4 mg, 96.2%). 1H NMR (400 MHz, CDCl3) δ (ppm)=7.12-7.08 (m, 4H), 6.85 (d, J=8.8, 2H), 5.36-5.30 (m, 1H), 5.28-5.22 (m, 1H), 4.27-4.09 (m, 4H), 3.97 (dd, J=5.2 Hz, 11.6 Hz, 1H), 3.87 (dd, J=5.6 Hz, 11.6 Hz, 1H), 3.71-3.57 (m, 3H), 2.14 (s, 3H), 2.09 (s, 3H), 1.61 (s, 6H), 1.15 (dd, J=2.0 Hz, 6.0 Hz, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=170.16, 169.78, 156.42, 148.77, 147.72, 141.03, 128.02, 127.20, 127.03, 113.91, 71.97, 71.25, 70.98, 70.30, 66.01, 65.72, 42.06, 41.76, 30.24, 21.60, 21.54, 20.74, 20.52; ESI-LRMS calcd for [M+Na]+611.1, found 611.1.
    • Example 23: Synthesis of (S)-1-(4-(2-(4-((S)-2-acetoxy-3-(ethylsulfonyl)propoxy)phenyl)propan-2-yl)-2,6-dichlorophenoxy)-3-chloropropan-2-yl acetate (Compound A14a)
  • Figure US20170298033A1-20171019-C00536
  • Compound A14a was synthesized according to Examples 21 by using Compound 14a prepared according to Example 9. Compound A14a was obtained as a colorless oil (3.4 mg, 97.3%). 1H NMR (400 MHz, CDCl3) δ (ppm)=7.13-7.08 (m, 4H), 6.84 (d, J=8.8, 2H), 5.63-5.57 (m, 1H), 5.36-5.30 (m, 1H), 4.29-4.18 (m, 4H), 3.97 (dd, J=5.2 Hz, 12.0 Hz, 1H), 3.87 (dd, J=5.6 Hz, 11.6 Hz, 1H), 3.54-3.40 (m, 2H), 3.10 (q, J=7.2 Hz, 2H), 2.14 (s, 3H), 2.12 (s, 3H), 1.61 (s, 6H), 1.44 (t, J=7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm)=170.41, 170.16, 158.50, 154.94, 142.86, 142.39, 128.70, 128.03, 127.66, 114.48, 71.87, 71.46, 67.79, 67.05, 52.48, 48.82, 42.69, 42.44, 30.86, 21.15, 20.90, 6.80; ESI-LRMS calcd for [M+Na]+645.1, found 645.1.
    • Example 24: Synthesis of (R)-1-(4-(2-(4-((S)-2-acetoxy-3-chloropropoxy)-3,5-dichlorophenyl)propan-2-yl)phenoxy)-3-morpholinopropan-2-yl acetate (Compound A11a)
  • Figure US20170298033A1-20171019-C00537
  • Compound A11a was synthesized according to Examples 21 by sing Compound 11a prepared according to Example 7. Compound A11a was obtained as a colorless oil (6.8 mg, 97.6%). 1H NMR (400 MHz, CDCl3) δ (ppm)=7.14-7.07 (m, 4H), 6.83 (d, J=8.8, 2H), 5.72-5.70 (m, 1H), 5.36-5.30 (m, 1H), 4.47-4.40 (m, 1H), 4.39-4.32 (m, 1H), 4.29-4.14 (m, 4H), 3.99-3.94 (m, 3H), 3.87 (dd, J=5.6 Hz, 11.6 Hz, 1H), 3.58-3.37 (m, 4H), 2.97 (m, 2H), 2.23 (s, 3H), 2.14 (s, 3H), 1.61 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=170.54, 170.37, 156.02, 149.12, 148.39, 142.61, 128.67, 128.06, 127.60, 114.34, 71.81, 70.90, 67.26, 65.89, 63.60, 58.52, 53.17, 52.58, 42.64, 42.40, 30.78, 29.87, 21.56, 21.11; ESI-LRMS calcd for [M+H]+616.1, found 616.1.
    • Example 25: Synthesis of (S)-1-(4-(2-(4-((R)-2-acetoxy-3-(1H-imidazol-1-yl)propoxy)phenyl)propan-2-yl)-2,6-dichlorophenoxy)-3-chloropropan-2-yl acetate (Compound A9a)
  • Figure US20170298033A1-20171019-C00538
  • Compound A9a was synthesized according to Examples 21 by using Compound 9a prepared according to Example 6. Compound A9a was obtained as a colorless oil (5.6 mg, 93.6%). 1H NMR (400 MHz, CDCl3) δ (ppm)=9.40 (s, 1H), 7.39 (s, 1H), 7.20 (s, 1H), 7.14-7.10 (m, 4H), 6.82 (d, J=8.4, 2H), 5.50 (m, 1H), 5.35-5.31 (m, 1H), 4.78-4.70 (m, 2H), 4.27-4.18 (m, 4H), 3.96 (dd, J=5.6 Hz, 11.6 Hz, 1H), 3.87 (dd, J=5.6 Hz, 11.6 Hz, 1H), 2.14 (s, 3H), 2.11 (s, 3H), 1.61 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=170.21, 169.67, 155.72, 148.93, 142.61, 136.02, 128.53, 127.97, 127.46, 121.62, 120.13, 114.19, 71.66, 70.76, 69.72, 65.27, 49.70, 42.49, 42.26, 30.65, 20.96, 20.91; ESI-LRMS calcd for [M+H]+ 597.1, found 597.1.
    • Example 26: Synthesis of (S)-1-(4-(2-(4-((R)-2-acetoxy-3-(N-(methylsulfonyl)acetamido)propoxy)phenyl)propan-2-yl)-2,6-dichlorophenoxy)-3-chloropropan-2-yl acetate (Compound A13a)
  • Figure US20170298033A1-20171019-C00539
  • Compound A13a was synthesized according to Examples 21 by using Compound 13a prepared according to Example 8. Compound A13a was obtained as a colorless oil (6.0 mg, 100%). 1H NMR (400 MHz, CDCl3) δ (ppm)=7.13-7.08 (m, 4H), 6.82 (d, J=8.4, 2H), 5.47-5.42 (m, 1H), 5.36-5.30 (m, 1H), 4.29-4.07 (m, 6H), 3.97 (dd, J=5.2 Hz, 11.6 Hz, 1H), 3.87 (dd, J=5.6 Hz, 11.6 Hz, 1H), 3.33 (s, 3H), 2.44 (s, 3H), 2.14 (s, 3H), 2.10 (s, 3H), 1.61 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=171.33, 170.47, 170.29, 156.42, 149.13, 148.29, 142.17, 128.58, 127.88, 127.54, 114.33, 71.74, 70.82, 70.36, 67.19, 46.69, 42.66, 42.57, 42.31, 30.73, 24.49, 21.07, 20.03; ESI-LRMS calcd for [M+H]+ 666.1, found 666.1.
    • Example 27: Synthesis of (S)-1-(4-(2-(4-((S)-2-acetoxy-3-chloropropoxy)-3,5-dichlorophenyl)propan-2-yl)phenoxy)-3-fluoropropan-2-yl acetate (Compound A8a)
  • Figure US20170298033A1-20171019-C00540
  • Compound A8a was synthesized according to Examples 21 by using Compound 8a prepared according to Example 5. Compound A8a was obtained as a colorless oil (5.8 mg, 95.9%). 1H NMR (400 MHz, CDCl3) δ (ppm)=7.13-7.10 (m, 4H), 6.84 (d, J=8.8 Hz, 2H), 5.39-5.29 (m, 2H), 4.79-4.71 (m, 1H), 4.67-4.59 (m, 1H), 4.27-4.18 (m, 2H), 4.16-4.14 (m, 2H), 3.97 (dd, J=5.2 Hz, 11.6 Hz, 1H), 3.87 (dd, J=5.6 Hz, 11.6 Hz, 1H), 2.14 (s, 3H), 2.13 (s, 3H), 1.61 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=170.58, 170.46, 156.65, 149.33, 148.43, 142.14, 128.73, 127.99, 127.70, 114.48, 82.13, 80.99 (d, J=513.0 Hz), 71.92, 70.98, 70.77, 70.64 (d, J=19.5 Hz), 65.19, 65.15 (d, J=6.0 Hz), 42.73, 42.46, 30.91, 21.22, 21.19; ESI-LRMS calcd for [M+H]+ 549.1, found 549.1.
    • Example 28: Synthesis of (S)-3-(4-(2-(4-((S)-2-acetoxy-3-chloropropoxy)-3,5-dichlorophenyl)propan-2-yl)phenoxy)propane-1,2-diyl diacetate (Compound A1a)
  • Figure US20170298033A1-20171019-C00541
  • Compound A1a was synthesized according to Examples 21 by using Compound 1a prepared according to Example 1. Compound A1a was obtained as a colorless oil (63.0 mg, 97.1%). 1H NMR (600 MHz, CDCl3) δ (ppm)=7.14-7.11 (m, 4H), 6.85 (d, J=12.0 Hz, 2H), 5.39-5.33 (m, 2H), 4.45 (dd, J=4.2 Hz, 12.0 Hz, 1H), 4.32 (dd, J=6.0 Hz, 12.0 Hz, 1H), 4.26 (dd, J=4.8 Hz, 10.2 Hz, 1H), 4.22 (dd, J=4.8 Hz, 10.2 Hz, 1H), 4.13-4.12 (m, 2H), 3.98 (dd, J=5.4 Hz, 12.0 Hz, 1H), 3.89 (dd, J=5.4 Hz, 12.0 Hz, 1H), 2.16 (s, 3H), 2.12 (s, 3H), 2.10 (s, 3H), 1.63 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=170.21, 169.90, 169.77, 156.07, 148.66, 147.76, 141.40, 128.04, 127.28, 127.02, 113.88, 71.24, 70.31, 69.30, 65.55, 62.10, 42.05, 41.77, 30.23, 20.56, 20.50, 20.35; ESI-LRMS calcd for [M+Na]+ 611.1, found 611.0.
    • Example 29: Compound Activity
  • LNCaP cells (3×104) were seeded into 24-well plates overnight. Next day, LNCaP cells were transiently transfected with 0.25 μg/well of PSA (6.1 kb)-luciferase reporter plasmid prior to pre-treatment with compounds of the invention or reference compounds (e.g., compounds A, B, C, 1a, 5a, 9a, 11a, 12a, 13a, and 14a) ranging in concentration from 0 μM to 35 μM for 1 hour before the addition of vehicle, or synthetic androgen, R1881 (1 nM) to induce luciferase production. After 48 h of exposure, cells were harvested in Passive lysis buffer (Promega). Luciferase activities were measured and normalized to protein concentration determined by the Bradford assay. IC50 calculations were done using OriginPro 8.1 Software (Northampton, Mass., USA). Transfection experiments to determine IC50 values were performed in at least 4 independent experiments (“trials”) using triplicate wells. Dose responses of representative compounds are shown in FIG. 2. Luciferase activity is presented as the mean±standard deviation of the technical replicates.
  • Figure US20170298033A1-20171019-C00542
  • TABLE 6
    IC50 values for selected compounds (μM) with standard error
    Compound Number of Trials Average IC50
    A 12 13.9 ± 2.6 
    B 6 10.68 ± 1.04 
    C 4 2.47 ± 0.26
     1a 11 1.41 ± 0.27
     5a 6 1.03 ± 0.39
     9a 11 3.12 ± 0.68
    11a 10 1.05 ± 0.15
    12a 4 2.26 ± 0.24
    13a 6 1.00 ± 0.16
    14a 11 0.95 ± 0.21
    • Example 30: Compound 1a Treatment in LNCaP Xenograft Model
  • LNCaP Cell Preparation:
  • LNCaP cells were passaged prior to seeding in T175flasks at a concentration of ˜2-3×107/mL. The cells were grown for 7 days until 90% confluent. Cell preparations were then prepared in RPMI with 5% FBS/Matrigel (50/50, v/v) yielding a final concentration of 1×108/mL.
  • Tumor Induction and Treatment:
  • Six to eight week old NOD-SCID mice were received from BC Cancer Research Centre's Animal Resource Centre and acclimated for 28 days. Tumors were initiated with sub-cutaneous back of each animal. Tumors were allowed to grow to an average size of approximately 100 mm3. Mice were then castrated and the tumors allowed to adapt for a period of one week before first dose was administered. Tumor volume was measured as length×width×height in mm multiplied by 0.5236.
  • Compound Preparation and Treatment:
  • Compound 1a was dissolved in 100% DMSO (ATCC Lot 61908420) to yield a stock solution of 157 mg/mL. Compound 1a was administered as an oral gavage once per day at dose levels of 10 and 30 mg/kg. Vehicle control animals were administered 1% CMC formulation as an oral gavage once daily. CMC (n=17 tumours); 10 mg/kg (n=15 tumours); 30 mg/kg (n=14 tumours). CMC (n=9 animals); 10 mg/kg (n=9 animals); 30 mg/kg (n=9 animals).
  • Oral treatment was initiated one week after castration. The start of treatment was designated “Day 1” and animals were treated once daily for a total of 24 doses. Two days after the last dose, the tumours were measured and harvested. Body weight was assessed daily throughout the treatment period. Tumor volume was measured on day −7 (castration day), and again on days 1, 4, 8, 12, 16, 20, 24 and 26.
  • Quantitative Real-Time Polymerase Chain Reaction (QPCR) Method:
  • LNCaP xenografts were homogenized using TRIzol® reagent (Invitrogen™), and total RNA was extracted using PureLink RNA Mini Kit (Life Technologies). Amplification Grade DNase I treatment (Sigma-Aldrich) was applied to the RNA before RT-PCR using High Capacity RNA-to-DNA kit (Life Technologies) to generate cDNA. cDNA and gene-specific primers were combined with Platinum® SYBR® Green qPCRSuperMix-UDG with ROX (Invitrogen™). Transcripts were measured by quantitative real-time PCR (QPCR) using ABI PRISM 7900 Sequence Detection System (ABI PRISM®, Applied Biosystems by Life Technologies) in triplicates for each biological sample. Gene expression levels were normalized to housekeeping gene RPL13A. Primers for PSA have been previously described (Andersen R. J., et al. Cancer Cell. 2010; Myung J. K., et al. J. Clin. Invest. 2013).
  • Daily oral treatment of Compound 1a at 10 mg/kg or 30 mg/kg resulted in inhibition of tumor growth and significant reduction of tumor volume at the end of the treatment period (FIGS. 3 and 4). There was no statistical difference in the tumor volumes between the 10 mg/kg and 30 mg/kg doses of Compound 1a. There were no significant differences between the start and finish body weights for the mice treated with Compound 1a and mice treated with control (CMC formulation) (FIG. 5). Since androgen receptor transcriptionally regulates the expression of PSA, the mRNA levels of PSA in the tumors were measured and examined to confirm the in vivo on-target activity of Compound 1a (FIG. 6). Indeed, Compound 1a demonstrated a dose-dependent inhibition of the mRNA expression of PSA, as 30 mg/kg treatment of Compound 1a caused a significant reduction of PSA expression when compared to the 10 mg/kg dose and control treatment. Together, these data indicated that Compound 1a significantly reduced the castration-resistant growth of LNCaP tumors, while demonstrating on-target activity to block androgen receptor transcriptional activity.
  • In FIG. 6, bars represent mean±SEM with n=5 representative tumors from each treatment group. One-way ANOVA post-hoc Tukey's multiple comparisons test was performed for statistical analysis. *p<0.05; **p<0.01; ***p<0.001.
  • Although various embodiments of the invention are disclosed herein, many adaptations and modifications can be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range. The word “comprising” is used herein as an open-ended term, substantially equivalent to the phrase “including, but not limited to”, and the word “comprises” has a corresponding meaning. As used herein, the singular forms “a”, “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a thing” includes more than one such thing. Citation of references herein is not an admission that such references are prior art to the present invention. Any priority document(s) and all publications, including but not limited to patents and patent applications, cited in this specification are incorporated herein by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein and as though fully set forth herein. The invention includes all embodiments and variations substantially as hereinbefore described and with reference to the examples and drawings.

Claims (67)

What is claimed is:
1. A compound having the following structure (I):
Figure US20170298033A1-20171019-C00543
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
X is —S(O)n— or —C(R8R9)—;
R1 is H, hydroxyl or —OC(═O)R13;
R2 is hydroxyl or —OC(═O)R13;
R3 is halo, —OH, —OR4; —OC(═O)R13, —NH2, —NHC(═O)R13, —N(C(═O)R13)2, —NHS(O)nR5, —N(C(═O)R13)(S(O)nR5), —N(C1-C6 alkyl)(S(O)nR5), —S(O)nR5, —N3, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R6;
R4 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R6;
R5 is each independently C1-C6 alkyl or aryl which are optionally substituted with one or more R6;
R6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123I, hydroxyl, oxo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C6-C12 aryl, wherein each R6 is optionally substituted with one or more of halogen, 123I, 18F, hydroxyl, —OS(O)2-aryl, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
R8 and R9 are each independently H or C1-C6 alkyl;
R11a, R11b, R11c and R11d are each independently H, methyl, F, Cl, Br, I, or 123I;
R13 is C1-C6 alkyl; and
n is 0, 1, or 2;
wherein at least one of R11a, R11b, R11c and R11d is methyl F, Cl, Br, I, or 123I.
2. The compound of claim 1, wherein at least two of R11a, R11b, R11c and R11d are methyl, F, Cl, Br, I, or 123I.
3. The compound of claim 1, wherein any two of R11a, R11b, R11c and R11d are independently methyl, F, Cl, Br, I, or 123I and the remaining two of R11a, R11b, R11c and R11d are each H.
4. The compound of claim 1, wherein R11a and R11b are each H; and R11c and R11d are each independently methyl, F, Cl, Br, I, or 123I.
5. The compound of claim 4, wherein R11c and R11d are each independently methyl, Cl, or Br.
6. The compound of claim 5, wherein R11c and R11d are each Cl.
7. The compound of claim 1, wherein R11a and R11c are each H; and R11b and R11d are each independently methyl, F, Cl, Br, I, or 123I.
8. The compound of claim 7, wherein R11b and R11d are each independently methyl, Cl, or Br.
9. The compound of claim 8, wherein R11b and R11d are each Cl.
10. The compound of claim 1, wherein X is —S(O)2—.
11. The compound of claim 1, wherein X is —C(R8R9)— and R8 and R9 are each independently C1-C3 alkyl.
12. The compound of claim 11, wherein R8 an R9 are each methyl.
13. The compound of claim 1, wherein R1 and R2 are each independently hydroxyl or —OC(═O)R13.
14. The compound of claim 13, wherein R1 and R2 are both hydroxyl.
15. The compound of claim 13, wherein R1 and R2 are both —OC(═O)R13.
16. The compound of claim 13, wherein R1 and R2 are both —OC(═O)R13, wherein R13 is methyl.
17. The compound of claim 1, wherein R1 is H.
18. The compound of claim 1, wherein R3 is —OH.
19. The compound of claim 1, wherein R3 is —OC(═O)R13.
20. The compound of claim 1, wherein R3 is —OC(═O)R13, wherein R13 is methyl.
21. The compound of claim 1, wherein R3 is —OR4 and R4 is C1-C6 alkyl.
22. The compound of claim 21, wherein R4 is a methyl, ethyl, n-propyl, or i-propyl.
23. The compound of claim 1, wherein R3 is F.
24. The compound of claim 1, wherein R3 is an optionally substituted 5 or 6 membered heteroaryl or an optionally substituted 3 to 7 membered heterocylyl, wherein said heteroaryl or said heterocyclyl respectively comprise at least one N atom.
25. The compound of claim 1, wherein R3 is selected from a group consisting of pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, oxazine, triazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, and tetrazine.
26. The compound of claim 1, wherein R3 is —NH2, —NHC(═O)R13, —N(C(═O)R13)2, —NHS(O)nR5, —N(C(═O)R13)(S(O)nR5), —N(C1-C6 alkyl)(S(O)nR5) or —S(O)nR5.
27. The compound of claim 26, wherein R3 is —NH2, —NHC(═O)(C1-C4 alkyl), —N[(C(═O)(C1-C4 alkyl)]2, —NHS(O)n(C1-C3 alkyl), —N[C(═O)(C1-C4 alkyl)][(S(O)n(C1-C3 alkyl)], —N[C1-C6 alkyl][S(O)n(C1-C3 alkyl)], or —S(O)n(C1-C3 alkyl).
28. The compound of claim 1, wherein each R13 is C1-C4 alkyl.
29. The compound of claim 28, wherein each R13 is methyl, ethyl, n-propyl, i-propyl, n-butyl, tert-butyl, i-butyl, or sec-butyl.
30. The compound of claim 1, wherein R1 and R2 are each independently —OH or —OC(═O)R13, wherein R13 is methyl.
31. The compound of claim 1, wherein at least one of R1, R2 and R3 is —OC(═O)R13, wherein R13 is methyl.
32. The compound of claim 1, wherein any two of R1, R2 and R3 are each —OC(═O)R13, wherein R13 is methyl.
33. The compound of claim 32, wherein R1 and R2 are each —OC(═O)R13, wherein R13 is methyl.
34. The compound of claim 1, wherein R1, R2 and R3 are each —OC(═O)R13, wherein R13 is methyl.
35. The compound of claim 1, wherein the compound has one of the following structures:
Figure US20170298033A1-20171019-C00544
Figure US20170298033A1-20171019-C00545
Figure US20170298033A1-20171019-C00546
Figure US20170298033A1-20171019-C00547
Figure US20170298033A1-20171019-C00548
Figure US20170298033A1-20171019-C00549
Figure US20170298033A1-20171019-C00550
Figure US20170298033A1-20171019-C00551
Figure US20170298033A1-20171019-C00552
Figure US20170298033A1-20171019-C00553
Figure US20170298033A1-20171019-C00554
Figure US20170298033A1-20171019-C00555
Figure US20170298033A1-20171019-C00556
Figure US20170298033A1-20171019-C00557
Figure US20170298033A1-20171019-C00558
Figure US20170298033A1-20171019-C00559
Figure US20170298033A1-20171019-C00560
Figure US20170298033A1-20171019-C00561
Figure US20170298033A1-20171019-C00562
Figure US20170298033A1-20171019-C00563
Figure US20170298033A1-20171019-C00564
Figure US20170298033A1-20171019-C00565
Figure US20170298033A1-20171019-C00566
Figure US20170298033A1-20171019-C00567
Figure US20170298033A1-20171019-C00568
Figure US20170298033A1-20171019-C00569
Figure US20170298033A1-20171019-C00570
Figure US20170298033A1-20171019-C00571
Figure US20170298033A1-20171019-C00572
Figure US20170298033A1-20171019-C00573
Figure US20170298033A1-20171019-C00574
Figure US20170298033A1-20171019-C00575
Figure US20170298033A1-20171019-C00576
Figure US20170298033A1-20171019-C00577
Figure US20170298033A1-20171019-C00578
Figure US20170298033A1-20171019-C00579
Figure US20170298033A1-20171019-C00580
Figure US20170298033A1-20171019-C00581
Figure US20170298033A1-20171019-C00582
Figure US20170298033A1-20171019-C00583
Figure US20170298033A1-20171019-C00584
Figure US20170298033A1-20171019-C00585
Figure US20170298033A1-20171019-C00586
Figure US20170298033A1-20171019-C00587
Figure US20170298033A1-20171019-C00588
Figure US20170298033A1-20171019-C00589
Figure US20170298033A1-20171019-C00590
Figure US20170298033A1-20171019-C00591
Figure US20170298033A1-20171019-C00592
Figure US20170298033A1-20171019-C00593
Figure US20170298033A1-20171019-C00594
Figure US20170298033A1-20171019-C00595
Figure US20170298033A1-20171019-C00596
Figure US20170298033A1-20171019-C00597
Figure US20170298033A1-20171019-C00598
Figure US20170298033A1-20171019-C00599
Figure US20170298033A1-20171019-C00600
Figure US20170298033A1-20171019-C00601
Figure US20170298033A1-20171019-C00602
Figure US20170298033A1-20171019-C00603
Figure US20170298033A1-20171019-C00604
or pharmaceutically acceptable salt thereof.
36. The compound of claim 1, wherein the compound has one of the following structures:
Figure US20170298033A1-20171019-C00605
Figure US20170298033A1-20171019-C00606
Figure US20170298033A1-20171019-C00607
Figure US20170298033A1-20171019-C00608
Figure US20170298033A1-20171019-C00609
Figure US20170298033A1-20171019-C00610
Figure US20170298033A1-20171019-C00611
Figure US20170298033A1-20171019-C00612
Figure US20170298033A1-20171019-C00613
Figure US20170298033A1-20171019-C00614
Figure US20170298033A1-20171019-C00615
Figure US20170298033A1-20171019-C00616
Figure US20170298033A1-20171019-C00617
Figure US20170298033A1-20171019-C00618
Figure US20170298033A1-20171019-C00619
Figure US20170298033A1-20171019-C00620
Figure US20170298033A1-20171019-C00621
Figure US20170298033A1-20171019-C00622
Figure US20170298033A1-20171019-C00623
Figure US20170298033A1-20171019-C00624
Figure US20170298033A1-20171019-C00625
Figure US20170298033A1-20171019-C00626
Figure US20170298033A1-20171019-C00627
Figure US20170298033A1-20171019-C00628
Figure US20170298033A1-20171019-C00629
Figure US20170298033A1-20171019-C00630
Figure US20170298033A1-20171019-C00631
Figure US20170298033A1-20171019-C00632
Figure US20170298033A1-20171019-C00633
Figure US20170298033A1-20171019-C00634
or a pharmaceutically acceptable salt thereof.
37. A compound having the following structure (II):
Figure US20170298033A1-20171019-C00635
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
R1 is H, —OH or —OC(═O)R;
R2 is —OH or —OC(═O)R13;
R3 is halo, —OH, —OR, —OC(═O)R13, —NH2, NHC(═O)R13, —N(C(═O)R13)2, —NHS(O)nR5, —N(C1-C6 alkyl)S(O)nR5, —N(C(═O)R13)(S(O)nR5), —S(O)nR5, —N3, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R6;
R4 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R6;
R5 is each independently C1-C6 alkyl or aryl which are optionally substituted with one or more R6;
R6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123I, hydroxyl, oxo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C6-C12 aryl, wherein each R6 is optionally substituted with one or more of halogen, 123I, 18F, hydroxyl, —OS(O)2-aryl, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl; and
n is 0, 1, or 2.
38. The compound of claim 37, wherein R1 is —OH or —OC(═O)R13.
39. The compound of claim 37, wherein R1 is H.
40. The compound of claim 37, wherein R3 is —OH.
41. The compound of claim 37, wherein R3 is —OC(═O)R13, wherein R13 is methyl.
42. The compound of claim 37, wherein R3 is —OR4, wherein R4 is C1-C6 alkyl.
43. The compound of claim 37, wherein R4 is methyl.
44. The compound of claim 37, wherein R3 is optionally substituted 5 or 6 membered heteroaryl or optionally substituted 3 to 7 membered heterocylyl, wherein said heteroaryl or said heterocyclyl respectively comprise at least one N atom.
45. The compound of claim 37, wherein R3 is selected from a group consisting of pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, oxazine, triazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, and tetrazine.
46. The compound of claim 1, wherein R3 is —NH2, —NHC(═O)R13, —N(C(═O)R13)2, —NHS(O)nR5, —N(C(═O)R13)(S(O)nR5), —N(C1-C6 alkyl)(S(O)nR5) or —S(O)nR5.
47. The compound of claim 46, wherein R3 is —NH2, —NHC(═O)(C1-C4 alkyl), —N[(C(═O)(C1-C4 alkyl)]2, —NH[S(O)n(C1-C3 alkyl)], —N[C(═O)(C1-C4 alkyl)][(S(O)n(C1-C3 alkyl)], —N[C1-C6 alkyl][S(O)n(C1-C3 alkyl)], or —S(O)n(C1-C3 alkyl).
48. The compound of claim 37, wherein each R13 is C1-C4 alkyl.
49. The compound of claim 37, wherein R1 and R2 are each independently OH or —OC(═O)R13, wherein R13 is methyl.
50. The compound of claim 37, wherein at least one of R1, R2 and R3 is —OC(═O)R13, wherein R13 is methyl.
51. The compound of claim 37, wherein any two of R1, R2 and R3 are each —OC(═O)R13, wherein R13 is methyl.
52. The compound of claim 37, wherein R1, R2 and R3 are each —OC(═O)R13, wherein R13 is methyl.
53. The compound of claim 37, wherein R1, R2 and R3 are each —OH.
54. The compound of claim 37, wherein the compound is:
Figure US20170298033A1-20171019-C00636
or a pharmaceutically acceptable salt thereof.
55. A pharmaceutical composition comprising a compound of any one of claims 1-54 and a pharmaceutically acceptable carrier.
56. The pharmaceutical composition of claim 55, further comprising an additional therapeutic agent.
57. The pharmaceutical composition of claim 56, wherein the additional therapeutic agent is for treating prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration.
59. The pharmaceutical composition of claim 56, wherein the additional therapeutic agent is enzalutamide, galeterone, abiraterone, bicalutamide, nilutamide, flutamide, cyproterone acetate, docetaxel, bevacizumab (Avastin), OSU-HDAC42, VITAXIN, sunitumib, ZD-4054, Cabazitaxel (XRP-6258), MDX-010 (Ipilimumab), OGX 427, OGX 011, finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 28260, SKF105,111, ODM-201, ODM-204, niclosamide, apalutamide, ARV-330, VPC-14449, TAS3681, 3E10-AR441bsAb, sintokamide, radium 233, or related compounds thereof.
60. A method for modulating androgen receptor activity, comprising: administering a pharmaceutical composition according to claim 55 to a subject in need thereof.
61. The method of claim 60, wherein the modulating androgen receptor (AR) is inhibiting androgen receptor.
62. The method of claim 61, wherein the modulating AR is inhibiting transactivation of androgen receptor N-terminal domain (NTD).
63. The method of claim 60, wherein the subject is human.
64. The method of any one of claims 60-63, wherein the modulating AR is for treating a condition or disease selected from prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration.
65. The method of claim 64, wherein the condition or disease is prostate cancer.
66. The method of claim 65, wherein the prostate cancer is primary or localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, advanced prostate cancer, metastatic prostate cancer, metastatic castration-resistant prostate cancer (CRPC), and hormone-sensitive prostate cancer
67. The method of claim 65, wherein the prostate cancer is CRPC.
68. The method of claim 65, wherein the prostate cancer express full-length androgen receptor (AR) or truncated AR splice variant.
US15/489,162 2016-04-15 2017-04-17 Bisphenol derivatives and their use as androgen receptor activity modulators Abandoned US20170298033A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/489,162 US20170298033A1 (en) 2016-04-15 2017-04-17 Bisphenol derivatives and their use as androgen receptor activity modulators
US16/848,061 US11142508B2 (en) 2016-04-15 2020-04-14 Bisphenol derivatives and their use as androgen receptor activity modulators
US17/404,589 US11919874B2 (en) 2016-04-15 2021-08-17 Bisphenol derivatives and their use as androgen receptor activity modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662323196P 2016-04-15 2016-04-15
US15/489,162 US20170298033A1 (en) 2016-04-15 2017-04-17 Bisphenol derivatives and their use as androgen receptor activity modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/848,061 Continuation US11142508B2 (en) 2016-04-15 2020-04-14 Bisphenol derivatives and their use as androgen receptor activity modulators

Publications (1)

Publication Number Publication Date
US20170298033A1 true US20170298033A1 (en) 2017-10-19

Family

ID=60039402

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/489,162 Abandoned US20170298033A1 (en) 2016-04-15 2017-04-17 Bisphenol derivatives and their use as androgen receptor activity modulators
US16/848,061 Active US11142508B2 (en) 2016-04-15 2020-04-14 Bisphenol derivatives and their use as androgen receptor activity modulators
US17/404,589 Active US11919874B2 (en) 2016-04-15 2021-08-17 Bisphenol derivatives and their use as androgen receptor activity modulators

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/848,061 Active US11142508B2 (en) 2016-04-15 2020-04-14 Bisphenol derivatives and their use as androgen receptor activity modulators
US17/404,589 Active US11919874B2 (en) 2016-04-15 2021-08-17 Bisphenol derivatives and their use as androgen receptor activity modulators

Country Status (13)

Country Link
US (3) US20170298033A1 (en)
EP (1) EP3442942B1 (en)
JP (2) JP7142577B2 (en)
KR (1) KR102409651B1 (en)
CN (1) CN109311807A (en)
AU (1) AU2017250025B2 (en)
BR (1) BR112018071183B1 (en)
CA (1) CA3021008A1 (en)
IL (1) IL262338B (en)
MX (1) MX2018012619A (en)
NZ (1) NZ748200A (en)
RU (1) RU2767257C2 (en)
WO (1) WO2017177307A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018045450A1 (en) * 2016-09-09 2018-03-15 British Columbia Cancer Agency Branch Bisphenol a compounds and methods for treating drug-resistant androgen receptor mediated cancers
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US10654811B2 (en) 2015-01-13 2020-05-19 The University Of British Columbia Heterocyclic compounds for cancer imaging and treatment and methods for their use
WO2020198712A1 (en) * 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CN112457366A (en) * 2019-09-06 2021-03-09 江西济民可信集团有限公司 Fused ring compound as protein degradation agent and preparation method and application thereof
US11059795B2 (en) 2018-10-18 2021-07-13 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
US11142508B2 (en) 2016-04-15 2021-10-12 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
US11242324B2 (en) 2020-04-17 2022-02-08 Essa Pharma, Inc. Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
RU2797622C2 (en) * 2018-10-18 2023-06-07 Эсса Фарма, Инк. Androgen receptor modulators and methods for their use
EP3947353A4 (en) * 2019-03-28 2023-07-05 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113648418B (en) * 2021-05-08 2022-08-05 南方医科大学 Application of Apelin-APJ inhibitor in preparation of medicine for treating blood testis barrier injury
KR20220157089A (en) * 2021-05-20 2022-11-29 연세대학교 산학협력단 A composition for preventing, alleviating or treating cancer
KR20220157096A (en) * 2021-05-20 2022-11-29 연세대학교 산학협력단 A composition for preventing, alleviating or treating cancer
WO2023046283A1 (en) 2021-09-22 2023-03-30 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Compounds and their use in a method for modulating ar (androgen receptor) transcriptional activity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8686050B2 (en) * 2008-07-02 2014-04-01 The University Of British Columbia Diglycidic ether derivative therapeutics and methods for their use
US20150010469A1 (en) * 2013-07-03 2015-01-08 British Columbia Cancer Agency Branch Bisphenol ether compounds with novel bridging groups and methods for their use
US9375496B2 (en) * 2013-09-09 2016-06-28 British Columbia Cancer Agency Branch Halogenated compounds for cancer imaging and treatment and methods for their use
US9388112B2 (en) * 2010-01-06 2016-07-12 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2571217A (en) 1951-10-16 Horace s
US2890189A (en) 1954-06-14 1959-06-09 Johnson & Son Inc S C Alkali soluble resins and compositions containing the same
US3074974A (en) * 1957-12-06 1963-01-22 Monsanto Chemicals Method for the preparation of diglycidyl ether of tetrachlorobisphenol-a
US3162615A (en) 1961-01-03 1964-12-22 Dow Chemical Co Polyesters from cyclic polyhaloalkane polyols and unsaturated dicarboxylic acids
FR1389005A (en) 1963-01-09 1965-02-12 Bayer Ag Advanced process for curing polyepoxides
SU638596A1 (en) 1975-09-01 1978-12-25 Государственный Научно-Исследовательский И Проектный Институт Полимерных Клеев Им. Э.Л.Тер-Газаряна Diallylisocyanuric acid chlorohydrin derivative as plasticizer of polyvinyl acetate emulsion
US4284574A (en) 1979-06-15 1981-08-18 Ciba-Geigy Corporation Diglycidyl ethers of di-secondary alcohols, their preparation, and curable compositions containing them
SU929630A1 (en) * 1980-02-06 1982-05-23 Научно-Исследовательский Институт Биологии При Иркутском Государственном Университете Им.А.А.Жданова Process for producing di- or trioxydiphenyl sulfones
US4369298A (en) 1980-05-27 1983-01-18 Tokuyama Soda Kabushiki Kaisha Novel cured resin, process for production thereof, and lens composed of said resin from bis(alkyleneoxyphenyl)-diacrylate, bis(alkyleneoxyphenyl)diallyl ether, bis(alkyleneoxyphenyl)diallyl carbonate monomers
DE3170223D1 (en) 1981-01-13 1985-06-05 Teijin Ltd Ion-permeable composite membrane and its use in selective separation
IN169231B (en) * 1984-03-15 1991-09-14 Ciba Geigy Ag
PL141793B1 (en) 1984-10-08 1987-08-31 Politechnika Warszawska Method of obtaining bisphenolic resins
US5753730A (en) 1986-12-15 1998-05-19 Mitsui Toatsu Chemicals, Inc. Plastic lenses having a high-refractive index, process for the preparation thereof and casting polymerization process for preparing sulfur-containing urethane resin lens and lens prepared thereby
JPH0832844B2 (en) 1987-02-09 1996-03-29 パイロツトインキ株式会社 Opaque ink for writing board
CA1311322C (en) 1987-04-27 1992-12-08 Morio Gaku Thermosetting resin composition
KR910003821B1 (en) 1987-06-01 1991-06-12 더 다우 케미칼 캄파니 Process for preparing propargyl ethers of hydroxyaromatic compounds
US5155196A (en) 1987-06-01 1992-10-13 The Dow Chemical Company Polymer resulting from the cure of a preformed chromene-containing mixture
JP2572020B2 (en) * 1987-06-19 1997-01-16 竹本油脂株式会社 Flame retardant for thermosetting resin
DE3821585A1 (en) 1987-09-13 1989-03-23 Hoechst Ag POSITIVELY WORKING RADIATION-SENSITIVE MIXTURE AND PRODUCTION OF RADIATION-SENSITIVE RECORDING MATERIAL FOR HIGH-ENERGY RADIATION
US4855184A (en) 1988-02-02 1989-08-08 Minnesota Mining And Manufacturing Company Radiation-curable protective coating composition
DE3939760A1 (en) 1989-12-01 1991-06-06 Bayer Ag METHOD FOR LACQUERING PLASTICS, LACQUERED PLASTICS AND THE USE OF ADHESIVES SUITABLE FOR THIS
EP0515128A1 (en) 1991-05-23 1992-11-25 Konica Corporation Silver halide color photographic light-sensitive material
JPH0649473A (en) 1992-08-04 1994-02-22 Asahi Chem Ind Co Ltd Refrigerant composition
DE4323512A1 (en) 1992-09-01 1994-04-28 Agfa Gevaert Ag Photographic recording material
JPH07117349A (en) 1993-10-27 1995-05-09 Asahi Denka Kogyo Kk Thermal recording material
EP0794771A1 (en) 1994-11-29 1997-09-17 Hoechst Marion Roussel, Inc. Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
DE19526146A1 (en) 1995-07-07 1997-01-09 Schering Ag Triphenylethylenes, processes for their preparation, pharmaceutical preparations containing these triphenylethylenes and their use for the preparation of medicaments
JPH09176240A (en) 1995-12-27 1997-07-08 Mitsubishi Chem Corp Photopolymerizable composition
JPH10133427A (en) 1996-11-05 1998-05-22 Fuji Xerox Co Ltd Carrier for developing electrostatic latent image, electrostatic latent image developer, and image forming method
AR011626A1 (en) 1997-02-07 2000-08-30 Shell Int Research A PROCEDURE FOR THE ELABORATION OF EPOXID COMPOUNDS, EPOXID RESINS OBTAINED THROUGH SUCH A PROCEDURE AND A PROCEDURE FOR THE ELABORATION OF INTERMEDIATE COMPOUNDS FOR THE ELABORATION OF EPOXID COMPOUNDS
JPH10316803A (en) 1997-05-16 1998-12-02 Teijin Chem Ltd Flame-retardant resin composition
IL125840A (en) 1997-08-22 2002-12-01 Teijin Chemicals Ltd Bromine compound production method
JPH11166087A (en) 1997-12-04 1999-06-22 Teijin Chem Ltd Flame-retardant resin composition
CA2302169A1 (en) 1998-06-30 2000-01-13 The University Of British Columbia Inhibitors of androgen-independent activation of androgen receptor
US6245117B1 (en) 1998-08-07 2001-06-12 Ipposha Oil Industries Co., Ltd. Modifier of cellulose fibers and modification method of cellulose fibers
US6218430B1 (en) 1998-08-24 2001-04-17 Ligand Pharmaceuticals Incorporated Vitamin D3 mimics
JP3795679B2 (en) 1998-09-01 2006-07-12 帝人化成株式会社 Method for producing bromine compound
WO2001027622A1 (en) 1999-10-14 2001-04-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
US6534621B2 (en) 2000-05-18 2003-03-18 Dow Global Technologies Inc. Process for manufacturing a hydroxyester derivative intermediate and epoxy resins prepared therefrom
US6472436B1 (en) 2000-07-17 2002-10-29 The Salk Institute For Biological Studies Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
WO2002018334A2 (en) 2000-08-31 2002-03-07 Theravance, Inc. Sodium channel modulators
US6646102B2 (en) 2001-07-05 2003-11-11 Dow Global Technologies Inc. Process for manufacturing an alpha-dihydroxy derivative and epoxy resins prepared therefrom
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
WO2003074450A2 (en) 2002-02-28 2003-09-12 The University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
EP1534663A4 (en) 2002-06-17 2006-08-30 Univ Tennessee Res Foundation N-bridged selective androgen receptor modulators and methods of use thereof
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
EP1687258A2 (en) 2003-11-20 2006-08-09 Eli Lilly And Company Vitamin d receptor modulators
JP2007524677A (en) 2004-02-13 2007-08-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア Radiolabeled compounds and compositions, their precursors and methods for their production
JP2005325301A (en) 2004-05-17 2005-11-24 Fuji Photo Film Co Ltd Cellulose acylate dope composition and cellulose acylate film
MX2007001993A (en) 2004-08-18 2007-05-10 Warner Lambert Co Androgen modulators.
JP2006208607A (en) 2005-01-26 2006-08-10 Fuji Photo Film Co Ltd Pattern forming material and device, and permanent pattern forming method
WO2006097474A1 (en) 2005-03-15 2006-09-21 Nycomed Gmbh N-sulphonylpyrroles and their use as histone deacetylase inhibitors
JP4753601B2 (en) 2005-03-23 2011-08-24 旭化成イーマテリアルズ株式会社 Photosensitive composition
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
FR2885904B1 (en) 2005-05-19 2007-07-06 Aventis Pharma Sa NOVEL FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF
EP1792622A1 (en) 2005-11-11 2007-06-06 GPC Biotech AG Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
SI1976828T1 (en) 2005-12-29 2017-07-31 Celtaxsys, Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
DK2368550T3 (en) 2006-03-27 2013-09-30 Univ California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
JP2007290980A (en) 2006-04-21 2007-11-08 Shin Etsu Chem Co Ltd Fluorine-containing (meth)acrylic acid ester
DE102006019044A1 (en) * 2006-04-25 2007-10-31 Merck Patent Gmbh antioxidants
TW200819421A (en) 2006-10-31 2008-05-01 Univ Nat Chunghsing The method of synthesizing biphenol A, BPA having di-alkoxyl group by using polycarbonate or its waste
KR20090115797A (en) 2007-02-20 2009-11-06 바스프 에스이 High refractive index monomers, compositions and uses thereof
JP2011530511A (en) 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション Therapeutic compounds
AR079975A1 (en) 2010-01-06 2012-03-07 British Columbia Cancer Agency THERAPEUTIC AGENTS DERIVED FROM BISPHENOL OR METHODS FOR USE, PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME
SG10201501202TA (en) 2010-02-16 2015-04-29 Aragon Pharmaceuticals Inc Androgen Receptor Modulators And Uses Thereof
EP2693875A4 (en) 2011-04-08 2014-10-22 British Columbia Cancer Agency Bisphenol compounds and methods for their use
WO2012145330A1 (en) 2011-04-18 2012-10-26 The University Of British Columbia Fluorene-9-bisphenol compounds and methods for their use
WO2012145328A1 (en) 2011-04-18 2012-10-26 The University Of British Columbia Dibenzylphenyl compounds and methods for their use
EP2744773B1 (en) 2011-08-19 2016-11-02 British Columbia Cancer Agency Branch Fluorinated bisphenol ether compounds and methods for their use
WO2013028791A1 (en) 2011-08-22 2013-02-28 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
US9365510B2 (en) * 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
CN108143728A (en) 2012-07-13 2018-06-12 Gtx公司 Purposes of the selective androgen receptor modulators in breast cancer is treated
MA37975B2 (en) 2012-09-11 2021-03-31 Genzyme Corp Glucosylceramide synthase inhibitors
JP6100439B2 (en) 2013-05-10 2017-03-22 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ Ester derivatives of androgen receptor modulators and methods for their use
CN103342892A (en) 2013-06-06 2013-10-09 西安交通大学 Bimaleimide resin toughening modifiers and preparation method thereof
TW201600499A (en) 2014-05-15 2016-01-01 巴斯夫歐洲公司 Ortho-terphenyls for the preparation of graphene nanoribbons
WO2016058082A1 (en) 2014-10-14 2016-04-21 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
WO2016058080A1 (en) 2014-10-14 2016-04-21 British Columbia Cancer Agency Branch Fluoro-chloro bisphenol ether compounds and methods for their use
DK3245193T3 (en) 2015-01-13 2022-03-07 British Columbia Cancer Agency Branch HETEROCYCLIC COMPOUNDS FOR IMAGE SCANNING AND TREATMENT OF CANCER AND PROCEDURES FOR THE USE OF THESE
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
CA2929345A1 (en) 2015-09-02 2017-03-02 British Columbia Cancer Agency Branch Co-targeting androgen receptor splice variants and mtor signaling pathway for the treatment of castration-resistant prostate cancer
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2017210771A1 (en) 2016-06-06 2017-12-14 British Columbia Cancer Agency Branch Compounds and compositions for radiation therapy and methods of using the same
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
WO2018157232A1 (en) 2017-02-28 2018-09-07 British Columbia Cancer Agency Branch Pharmaceutical compositions 'and combinations comprising inhibitors of the androgen receptor a1wd uses thereof
WO2019023651A2 (en) 2017-07-28 2019-01-31 Massachusetts Institute Of Technology Small molecule modulators of the androgen receptor
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
SG11202103325WA (en) 2018-10-18 2021-05-28 Essa Pharma Inc Androgen receptor modulators and methods for their use
MX2021005075A (en) 2018-12-07 2021-07-15 Sumitomo Pharma Oncology Inc Methods for treating castration-resistant and castration- sensitive prostate cancer.
US20230078913A1 (en) 2019-03-28 2023-03-16 Essa Pharma, Inc. Androgen receptor modulators and methods for use as proteolysis targeting chimera ligands
US20220218632A1 (en) 2019-03-28 2022-07-14 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CA3134545A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CA3174422A1 (en) 2020-04-17 2021-10-21 Essa Pharma, Inc. Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof
WO2022060969A1 (en) 2020-09-16 2022-03-24 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8686050B2 (en) * 2008-07-02 2014-04-01 The University Of British Columbia Diglycidic ether derivative therapeutics and methods for their use
US9388112B2 (en) * 2010-01-06 2016-07-12 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
US20150010469A1 (en) * 2013-07-03 2015-01-08 British Columbia Cancer Agency Branch Bisphenol ether compounds with novel bridging groups and methods for their use
US9375496B2 (en) * 2013-09-09 2016-06-28 British Columbia Cancer Agency Branch Halogenated compounds for cancer imaging and treatment and methods for their use

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10654811B2 (en) 2015-01-13 2020-05-19 The University Of British Columbia Heterocyclic compounds for cancer imaging and treatment and methods for their use
US11345670B2 (en) 2015-01-13 2022-05-31 The University Of British Columbia Heterocyclic compounds for cancer imaging and treatment and methods for their use
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US11779550B2 (en) 2015-03-12 2023-10-10 The University Of British Columbia Bisphenol ether derivatives and methods for using the same
US11919874B2 (en) 2016-04-15 2024-03-05 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
US11142508B2 (en) 2016-04-15 2021-10-12 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2018045450A1 (en) * 2016-09-09 2018-03-15 British Columbia Cancer Agency Branch Bisphenol a compounds and methods for treating drug-resistant androgen receptor mediated cancers
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
CN113195441A (en) * 2018-10-18 2021-07-30 埃萨制药股份有限公司 Androgen receptor modulators and methods of use thereof
RU2797622C2 (en) * 2018-10-18 2023-06-07 Эсса Фарма, Инк. Androgen receptor modulators and methods for their use
US11059795B2 (en) 2018-10-18 2021-07-13 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
EP3867216A4 (en) * 2018-10-18 2022-07-13 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
WO2020198712A1 (en) * 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
EP3947353A4 (en) * 2019-03-28 2023-07-05 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CN112457366A (en) * 2019-09-06 2021-03-09 江西济民可信集团有限公司 Fused ring compound as protein degradation agent and preparation method and application thereof
US11518747B2 (en) 2020-04-17 2022-12-06 Essa Pharma, Inc. Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof
US11358938B2 (en) 2020-04-17 2022-06-14 Essa Pharma, Inc. Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof
US11814357B2 (en) 2020-04-17 2023-11-14 Essa Pharma Inc. Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof
US11242324B2 (en) 2020-04-17 2022-02-08 Essa Pharma, Inc. Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof

Also Published As

Publication number Publication date
AU2017250025B2 (en) 2021-06-24
JP2019513795A (en) 2019-05-30
MX2018012619A (en) 2019-06-24
US20200317628A1 (en) 2020-10-08
EP3442942A1 (en) 2019-02-20
KR102409651B1 (en) 2022-06-16
WO2017177307A1 (en) 2017-10-19
US11919874B2 (en) 2024-03-05
IL262338A (en) 2018-11-29
AU2017250025A1 (en) 2018-11-29
KR20190011240A (en) 2019-02-01
JP7142577B2 (en) 2022-09-27
NZ748200A (en) 2023-05-26
JP2022120018A (en) 2022-08-17
CA3021008A1 (en) 2017-10-19
CN109311807A (en) 2019-02-05
EP3442942C0 (en) 2023-11-15
RU2767257C2 (en) 2022-03-17
US20210387957A1 (en) 2021-12-16
RU2018140071A3 (en) 2020-06-01
EP3442942A4 (en) 2019-12-04
BR112018071183A2 (en) 2019-02-12
IL262338B (en) 2022-01-01
BR112018071183B1 (en) 2022-06-07
US11142508B2 (en) 2021-10-12
EP3442942B1 (en) 2023-11-15
RU2018140071A (en) 2020-05-19

Similar Documents

Publication Publication Date Title
US11919874B2 (en) Bisphenol derivatives and their use as androgen receptor activity modulators
US11345670B2 (en) Heterocyclic compounds for cancer imaging and treatment and methods for their use
US9365510B2 (en) Aziridine bisphenol ethers and related compounds and methods for their use
US11779550B2 (en) Bisphenol ether derivatives and methods for using the same
US9173939B2 (en) Ester derivatives of androgen receptor modulators and methods for their use
US9375496B2 (en) Halogenated compounds for cancer imaging and treatment and methods for their use

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE UNIVERSITY OF BRITISH COLUMBIA, CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANDERSEN, RAYMOND JOHN;JIAN, KUNZHONG;SIGNING DATES FROM 20171121 TO 20171123;REEL/FRAME:044684/0151

AS Assignment

Owner name: PROVINCIAL HEALTH SERVICES AUTHORITY, CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SADAR, MARIANNE DOROTHY;MAWJI, NASRIN R.;WANG, JUN;AND OTHERS;SIGNING DATES FROM 20180906 TO 20180910;REEL/FRAME:046939/0482

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, MARYLAND

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:BRITISH COLUMBIA CANCER AGENCY;REEL/FRAME:063487/0439

Effective date: 20230427